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Abstract
Cardiovascular disease (CVD) is a global health problem and there has been an 
epidemiological transition of CVD from high income countries to low-middle income 
countries. In the case of Thailand, the prevalence of heart disease and stroke is 
increasing. In order to reduce the risk of CVD, the Ministry of Public Health in 
Thailand has implemented a number of primary CVD prevention strategies within the 
last decade. These strategies are being specifically implemented to address the future 
potential economic burden of increasing CVD. However, the economic impact of 
reducing multiple risk factors, at a population level in Thailand, in terms of health care 
costs is unclear. In order to plan for investment in public health interventions within 
finite resources, it is imperative that decision makers have sufficient information to 
identify the target populations and risk reduction strategies, and to assess the impact of 
these strategies on the population.
This study aims to estimate the future prevalence of CVD in Thailand over the 
next 5 - 1 0  years and the potential economic and health benefits of strategies to reduce 
the population risk factors during this period.
The mathematic CVD cost-offset model has been developed in this study in 7 
stages. 1) Descriptive analysis of the CVD risk profile data from the 4th National Health 
Examination Survey (NHESIV) 2008-2009 data set in order to explore the association 
of CVD risk factors in Thailand. 2) Calculate the probability of future CVD event which 
applies the CVD risk prediction equation. 3) Estimate of the number of future CVD 
events. 4) Validation of the estimated number of annual CVD event with the actual 
CVD hospitalisation event in Thailand. 5) Calculate the cost of hospital admission due 
to CVD from the Universal Coverage Health Care Scheme (UC) data in 2009. 6) 
Estimate the burden of CVD in terms of the DALYs. 7) Estimate the impact of reducing
CVD risk factors in different scenarios. The study outcomes being the number of 
hospitalisation cost savings, number of premature death savings, DALY savings and 
health care cost savings. The outcomes will also account for the uncertainty analysis.
As indicated above, no studies currently exist that focus specifically on the 
mathematic model for estimating the future situation of CVD in Thailand. Therefore, 
this study represents an original contribution to that knowledge. The findings of this 
study will contribute to health policy by providing specific new knowledge and 
information regarding Thai CVD risk factors and the impact of the risk reduction which 
will assist health policy makers in the planning and future investment in prevention 
programs for CVD in Thailand. Moreover, it is expected that the finding from this 
research will establish a CVD prediction model for Thailand, and one which may be 
applicable and compatible to the Asia and Pacific regions.
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Terms and Definitions
1. Cardiovascular diseases (CVD)
The World Health Organization (WHO) defined CVD as a group of disorders of 
the heart and blood vessels which include coronary heart disease, cerebrovascular 
disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, 
deep vein thrombosis and pulmonary embolism. Coronary heart disease (CHD) is the 
disease of the blood vessels that supplyblood to the heart muscle. Cerebrovascular 
disease or stroke is the disease of blood vessels supplying blood to the brain. Peripheral 
arterial disease is disease of blood vessels supplying blood to the arms and legs. 
Rheumatic heart disease is caused by streptococcus bacterial infection which results in 
damage of the heart muscle and heart valves from the rheumatic fever. Congenital heart 
disease is the malformation of the heart structure which exists at birth. (World Health 
Organization, Regional Office for Euroupe 2011)
2. Coronary heart disease (CHD)
CHD is a condition where there is thickening of the coronary artery wall 
(Lindsay and Gaw 2004). It is also known as atherosclerosis, ischemic heart disease 
(IHD) or coronary artery disease (CAD) (World Health Organization 2004b). 
Atherosclerosis is the restriction of the blood supply to the heart due to either a blood 
clot or blockage in the circulation system (Healey 2012). The progression of CHD 
which often presents in clinical practice include, angina, acute coronary syndromes 
(ACS), myocardial infarction, ischemic cardiomyopathy, chronic heart failure and 
sudden cardiac death. Patients with CHD conditions may get the initial symptom of 
having chest pains which may be stable or unstable angina pectoris. Then, it is likely to 
develop to the next state, which is called acute coronary syndrome (ACS) (Luepker et al.
xiv
2003) . ACS covers unstable angina and myocardial infarction. The symptoms are 
prolonged ischemic chest pains which are not relieved by rest. Myocardial infarction 
(commonly known as a heart attack), occurs when there is a blood flow reduction, 
which may lead to chronic conditions such as intracoronary thrombosis, platelet 
aggregation and heart attack (Thygesen et al. 2012).
3. Cerebrovascular disease or Stroke
Stroke or cerebrovascular disease is a condition that occurs when there is an 
interruption of blood supply to the brain which may result in neurological symptoms 
(Sacco et al. 2013). There are two major types of stroke which are ischemic or 
haemorrhagic stroke. The former occurs when there is inadequate blood supply to some 
part of the brain caused by an obstruction in a blood vessel to the brain, thrombosis or 
embolism (American stroke association 2013b). The latter occurs as a spontaneous 
haemorrhage into the brain which is associated with hypertension (American stroke 
association 2013a). Both types can lead to an acute loss of brain function and disability.
IHD and Stroke are a major concern to health policy makers in Thailand. 
Therefore within this thesis, the definition of CVD refers specifically to IHD and 
Stroke and includes all fatal and non-fatal events. It does not include dysfunction of the 
vascular system caused by infection or disorder of the heart at birth (such as the 
congestive heart failure or rheumatic heart disease.
4. Disability Adjusted Life Years (DALYs)
The sum of years of potential life lost due to premature mortality and the years 
of productive life lost due to disability. One DALY refers to the one year loss of healthy 
life. The sum of DALYs across the population can measure the gap between the current
xv
situation of the health status and the ideal health status in terms of the lives with free of 
diseases and disability (World Health Organization 201 lb).
5. The years of life lost (YLL)
The years of life lost (YLL) defined as potential years of life lost due to 
premature deaths. It takes into account the age weight which means giving the greater 
weight to deaths at a younger age and the lower weight to deaths at the older age (World 
Health Organization 201 lb).
6. The years lost due to disability (YLD)
The years lost due to disability (YLD) defined as the number of the years of 
living with disability which can be calculated by multiplying the number of incident 
cases, duration of diseases and a disability weight according to the severity of the 
diseases. The disability weight is scale from 0 refers to the perfect health and 1 refers to 
dead.
7. Age and gender
There were gender and age differences in the risk of CVD, which have to be 
considered in the analysis. According to the ATPIII guideline, (Expert Panel on 
Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults 2001), it was 
suggested that the risk to CVD was increasing with an advancing of age. Younger adults 
were less likely to be susceptible to CVD, whereas older adults were more prone to 
having a higher risk of suffering from CVD. In addition, middle age men, (35-65 years), 
had a higher risk of CHD than in women of the same age group. Women in the middle 
age groups who had high risk factors, may experience a delay in the occurrence of CHD 
by approximately 10-15 years, compared to men. In this analysis, age was categorised
into 7 age groups, according to the application of the Framingham 10-years CVD risk 
calculation, which are 15-24, 25-34, 35-44, 45-54, 55-64, 65-74 and >75 years.
8. Regular smoking
The definition of smoking behaviour in this study referred to people who 
smoked all kinds of tobacco products which were cigarettes, hand-rolled cigarettes, 
pipes, cigars and non-smoked tobacco. Regular smokers were classed as people who 
were current smokers during the past 12 months of the NHESIV survey period and 
smoked every day.
9. Body mass index (BMI)
Body mass index (BMI) is the measurement of human body shape, based on 
weight and height. The calculation of BMI is defined as body weight (kg) divided by 
the square of height (m) in metric measurements. The classification of BMI levels of the 
Asian population is different from American and European countries. According to the 
world health organization’s guideline in 2004 (World Health Organization 2004a) , at 
BMI level > 23 kg/m2 is regarded as overweight and BMI level > 25 kg/m2 is regarded 
as obese, in the Thai population. The BMI was categorised by the WHO definition, BMI 
<18.5 kg/m2 is regarded as underweight, 18.5-<25 kg/m2 is normal, 25-<30 kg/m2 is
'y
overweight and >30 kg/m is obese.
10. Lipid profiles
Participants aged 15 years and over of the 4th National Health Examination 
Survey (NHESIV) 2009, Thailand were asked to undertake a fasting blood test. The 
lipid profiles were examined for total cholesterol (TC), high density lipoprotein 
cholesterol (HDL-C) and triglyceride (TG). Dyslipidemia was identified by using the 
international standard cutoff points from the Third Report of the Expert Panel on
xvii
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III, ATPIII) (Expert Panel on Detection, Evaluation,and Treatment of 
High Blood Cholesterol in Adults 2001). The high total cholesterol referred to people 
who had a total cholesterol level > 200 mg/dL. The high triglyceride level referred to 
people who had a serum triglyceride level > 150 mg/dL. The low HDL-C was classified 
by using the cut-point at <40mg/dL for men and <50mg/dL for women.
11. Hypertension
Hypertension was defined according to the 7th JNC guideline for high blood 
pressure (Chobanian et al. 2003). The definition of high blood pressure in NHESIV 
referred to people who currently had systolic blood pressure >140 mmHg or had 
diastolic blood pressure > 90 mmHg or on medication or received treatment for high 
blood pressure, during the past 12 months of the NHESIV survey period.
12. Diabetes mellitus
Diabetes mellitus is defined as people who had fasting plasma glucose > 126 
mg/dL or those who had been told, after being diagnosed by medical doctors or health 
personnel, that they had DM or those who were on medication and treatment for DM 
during the past 2 weeks of the NHESIV survey period.
xviii
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Chapter 1 : Introduction
This introductory chapter outlines the background and rationale of the study; 
points out the research questions, aims and objectives and the original contribution of 
this work; describes the terms and definitions which are used in this thesis and provides 
an overview of the structure of the thesis.
1.1 Origins of the study/setting the scene
Cardiovascular diseases (CVD) are viewed as a global health problem. In 2008, 
the World Health Organization (WHO) estimated that there were 17.3 million deaths 
from CVD worldwide, which were primarily attributed to CHD and strokes.
This equates to approximately 30% of all global deaths. It was also estimated that the 
number of CVD deaths will reach 23.3 million by 2030 (World Health Organization 
September,2011). It was also reported that there has been an epidemiological transition 
of CVD from the high income countries to low and middle income countries, where 
80% of CVD were taking place (World Health Organization 201 la). Although, over the 
past decade, the CVD mortality rate has declined in high income countries such as the 
United States of America, United Kingdom and some European countries, (i.e. Sweden 
and Switzerland), the CVD mortality rate in northern Asia or Eurasia countries, central 
Asia and Africa countries such as the Russian Federation, Ukraine and Sudan have 
incrementally increased year on year (Levi et al. 2002, Murray and Lopez 1997, Yach et 
al. 2004, Ueshima et al. 2008). It is noted that the CVD mortality rate is lower in south­
east Asian countries such as Thailand, Malaysia and Singapore, (Mirzaei et al. 2009).
Although the mortality rate of CVD in Thailand is lower when compared to 
other countries in Northern Asia and Central Asia, CVD has become the leading cause 
of premature death and disability in Thailand. In 2009, strokes became the leading cause
1
of mortality accounting for 10.4% of all deaths in men and 14.4% of all deaths in 
women. Ischemic heart disease (IHD) ranked third and contributed to 7.7% of all deaths 
in men and 8.9% of all deaths in women (International Health Policy Program 2012). 
CHD and strokes are now in the top 5 causes of death in both men and women in 
Thailand (International Health Policy Program 2012). In 2010, the Global Burden of 
Diseases study estimated that CVD accounts for 27% of the total deaths in Thailand 
(Institute for Health Metrics and Evaluation 2013). The mortality rate of CVD and 
diabetes together are 343 (per 100,000) in males and 280 (per 100,000) in females, 
(World Health Organization 2011c). The trend of IHD mortality shows a continuous 
increase from 1998 to 2003. The trend of stroke mortality also increased rapidly from 
1998 to 2004 but declined after 2004 due to improvements in health technology and 
accessibility to health care services (Bureau of Non-Communicable Disease,Department 
of Disease Control,Ministry of Public health 2010) In terms of the morbidity, the 
prevalence of IHD and strokes have steadily increased year on year. 
(Health Information System Development Office 2011)
The increased prevalence of CVD in Thailand may be due to the effect of
growth in economic development over the past decade. Thailand is also currently in
transition from being primarily an agricultural based culture to one of industrialisation
and urbanization. The increase of CVD in Thailand has been explained in terms of
changing life styles and diet, with people doing less physical activities, having a high
salty, fatty food, less fruit and vegetable consumption, increased alcohol consumption,
cigarette smoking and an increasing ageing population (Aekplakom, et al. 2010).
People are also more likely to experience stress than in the past (National Statistical
Office 2011), and have shifted from a healthy diet to a high-fat and low-fibre diet
(Satheannoppakoa et al. 2010). As a consequence this may result in a higher body mass
index, hypercholesterolemia and subsequently result in an increased risk of CVD in the
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population. The results from the National Health Examination Survey (NHES) in 
Thailand also show that the trend of obesity in Thai adults aged 18 to 59 year old has 
significantly increased in both men and women from 1997 to 2004 (Aekplakom, et al. 
2010). The prevalence of hypertension was relatively stable at 21% between 2004 to 
2009 due to the rising of awareness of the pharmaceutical treatments and controls for 
managing blood pressure. Among individuals with high blood pressure there was also 
an increase in obesity between 2004 and 2009 (39.1% to 47.5% in men and 53.6% to 
62.9% in women) (Aekplakom, et al. 2010). The prevalence of hypercholesterolemia 
has increased from 11.3% to 15.5% and the prevalence of regular smoking has 
increased from 20.6% to 25.3% (Chooprapawan 1996, Porapakkham and 
Punyaratanapundhu 2006, Aekplakom, et al. 2010). However, the overall trend of 
people smoking was continuously in decline over the past decade (World Health 
Organization, Regional Office for South East Asia 2009, World Health Organization 
2009).
A possible explanation for the increasing prevalence of IHD and strokes, but
declining mortality may be due to improvements in health care services, pharmaceutical
and medical technology. As a result, patients who have CVD conditions may live longer,
reducing their mortality rate, whilst increasing overall morbidity. The consequence of
this being that this group of patients will arguably require more health care services and
rehabilitation. Moreover, new cases of CVD patients are occurring every year, which
will increase the economic burden within Thailand (International Health Policy
Program 2012). Additionally, it also increases the economic burden of health care costs
and the loss of productivity. An update of the burden of disease and injury studied in
Thailand during 2009 reported that IHD and strokes were in the top rank causes of
Disability Adjusted Life Years (DALYs) lost. DALY is the summation of years of
potential life lost due to premature mortality and the years of productive life lost due to
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disability. One DALY refers to one year loss of healthy life (Murray and Acharya 1997). 
The number of DALYs lost due to strokes was 368,701 DALYs in men (6.4% of 
DALYs overall) and 349,859 DALYs (8.0% of DALYs) overall in women. The number 
of DALYs lost due to IHD was 249,610 DALYs in men (4.3% of DALYs overall) and 
177,894 DALYs (4.0% of DALYs overall) in women (International Health Policy 
Program 2012).
The combination of the multiple risk factors to CVD is increasing. The results 
from the national health examination survey 2008-2009 reported that 18.8% of the Thai 
population (aged 15 and over) have at least 2 CVD risk factors, and 21.1% have the 
metabolic syndrome (Aekplakom et al. 2011). Most modifiable risk factors such as 
blood pressure, body mass index, blood cholesterol and cigarette smoking can be 
avoided and controlled, which will ultimately reduce the risk to the individual of getting 
CVD.
The linkages between the multiple risk factors of CVD have been identified. 
For example, reducing body weight reduces blood pressure (Mulrow et al. 2008) and 
lowering blood sugar level is likely to reduce the level of cholesterol (Welsh et al. 2010). 
Therefore, arguably each primary intervention has the potential to reduce the 
combination of CVD risk factors. Changing modifiable risk factors is more likely lead 
to change risk factor profiles among the Thai population (Sritara et al. 2003). It would 
be reflected the probability of absolute risk of CVD of the individual and decrease the 
burden of CVD in the future. Modifiable risk factors have been used in CVD risk 
assessment equations as the predictors for calculating the probability of getting CVD. 
The risk functions and risk scores such as the Framingham’s equation, QR1SK2 and 
SCORE, have been recommended as guidelines for the individual risk assessment, to 
identify the high-risk groups in the populations and provide suitable interventions for
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the target population (National Vascular Disease Prevention Alliance 2009, National 
Institute for Health and Clinical Excellence 2008).
To reduce the risk of CVD, the Ministry of Public Health in Thailand has 
implemented a number of primary CVD prevention strategies within the last decade 
(Bureau of Non-Communicable Disease,Department of Disease Control,Ministry of 
Public health 2010). These strategies include: the comprehensive tobacco programs, 
smoking regulation, dietary programs to reduce obesity, and early diagnosis of 
hypertension, diabetes and hypercholesterolemia. These strategies are being specifically 
implemented to address the future potential economic burden of increasing CVD. 
However, the economic impact of reducing multiple risk factors, at a population level in 
Thailand, in terms of health care costs is unclear (Teerawattananon, Russell and 
Mugford 2007).
In order to plan for investment in public health interventions within finite 
resources, it is imperative that decision makers have sufficient infoimation to identify 
the target populations and risk reduction strategies, and to assess the impact of these 
strategies on the population. As a result of the above, the following factors need to be 
considered. Whether a primary intervention should be implemented to reduce the 
burden of CVD? What is the future trend of the CVD prevalence and burden in 
Thailand? What are the savings from the impacts on the number of hospitalisations, 
from CVD? How much benefit is gained from saving DALYs in the population? 
And, How much health care cost savings can be achieved as a direct result of the risk 
reduction strategies?
1.2 Rationale of the Study
There were a number of reasons for undertaking this study. Firstly, as indicated
above, CVD is significant health problem in Thailand. There continues to be a year on
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year increase in the prevalence of CVD, an increased number of hospitalisations, an 
increase in the number of patients who are living with disability and an increase in the 
associated long term health care. The impact of this is an increase in the government 
health care burden and spending. The Thai government spent approximately $36.5 
million on inpatient health care in 2007 with 21% of this budget being spent on 
non-communicable diseases and injury and 10% on CVD (Garg and Evans 2011). 
Additionally, the loss due to premature death and disabilities have a direct impact on the 
individual’s finances, productivity- and wellbeing.
Secondly, there are a limited number of studies that focus specifically on 
estimating the future prevalence of CVD in the population and the impact of reducing 
the CVD risk factors in Thailand. Previous studies have been conducted in several 
countries using the health economic modelling technique to estimate the prevalence of 
CVD, for example, the CHD policy model in the US-population and China (Weinstein 
et al. 1987), the CVD policy model in Australia (Mui 1999), the POHEM model in 
Canada (Statistic Canada 2010) and the IMPACT model in England (Unal, Critchley 
and Capewell 2005). However, to the best of my knowledge, there are no studies that 
have specifically focused on the development of the mathematic model for estimating 
the future situation of CVD in Thailand. Furthermore, few studies have been conducted 
in Thailand that have explored the impact of prevention interventions in this specific 
population. For example, the cost-effectiveness analysis of the pharmaceutical 
interventions to prevent an occurrence of CVD (Khonputsa et al. 2012) or the 
randomisation control trial for reducing the salt intake, (Aung et al. 2012) are examples 
of the studies on the impact and effectiveness of CVD interventions. Although it is well 
known that reducing CVD risk factors can prevent an occurrence of CVD in each 
individual, little is known regarding the impact in terms of the health care costs and
DALYs avoidable at a population level in Thailand.
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1.3 Research Questions
The research sets out to address the following questions:
• How will the prevalence of CVD develop in Thailand over the next 5-10 years 
if the health system continues as it is?
• How much could the cost of hospital admissions and the number of DALYs 
from CVD be reduced, if the major multiple population risk factors, such as 
hypertension, obesity, diabetes, hypercholesterolemia and regular smoking were 
reduced through investment in public health initiatives?
1.3.1 Aims and Objectives
This study aims to estimate the future prevalence of CVD in Thailand over the 
next 5 - 1 0  years and the potential economic and health benefits of strategies to reduce 
the population risk factors during this period.
1.3.2 Research Objectives
1) To obtain a mathematical model that can be applied for estimating the future 
prevalence of CVD in Thailand if the health system remains as it is.
2) To estimate the potential reduction in the cost of hospital admissions and 
the number of hospital admission avoided, if the population level risk factors 
such as body mass index, smoking, hypertension and high cholesterol levels can 
be reduced or contained.
3) To estimate the potential DALYs from CVD which could be avoided if the 
population level risk factors such as body mass index, smoking, hypertension 
and high cholesterol levels can be reduced or contained.
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1.4 Original contribution
As previously highlighted, no studies currently exist that focus specifically on 
the development of a mathematic model for estimating the future situation of CVD in 
Thailand. Therefore, this study represents an original contribution to that knowledge. 
This study will develop a decision model for predicting the impact of risk reduction 
strategies for CVD in the Thai population. This will be developed by applying the 
appropriate risk assessment equations which are specifically focused on the Thai 
population and will enhance the capability of the model to estimate the impact of the 
risk reduction strategies, not only for the health care costs but also the burden of 
diseases in terms of DALYs. The findings of this study will contribute to health policy 
by providing specific new knowledge and information regarding Thai CVD risk factors 
and the impact of the risk reduction which will assist health policy makers in the 
planning and future investment in prevention programs for CVD in Thailand. 
Moreover, it is expected that the finding from this research will establish a CVD 
prediction model for Thailand, and one which may be applicable and compatible to the 
Asia and Pacific regions.
1.5 The structure of the thesis
This thesis comprises 8 chapters:
Chapter 1: The introduction provides the background information and context of 
CVD in Thailand and the rationale for the research study. The research questions and 
research objectives are outlined in the structure of the thesis.
Chapter 2: The literature review provides a critical review of the literature used 
to derive the evidence for developing a CVD mathematic model. The literature review 
included 1) The natural history of CVD and epidemiology, 2) The risk assessment
equation for CVD, 3) The health economic modelling for CVD, 4) The Disability 
Adjuted Life Years and 5) The public health risk reduction strategies for CVD.
Chapter 3: Method; this chapter will describe the detailed design and 
methodology for the study. This will include stages of developing of the mathematic 
model. It will outline the study population, data requirement and data sources, data 
analysis, outcomes of interests in each stages. The data collection process, data 
management procedure and the ethical considerations will be described in this chapter.
The results will be presented from chapter 4 to chapter 7.
Chapter 4: Risk factors for CVD in Thailand. This chapter will outline and 
describe the results from the descriptive analysis of the 4th Thailand National Health 
Examination Survey (NHESIV) 2009 dataset, which has been used as the baseline data 
to simulate the model. All coronary risk factors which were included in the CVD model 
will be analysed for the distribution and the association with CHD and strokes.
Chapter 5: Application of CVD risk assessment equations to the Thai population. 
This chapter will present the results of the 8 to 10 years CVD probability when applied 
to the 3 difference equations such as the APCS equation, the Framingham-Asia equation 
and the original-Framingham equation. Then, the estimated number of CVD events and 
the validation of the CVD modelling will also be presented.
Chapter 6: Cost of hospitalisation for CVD patients in Thailand. This chapter 
will present the 10-years estimated outcomes of the cost of hospitalization in terms of 
both direct health care costs and indirect costs and the long term care or rehabilitation 
for the CVD patients.
Chapter 7: Impact of reducing risk factors for CVD in Thailand. This chapter 
will demonstrate the finding from the CVD modelling by comparing the “target risk
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reduction scenario” against “without risk reduction scenario”. The estimation of the 
disability adjusted life year (DALY) and the estimated burden of CVD in Thailand over 
a 8 year period will be presented. The expected outcomes will be presented in terms of 
the number of hospitalisation cost savings, number of hospital admission avoided, 
DALY savings and health care cost savings.
Chapter 8: Conclusion and Recommendations. This chapter discusses the 
finding arising from the study and examines the comparison to previous studies. The 
results will be discussed by using the conceptual link of the theoretical contribution to 
the published literature and knowledge to the area. It will also provide the 
methodological critique, the strength and limitation of the CVD model and the potential 
impact of this study on policy and practice. This chapter will also summarise the 
research and provide recommendations for further research and provide 
recommendations for public health policy and practice in Thailand.
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Chapter 2 : Literature Review
2.1 Introduction
This chapter presents the literature review which is explored in five sections to 
achieve the research aims and objectives and address the research questions. The first 
section is the natural history of CVD and epidemiology. This section provides an 
overview of CVD, the global burden of diseases and trend of the mortality and 
morbidity of CVD in Thailand and compares this to the global epidemiological trend. 
The second section is the risk assessment equations for CVD. This provides a review of 
the CVD risk prediction equations and algorithms. Those CVD risk calculations have 
been derived from a number of cohort studies such as the Framingham's equation, 
QRISK, Asia pacific collaboration cohort studies etc. The third section reviews the 
health economic evaluation techniques and the health economic decision modelling. 
The most common three types of modelling techniques which have been used in the 
health economic studies, the decision tree model, Markov's model and the discrete event 
simulation model (DES), as well as the other types of model will also be discussed. 
Specifically, this section will explore the benefits and limitations of each model, as well 
as reviewing the previous studies of the CVD modelling in the health economic aspects. 
The fourth section provides a theoretical review of the concept of the summary 
measurement of population health and DALYs, which are the indicators that are used to 
present the burden of diseases. The final section presents the review of the public health 
risk reduction strategies for CVD and the target risk reduction strategies, which focus 
on the primary prevention interventions for the general population in Thailand. The 
literature search strategies are provided in the appendix A.
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2.2 Natural history of CVD and Epidemiology
2.2.1 Natural history of CVD
This section reviews the natural history of CVD, the definition and the 
progression of disease. The World Health Organisation (WHO) defined CVD as a group 
of disorders of the heart and blood vessels, which include CHD, strokes, peripheral 
arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis 
and pulmonary embolism (World Health Organization, Regional Office for Euroupe
2011). This review focuses on the natural history and the progression CHD and strokes, 
which are the major causes of death and disability among the Thai population. 
In general, most people have no sign or symptoms of CVD until they have a heart attack 
or stroke. Heart attacks or strokes occur in people who have an underlying condition 
affecting the blood vessels such as a blockage on the inner wall of a blood vessel, which 
blocks the flow of blood to the heart or brain. However, strokes can be caused by blood 
clots or rupturing of blood vessels in the brain.
2.2.1.1 Coronary heart disease (CHD)
Coronary heart disease (CHD) is a condition where there is thickening of the
coronary artery wall (Lindsay and Gaw 2004). It is also known as atherosclerosis,
ischemic heart disease (IHD) or coronary artery disease (CAD) (World Health
Organization 2004b). Atherosclerosis is the restriction of the blood supply to the heart
due to either a blood clot or blockage in the circulation system (Healey 2012).
The progression of CHD which often presents in clinical practice include, angina, acute
coronary syndromes (ACS), myocardial infarction, ischemic cardiomyopathy, chronic
heart failure and sudden cardiac death. Patients with CHD conditions may get the initial
symptom of having chest pains which may be stable or unstable angina pectoris. Then,
it is likely to develop to the next state, which is called acute coronary syndrome (ACS)
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(Luepker et al. 2003) . ACS covers unstable angina and myocardial infarction. The 
symptoms are prolonged ischemic chest pains which are not relieved by rest. 
Myocardial infarction (commonly known as a heart attack), occurs when there is a 
blood flow reduction, which may lead to chronic conditions such as intracoronary 
thrombosis, platelet aggregation and heart attack (Thygesen et al. 2012). The initial 
common symptoms of a myocardial infarction are central chest pains or the feeling of 
discomfort in the chest, arms, left shoulder, elbows, jaw or back. The person having a 
heart attack may experience difficulty in breathing, nausea or vomiting. This may then 
result in heart failure or sudden death. Individuals who get CHD conditions can move 
from one event to another event because there are different endpoints for the CHD 
developing process. It is important to consider that these events are interrelated to each 
other (Lindsay and Gaw 2004)
2.2.1.2 Stroke
Stroke or cerebrovascular disease is a condition that occurs when there is an
interruption of blood supply to the brain which may result in neurological symptoms
(Sacco et al. 2013). There are two major types of stroke which are ischemic or
haemorrhagic stroke. The former occurs when there is inadequate blood supply to some
part of the brain caused by an obstruction in a blood vessel to the brain, thrombosis or
embolism (American stroke association 2013b). The latter occurs as a spontaneous
haemorrhage into the brain which is associated with hypertension (American stroke
association 2013a). Both types can lead to an acute loss of brain function and disability.
The signs and symptoms of a stroke are weakness of the face muscles, arms and/or legs
on either side of the body (World Health Organization 2004b). Depending on the region
within the brain that the stroke occurs, the person with may have difficulties such as
limitations in movement, loss of speech, loss of sensation and visual field defect (Sacco
et al. 2013) .The symptoms may last for more than 24 hours or lead to death. However,
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if the duration of the symptoms last for less than 24 hours, it is often referred to as a 
Transient Ischemic Attack (TIA) (Lindsay and Gaw 2004, Sorensen and Ay 2011).
2.2.2 The global epidemiology and burden of CVD
This section provides a background and overview of the epidemiology and the 
global burden of CVD. The aims of the review are to address the global CVD epidemic 
and to address the specific CVD epidemic in Thailand. The review covers the incidence, 
prevalence, mortality, morbidity, trends and current situation, and the burden of CVD 
and disabilities globally and compares this to the situation of CVD in Thailand.
CVD is the leading cause of mortality around the world WHO estimated that 
approximately 23.6 million people will die from heart diseases and strokes by 2030 
(World Health Organization September, 2011). There was an epidemiological transition 
from the developed countries to the developing countries. According to the global age 
standardized mortality rate from CVD in 2004, the mortality rate increased in the low 
and middle-income countries, which are higher than in the high-income countries. It is 
estimated that the morbidity will increase in the Eastern Mediterranean region and 
mortality will rise in the South-East Asia region (Yach et al. 2004, Lopez et al. 2006, 
Gaziano et al. 2010).
The trend of CVD mortality has been different across geographical continents 
and ethnicity (Yusuf et al. 2001a). For example, CVD was considered as leading cause 
of death in USA over 50 years ago(Roger et al. 2012). However, the trend of CHD 
mortality in USA has continuously declined since this period, with a slower rate than 
from 1970 -1990. The stroke mortality has been decreasing slightly since 1990. The 
CHD mortality was respectively high in the black, non-Hispanic white and Hispanic 
population while the stroke mortality was high in black, non-Hispanic white and Asian 
race.
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The trend of CVD mortality in the European countries has varied across regions 
(Levi et al. 2002). Western Europe had a similar trend of CHD mortality as in the USA 
with a rapid increase during 1965-1975 but then with a dramatic decline after 1975. 
The stroke mortality has also declined by more than 55% in both men and women 
during 1965-1975. In Eastern Europe such as Poland and the Czech Republic, both 
CHD and stroke mortality increased up to the early 1990s and then declined over a few 
years. Conversely, the mortality of CHD and CVD in the Russian republic has reached 
the highest rate worldwide (Levi et al. 2002). Stroke was a predominant cause of 
mortality over CHD in Asian countries. The trend of stroke mortality in Japan, South 
Korea and China was similar to that in the western countries (Ueshima et al. 2008).
CVD epidemiological patterns vary across geographical regions and continents 
(World Health Organization 201 la). Mirzaei (2009) examined CHD mortality data from 
1950 to 2000 and reported trends of CHD mortality that were found to be different 
across continents, with three natural history patterns of CHD being suggested (Mirzaei 
et al. 2009). Firstly, the classic epidemic pattern which showed the rise and fall of CHD 
mortality. This pattern was found in many high income or developed countries such as 
Canada, United Stated, Australia, United Kingdom and the Scandinavian countries. 
A similar pattern was also found in many countries which have a lower case mortality 
rate such as western European countries, some South American countries such as 
Argentina, Brazil, Chile and some Asia countries such as Singapore, Japan and Hong 
Kong. Secondly, the rising pattern or the beginning of the CHD epidemic, which has 
been found in some countries in Central Asia such as the Russian Republic, Ukraine, 
Belarus, and Uzbekistan and some Asian countries such as urban China and Sri Lanka 
as well as Mexico in Central America. Thirdly, the "Flat" pattern or stable epidemic, 
which has been found in South Korea, rural China, Peru and Thailand.
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The trend of stroke mortality of the population between the ages of 35 to 74 
years was analysed in 48 countries worldwide, from 1950 to 2005 (Mirzaei et al. 2012). 
The highest mortality rates of stroke were in Japan, the Russian Republic and Bulgaria. 
On the other hand, the lowest mortality rates of stroke were in Canada and Australia. 
The mortality patterns for stroke were reported in “decline only”, “rise and fall”, “rise 
only” and “flat”. The countries with the decline pattern in stroke mortality trends were 
the USA, Canada, the UK, Sweden, Denmark, Finland, Italy, Australia, and in Hong 
Kong. The rise and fall pattern was found in Japan, Portugal and in Eastern Europe. 
The rising pattern in the 20th century was in Kyrgyzstan, Kazakhstan and Armenia. 
The flat patterns were in Mexico, Cuba, El Salvador, Egypt, Kuwait, Peru and Thailand. 
The epidemiological characteristic of the stroke incidence and case fatality has also 
been reviewed and the pooled data analysed in 56 population-based studies from 1970 
to 2008 (Feigin et al. 2009). This study reported that over four decades, the stroke 
incidence decreased by 42% in high-income countries, whereas, there was over a 100% 
increase in low to middle income countries. During 2000-2008, the stroke incidence rate 
continuously increased in the low to middle income countries. This was significant, as it 
was the first time that incidence of stroke, in low to middle income countries, had 
become as high as those in the high-income countries (Feigin et al. 2009).
Considering the epidemiological pattern above, most developing countries (such
as in Africa, urban India, Latin America and some Asian countries) are in a stage of
double burden, which includes both infectious disease and a chronic disease burden.
Whilst on the other hand, many developed countries (such as in Western Europe, North
America, Australia and New Zealand) are shifting to the next stage, which is the
prevention and treatment for the CHDs and strokes, which is advancing the
pharmaceutical and medical technology as well as enhancing the primary prevention
programs. People in low and middle income countries are more exposed to CVD risk
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factors but less likely to have access to adequate health care services than those who 
live in the high income countries. As a result, the death rates from CVD in these 
developed countries are decreasing and the life expectancy in the population is 
increasing, whilst in the developing countries both death rates and prevalence of CVD 
are increasing and the average life expectancy is also increasing but is still lower than 
that of developed countries (Yusuf et al. 2001a).
2.2.3 Epidemiology and burden of CVD in Thailand
Thailand is situated in the South East Asia region and has five geographical 
regions; north, central, north-east, south and Bangkok. The population in Thailand is 
approximately 63.9 million of which 23.1 million live in urban areas (inside 
municipalities), and 40.8 million live in rural areas (outside municipalities). 
The life expectancy at birth is 71 years in men and 77 years in women. However, when 
estimating healthy adjusted life years (HALE) or the years of living without any health 
problems or disability, the healthy life expectancy in Thailand was 65 years in men and 
71 years in women (International Health Policy Program 2012).
The non-communicable diseases (NCDs) such as CVD, cancer, chronic 
respiratory disease and diabetes are a major concern in Thailand (Kaufman et al. 2011). 
In 2005, stroke was the number one cause of death accounting for 9.4% of all deaths in 
the male population and 11.3% of all deaths in the female population. CHD was the 
fourth most common cause of death in the male population (6.1%) and the third most 
common cause of death in the female population (7.5%) (Porapakkham 2009).
Recently, the burden of disease and injury in Thailand in 2009, (International
Health Policy Program 2009), reported that the number of DALYs was calculated by
combining the years of life lost due to premature death and the years of living with a
disability. The number of DALYs lost due to stroke was 368,701 DALYs in men (6.4%
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of DALYs overall) and 349,859 DALYs (8.0% of DALYs) overall in women. 
The number of DALYs lost due to IHD was 249,610 DALYs in men (4.3% of DALYs 
overall) and 177,894 DALYs (4.0% of DALYs overall) in women (International Health 
Policy Program 2012). shows the top 10 rankings of the number of DALYs lost in 
Thailand in 2009.
Table 2.1 The Ranking of the DALYs in Thailand 2009 by gender (International 
Health Policy Program 2012)
Rank Male Female
Diseases DALYs 
(x 1000)
% Diseases DALYs 
(x 1000)
%
1 Alcohol addict 506 8.7 Diabetes mellitus 380 8.6
2 Road traffic 
injury
501 8.6 Stroke 350 8.0
3 Stroke 369 6.4 Depression 236 5.4
4 HIV/AIDS 282 4.9 Ischemic heart disease 
(IHD)
178 4.0
5 Liver Cancer 262 4.5 HIV/AIDS 160 3.6
6 Ischemic heart 
disease (IHD)
250 4.3 Cataract 154 3.5
7 Diabetes
mellitus
218 3.8 Osteoarthritis 138 3.1
8 Chronic 
obstruction 
pulmonary 
disease (COPD)
206 3.5 Road traffic injury 129 2.9
9 Cirrhosis 176 3.0 Anaemia 117 2.7
10 Lung cancer 133 2.3 Liver cancer 114 2.6
Although CVD mortality trends in Thailand have had a slower decrease from 
63.3 (per 100,000) in 2004 to 56.0 (per 100,000) in 2008, the inpatients hospitalization 
rate of CVD has steadily tripled from 614.3 (per 100,000) in 1999 to 1927.0
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(per 100,000) in 2008 (Bureau of Non-Communicable Disease,Department of Disease 
Control,Ministry of Public health 2010).
In terms of CVD trends, the mortality rate increased during 1998-2008. 
Geographical regional differences were also identified within Thailand, with Bangkok 
having the highest mortality rate from ischemic heart disease (IHD) and stroke. 
The current trend for IHD shows an increase in mortality from 1998, reaching an 
accelerated peak in 2003 and showing a continuing but slower increase up to 2008. 
(Figure 2.1)
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Figure 2.1 Mortality rate (per 100,000 populations) from ischemic heart disease by 
geographical regions in Thailand 1998-2008 (Health Information System 
Development Office 2011).
In addition, the trend of the mortality rate from stroke is different from the IHD 
mortality (Bureau of Non-Communicable Disease, Department of Disease 
Control,Ministry of Public health 2010). There was a dramatically increase in the stroke 
death rate from 1998 to 2004. Then, it rapidly decreased from 2004 to 2006. After 2006,
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the stroke mortality has remained constant but is still at a higher level than in the past 
decade. The highest mortality rate was found in Bangkok when compared to other 
regions and the lowest death rate was found in north eastern Thailand. (Figure 2.2)
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Figure 2.2 Mortality rate, (per 100,000 population) from stroke by region in 
Thailand 1998 -  2008, (Health Information System Development Office 2011).
The Thailand National Health Security Office (2010) recently reported that the 
hospital admission rate from CVD has dramatically increased. The rates of hospital 
admissions from IHD and stroke have increased three fold since 1992 (National Health 
Security office 2010). An increased number of patients to hospital has also resulted in 
an increase in the demand for treatment and medication in hospitals and an increase in 
the number of the patients receiving heart surgery through the Universal Coverage 
Scheme, which is a free national health care insurance scheme, from 21,162 (4.8%) in 
2004 to 32,233 (5.99%) in 2009. Figure 2.3 demonstrates the rate of hospital admissions 
from stroke and IHD.
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Hospital admission rate from cardiovascular diseases in Thailand
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Figure 2.3 Inpatient admission rates from CVD in Thailand 1992-2008 (Bureau of 
Non-Communicable Disease,Department of Disease Control, Ministry of Public 
health 2010)
In terms of the incidence of CVD in Thailand, the chronic diseases surveillance 
system has been established since 2003 by the Bureau of Non-Communicable Disease 
(Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health
2012). This surveillance system was set up mainly for the public health care providers, 
such as the central hospitals, general hospitals and community hospitals, to report new 
cases from the non-communicable diseases (such as diabetes mellitus, hypertension, 
ischemic heart disease, stroke and chronic obstruction pulmonary disease), through the 
Ministry of Public Health. The incidence of IHD and stroke were recently reported in 
2010. The incidence rate of hypertension was 566.17 per 100,000 population (360,658 
cases), IHD was 59.93 per 100,000 population (38,176 cases) and stroke was 50.56 per
100,000 population (32,210 cases). The trends of the incidence rate of IHD and stroke 
from 2006 to 2010 showed that there was an increase in the incidence of cases during 
2006 to 2009 but it slightly decreased in 2010. However, the prevalence of IHD and
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stroke overall was continuously increasing (Bureau of Epidemiology, Department of 
Disease Control, Ministry of Public Health 2012).
2.2.4 The modifiable risk factor for CVD
Over the last decade, there has been an increase in mortality and morbidity 
globally which is related to the traditional risk factors. These risk factors are relating to 
globalisation, industrialisation and ageing populations (Yusuf et al. 2001b). Aside from 
the genetic factors such as age and gender, the modifiable risk factors have been 
confirmed. Common potential risk factors were hypercholesterolemia, hypertension, 
cigarette smoking, which can be long term predictors for CVD regardless of ethnicity or 
gender.
The following studies have confirmed the association between those multiple 
risk factors and CVD. The INTERHEART study was a case-controlled study of acute 
myocardial infarction in 52 countries across the world. This study found nine 
modifiable risk factors as being significantly associated with MI in both men and 
women (Yusuf et al. 2004). Risk factors identified included smoking, hypertension, 
diabetes, obesity, blood lipids, exercise, alcohol consumption, fruit and vegetable 
consumption and psychosocial factors (Yusuf et al. 2004).
More recently, a meta-analysis of 18 cohorts of the black and white population
in the USA to identify the lifetime risk of CVD was undertaken (Berry et al. 2012). The
cohorts were measured for the CVD risk factors every ten years at the ages of 45, 55, 65
and 75 years. The participants were stratified by blood pressure, cholesterol level,
smoking status and diabetes status. The life time risk to CVD was calculated in terms of
free from CVD conditions, fatal and non-fatal CVD. The finding from this study
emphasized that the traditional risk factors continued to have the most influential effect
on the lifetime risk of CVD. For example, participants aged 55 years with a low CVD
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risk profile (total cholesterol <180mg/dL, blood pressure below 120/80 mmHg, non- 
smokers and non-diabetes) have a relatively lower risk of death from CVD than 
participants who had two or more major CVD risk factors. Overall, the mortality from 
CVD in the low risk groups was 4.7% in men and 6.4% in women, while the mortality 
from CVD in participants with more than two risk factors was 29.6 % of men and 
20.5% of women. A low risk group also had approximately 10 times lower lifetime 
risks of death from CHD, MI or stroke. These findings were also consistent when 
comparing different ethnicity cohorts.
A large multinational cohort study (WHO-MONICA project) (Evans et al. 2001, 
Kuulasmaa et al. 2000), found that over a ten year period (1980 - 1990) the coronary 
event rate had declined by 17% largely due to changes in risk factors (i.e. decreased 
blood pressure and serum cholesterols and increased BMI). Overall, trends of smoking 
rates decreased in males but increased in women. The trend of systolic blood pressure 
declined in both genders. There was a slight decrease in the trend of serum cholesterol 
levels, which had a significant effect on the risk of CVD. Conversely, BMI had 
increased in both genders. However, the change in the trends of CHD was partly 
associated with the change in the classical risk factors. This might be explained due to 
the time lag, the complexities in the relation between the changes in risk factors and 
event rates and the heterogeneity across populations (Kuulasmaa et al. 2000). In 
addition, there were strong negative correlations between regular smoking and high 
cholesterol in males and strong negative relation in regular smoking and high blood 
pressure.
In terms of the association between mortality and the risk factors, high blood 
pressure has the largest correlation of the risk factors with all the mortality measures, 
except for stroke mortality in males. High cholesterol has a strong negative association
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with the stroke mortality in females (The World Health Organisation MONICA project 
1994). A small change in the overall risk scores was found. There was a heterogeneity 
in stoke events across the populations. The changing of systolic blood pressure 
associated with stroke events only occurred in women. However, the combination risk 
factors score found a small association with the change in stroke events (Tolonen et al. 
2002).
The trend of CVD risk factors such as total cholesterol, BMI, SBP has also 
changed globally. The worldwide trend of total cholesterol has changed less than 0.1 
mmol/L per decade in both genders (Farzadfar, et al. 2011). There has been a decrease 
in the mean of total cholesterol (mmol/L) in high-income regions such as Australasia, 
North America and Western Europe. However, the mean total cholesterol has slightly 
increased 0.08-0.09 mmol/L per decade in East and South-East Asia and Pacific 
(Farzadfar, et al. 2011). Trends of Body Mass Index (BMI) have also increased 
globally 0.4-0.5 kg/m2 per decade from 1980 to 2008. The highest mean BMI was in 
some Oceania countries (Nauru and Cook Islands), reaching 33.9 kg/m2 in men and
35.0 kg/m2 in women. The mean BMI has also increased in sub-Saharan Africa, and 
East, South and Southeast Asian countries (Finucane et al. 2011).
The age-standardized mean systolic blood pressure (SBP) has decreased by 0.8 
mm Hg per decade in men and 1.0 mm Hg per decade in women. The trends of SBP 
have increased in both genders in Oceania, East Africa, South and Southeast Asia. 
However, in developed countries such as Australasia, North America and Western 
Europe, there has been a decrease (Danaei, et al. 2011).
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2.2.5 CVD risk factors in Thailand
The increase of CVD in Thailand has been explained in terms of changing life 
styles and diet, with people doing less physical activities, having a high salty, fatty food, 
less fruit and vegetable consumption, increased alcohol consumption, cigarette smoking 
and an increasing ageing population (Aekplakom, et al. 2010). The estimation from a 
population projection study (UNFPA Thailand October,2006) reported that the 
proportion of elderly people (defined as people who age 60 years and over) in the 
population will increase to nearly 30% of the total population by 2050 and therefore it 
will increase the target population of CVD in the future.
The National Health Examination Survey (NHES) in Thailand 1992 to 2004 has
also demonstrated an increase in CVD risk factors and an increase in the prevalence of
hypertension from 5.4% to 22.0%, hypercholesterolemia 11.3% to 15.5%, diabetes
2.3% to 6.6% and regular smoking 20.6% to 25.3% respectively (Chooprapawan 1996,
Aekplakom, et al. 2010). A survey from the National Statistical Office (National
Statistical Office 2008, World Health Organization, Regional Office for South East Asia
2009) has identified the continuous decreasing trend of cigarette smoking during the
past 16 years due to the smoking ban policy. Recently, the global tobacco adults survey
(GATS) (World Health Organization, Regional Office for South East Asia 2009) in
Thailand 2008 revealed that 15% of the overall Thai population has smoked
manufactured cigarettes (29.6% men and 1.6% women), with more young adults
engaging in smoking practices. Recently, the result from the 4th National Health
Examination Survey (NHESIV) (Aekplakom, et al. 2010) found that 27.2% of the Thai
population had at least 2 CVD risk factors, which increased in women from 21.3% in
2004 to 25.2% in 2009, but remained the same 29.0% in men. Trends of obesity in the
Thai population aged between 18- 59 increased from 1997 to 2004, with a significant
increase in women. Perhaps, with the changing in life style, women are less likely to do
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exercise and have increasingly unhealthy diets. Men residing in urban areas were more 
likely to become obese, whereas women residing in rural areas were less likely to have 
class II obesity than women residing in urban areas. In addition, men with a high 
educational level were more likely to be clinically obese. There was a converse 
relationship in women, where lower educational levels displayed a likelihood of 
becoming obese (Aekplakom et al. 2007).
The cardiovascular risk factors also varied across administrative areas and
regions. The International Collaborative Study of CVD in Asia (Inter-ASIA
Collaborative Group 2003) was a complex cross-sectional study, which was conducted
to estimate the CVD risk factors in the adult population in Thailand during the year
2000. The mean level of CVD risk factors was analysed and the sampling weight was
applied to estimate the Thai population. It was found that the CVD risk factors in
Thailand were high. When comparing the CVD risk factors in urban and rural area,
smoking was higher in rural areas than other CVD risk factors. The mean level of blood
pressure, total cholesterol, BMI, fasting plasma glucose and diabetes in urban areas
were higher than in rural areas. However, the prevalence of high risk factor levels was
in mral areas. The results from the Inter-ASIA study in 2000 suggested that the highest
mortality rate of CVD was in Bangkok and the Central region. This might be the effect
of the variation of CVD risk factors and health behaviour across five regions in
Thailand. When comparing the risk factors across regions, it was found that Bangkok
and the Central region had a higher prevalence of hypertension, high BMI, abdominal
obesity, high LDL-c and diabetes mellitus, than the other regions. The highest
prevalence of smoking and high triglyceride was in North Eastern region
(Chongsuvivatwong et al. 2010). The association between the adiposity and serum
glucose level was investigated in the Inter-ASIA study, in Thai adults who were aged 35
years and over. The adiposity was measured by using the waist circumference and the
26
distribution of fat was measured by using the waist to hip ratio (WHR). An increase in 
the plasma glucose was a linear association with the increasing of body weight, BMI, 
waist circumference and WHR. The waist circumference and WHR showed more 
relationship with plasma glucose and diabetes status, than body weight or BMI. 
This finding suggested that measuring the abdominal obesity may be more suitable for 
the Asia population, than BMI (Stolk et al. 2005).
In terms of the association of the risk factors, to date, only one CVD cohort 
study has been undertaken in Thailand (Sritara et al. 2003). This study followed up 
3,499 adults aged 35- 54 years, who worked at the Electricity Generation Authority in 
Thailand (EGAT) from 1985 to 1997. There were 46 deaths from CVD during the 12 
year follow-up period. This was significantly related to age, systolic and diastolic blood 
pressure, smoking status, diabetes, male gender and total cholesterol. The association 
between CVD mortality and serum lipid profile was explored after 17 years of follow- 
up. There was a significant association between HDL-C and CVD in this cohort (Sritara 
et al. 2008). Arguably the EGAT employees were not representative of the Thai 
population, i.e. most were middle-class, living in urban areas, well educated, and with 
only 23% of the participants being female. Another study in this cohort (Khonputsa et 
al. 2010) reported that an increase of 1 mmol/1 in total cholesterol was associated with a 
fivefold increase in ischemic heart disease risk in adults aged 30-44 years but no 
significant association with stroke. The increase of 10 mmHg of blood pressure was 
associated with increasing the risk of ischemic heart disease and stroke, which the 
relative risk (RR) 1.31 and 1.46 respectively in this cohort.
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2.2.6 Summary
In summary, when comparing the overall trend of CVD in Thailand with the 
global trend, although it appears that Thailand is considered as being low-risk in terms 
of CVD with the flat trend of prevalence compared to other high-income countries such 
as UK and USA the trend of CVD morbidity is rising continuously while the mortality 
rate is also steadily increasing. Overall the global trend of CVD risk factors are 
increasing in terms of body mass index, serum cholesterol and blood pressure is 
declining. Trends for cigarette smoking vary by country and gender. Comparing this 
with Thailand, there is an increase within the population in obesity, hypertension and 
hypercholesterolemia whilst the trend of cigarette smoking is in decline. However, the 
prevalence of CVD is increasing overall as a result from the changes in the modifiable 
risk factors.
2.3 The risk assessment equations for CVD
In the past decade, CVD risk assessment equations have been developed as a 
tool to estimate the risk of individuals developing CVD conditions, such as MI, CHD 
and stroke. The risk assessment tools assist in identifying the target population and 
target intervention, which is necessary for the policy implementation for planning the 
primary prevention program. Many cardiovascular risk assessments are derived from 
cohort studies, which follow up people who are initially free from CVD for a long 
period of time, until they experience the cardiovascular conditions. Most prediction 
equations are derived from statistical regression models, such as the Cox proportional 
hazard model, Weibull model and the multiple logistic regressions. Then, the prediction 
algorithm examines the effectiveness in terms of calibration and discrimination in 
identifying potential casualties. The calibration of models refers to the accuracy of the 
algorithm when comparing the number of the observed instances of CVD, to the
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expected (Cui 2009). Discrimination refers to the capability of the algorithm to identify 
the target population who will contract a disease or who will be free from disease.
The advantage of using the risk assessment equation was the combination of the 
CVD risk factors. The set of factors that relate to CVD was included in the algorithm, 
which provides a better prediction than only considering a single risk factor. 
The concept of CVD risk prediction has been used in the clinical setting to calculate the 
absolute risk of the individual and raise the awareness of the ‘high risk’ group, to 
control or reduce the risk of CVD. The most classical risk prediction equation was 
derived from the Framingham heart study (Framingham Heart Study 2011), which has 
been used widely around the world and is recommended to be used as the standard risk 
assessment for the CVD in many countries, such as United States, Australia and New 
Zealand (Eichler et al. 2007). For example, the ACCF/AHA guidelines for the 
assessment of cardiovascular risk in the United States, recommended the use of 
Framingham’s equation or another similar type of multivariate risk score, based on the 
classical CVD risk factors, for assessing the risk of CVD in all asymptomatic adults 
(Writing Committee members 2010). The National Health and Medical Research 
Council (NHMRC), in Australia, reviewed the guidelines for the assessment of absolute 
CVD risk, which mainly uses the risk calculation from the Framingham study, to 
identify the level of CVD risk to low, moderate or high risk groups (National Vascular 
Disease Prevention Alliance 2009). The CVD risk assessment equations and risk score 
has been developed in many studies in order to estimate the total CVD risk in the 
asymptomatic people. Those equations were derived from the follow-up studies in the 
different setting.
The modified Framingham equation (Anderson et al. 1991), has also been 
recommended to be incorporated as the risk assessment for primary prevention, by the
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National Institute for Health and Clinical Excellence (NICE) in the UK. 
The recommendation has been changed to select the risk assessment algorithm most 
suitable to the population in 2010 (National Institute for Health and Clinical Excellence 
2011). However, the Framingham’s equation has been deemed suitable for populations 
who have the same baseline characteristics. Many cohort studies in other countries have 
been conducted in order to derive their own risk prediction equations and calibration, 
which are suitable to their populations, to be incorporated with the Framingham 
algorithm.
The purpose of this review is to explore the mathematical risk assessment 
methods, which have been used to estimate the CVD prevalence or incidence among 
populations and to establish the most appropriate CVD prediction equation suitable for 
use with the Thai population.
2.3.1 The Framingham’s equation
The Framingham Heart Study (Framingham Heart Study 2011), undertaken in 
Framingham, Massachusetts, USA, is the first known cohort study to be undertaken that 
focuses on CVD and identifies the risk factors. Over 60 years, there have been 5 cohorts 
enrolled in this study. The original cohort included 2/3 of the adult population in 
Massachusetts (5,209 participants aged 30 - 62 years). The second generation cohort 
was the offspring cohort, consisting of the 5,124 offspring and spouses of the original 
cohort who were aged <10 - 70 years. The third generation cohort were recruited by 
enrolling participants who had a least one parent in the offspring cohorts and aimed to 
explore the genetics and clinical association of the cohort. The 103 new offspring 
spouses cohort were enrolled in 2005 and the Omni cohort which recruited 506 
residents in 1994 with varied nationality, such as African-American, Hispanic, Asian, 
Indian, Pacific Islander and Native American origins. The Framingham's heart study
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identified the modified risk factors which contributed to developing CVD, such as 
smoking, cholesterol level, triglyceride, high density lipoprotein (HDL), blood pressure, 
body mass index (BMI), diabetes, age and gender. The Framingham study derived 
several versions of prediction equations and risk scores to predict the cardiovascular 
event among the population. The following CVD risk scores and risk equations had 
been developed in this study.
The parametric model was developed in 1990 from 5,573 participants aged 
between 30- 74 years, from the Framingham original cohort and the Framingham 
offspring. The equation developed had been calculated using the baseline risk factors 
such as age, gender, systolic and diastolic blood pressure, cigarette smoking, diabetes 
and ECG-LVH level. There are 6 major outcomes of interest. These include CHD, 
myocardial infarction, death from CHD, stroke, CVD (including all cardiovascular 
events, CHF and PVD), and death from CVD. The strength of the parametric statistical 
equation is in its ability to calculate the probability of each outcome at a particular point 
of time until cardiovascular events occur (Anderson et al. 1991).
In 1998, Wilson et.al (1998) derived the risk prediction score from the original 
and the offspring Framingham study, aged 30 -74 years old, with a 12 year follow up 
period by using the Cox proportional hazard model. This study derived the multivariate 
CHD risk score, which included blood pressure, total cholesterol, LDL cholesterol, 
HDL cholesterol and gender. The p coefficients of each risk factor from the model were 
used to calculate the risk of developing fatal and non-fatal CHD and MI and coronary 
insufficiency. It was suggested that the risk score for CHD, using the risk factor 
categories, generalize in middle-aged white population samples or individuals, with the 
same characteristic (Wilson et al. 1998).
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In the following year, a shorter time risk score for CHD was developed, to 
estimate risk over 1-4 years. The gender-specific risk equations were derived. The 
probability for initial and subsequent CHD could be calculated in the point estimation 
for 2-year risk to CHD or directly compute the risk at any time between 0 and 4 years 
by the Weibull accelerated failure regression model. The risk predictors in this equation 
were age, systolic blood pressure, cigarette smoking status, fasting lipid level, diabetes 
mellitus and the use of antihypertensive medication. Additionally, it also included the 
menopause status in the women’s risk function (D'Agostino et al. 2000).
The risk prediction equations for the recurring CHD had been derived in another 
study, using the Weibull accelerated failure regression model. This study recruited 
10,156 participants who were free from CVD and 1,176 participants who had 
experience of CHD or ischemic stroke. The recurring CHD events referred to 
subsequent CHD including mostly hospitalized events, consisting of myocardial 
infarction, coronary insufficiency, angina pectoris, and sudden and non-sudden coronary 
death, during a 4 year-period. The significant predictors for recurring CHD were age, 
lipid profiles (total cholesterol and HDL-c), and diabetes status (DAgostino et al. 2000). 
The Weibull model was more feasible than the Cox proportional hazard model because 
it can calculate the risk at any period of time.
The estimated 10-year risk score for the Hard CHD had been derived in 2001, 
which was published in the third report of the national cholesterol education program 
(NCEP) expert panel. The Hard CHD referred to MI or coronary death. The risk score 
was presented by gender-specifically for men and women which included age, total 
cholesterol, smoking status, systolic blood pressure and treatment for hypertension 
(Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in 
Adults 2001).
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The general 10-year risk algorithms for the first ever CVD event were developed 
in 2007 by using the Cox proportional hazards model. This study recruited 8,491 
participants from the original cohort and offspring cohort, who were free from CVD and 
had been followed up for 12 years (D’Agostino et al. 2008). The CVD events in this 
study referred to CHD, stroke, peripheral artery disease, or heart failure. Two versions 
of the risk algorithms had been derived, based on the traditional risk factors and the 
simpler version based on non-laboratory risk predictor, which can be used in the 
primary prevention care (Expert Panel on Detection, Evaluation,and Treatment of High 
Blood Cholesterol in Adults 2001).
A recent Framingham equation was derived in 2008 for estimating a 30-year risk
of CVD. It was a longer-term risk equation than the previous version of Framingham's.
The offspring cohort aged 20 to 59 years and free from CVD and cancer were being
used as baseline study population. The modified Cox model was performed and
adjusted for the competing risk of non-cardiovascular death, to derive the 30-year risk
of the Hard CVD events. The Hard CVD events referred to coronary death, MI and
stroke. The risk predictors in this equation were male gender, systolic blood pressure,
antihypertensive treatment, total and high-density lipoprotein cholesterol, smoking and
diabetes mellitus. However, the BMI was a weakly significant association; therefore, it
was not including in the equation. The advantage of this equation was in predicting the
long-term risk of CVD because the shorter period of the follow-up study may have
missed cases, which might occur in the longer time periods. Additionally, the treatment
effects might influence the short-term prediction equation. However, the limitation of
this equation was pointed out. For example, the generalizability to other ethnic groups
was limited because the base population comprised only of an all-white cohort, and the
novel biomarkers risk factors were not included in the equation (Pencina et al. 2009).
This 30-year risk prediction algorithm has been validated and compared to the earlier
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version of Framingham algorithm (Anderson et al. 1991), in the Australian population 
in 2009. The results suggested that the older Framingham equations overestimated the 
CVD risks in the low risk group and under estimated the CVD risks in the high risk 
groups. It is essential to undertake a review of the calibration and validation parameters 
when applying the equation to specific populations (Zomer et al. 2011).
In terms of stroke, the risk predication algorithm had been developed in 1991, 
within the Framingham's cohort using the Cox proportional hazards regression model. 
Participants aged between 55-84 years were recruited onto this study. The 10-year risk 
score of the first ever stroke has been derived. The risk predictors were age, systolic 
blood pressure, the use of antihypertensive therapy, diabetes mellitus, cigarette smoking, 
prior instances of CVD, atrial fibrillation and left ventricular hypertrophy by 
electrocardiogram (D'Agostino et al. 1994). The stroke risk function had been 
developed further in 1994 by using the Cox proportional hazards regression model in 
participants within the same age groups and having the same risk predictors. However it 
was adjusted for the use of antihypertensive medication and systolic blood pressure. It 
provided a new predictor variable to be included into the risk function. The risk score 
derived provided a more accurate result allowing for a better understanding in 
controlling the systolic blood pressure impact (below 110 or greater than 200 mmHg) 
(D'Agostino et al. 1994).
Another version of the risk function for stroke had been developed for 
individuals who had ever experienced atrial fibrillation but never had stroke or TIA and 
were not on Warfarin medication. The Cox proportional hazard model derived two 
versions of the risk calculation, which were the 5 years-risk of stroke and the 5 years- 
risk of the combination of stroke or death. The risk predictors were age, female gender, 
systolic blood pressure, prior stroke or TIA, and diabetes status. Although, this risk
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score was suitable for patients with atrial fibrillation, it may underestimate the stroke 
risk for the individual with left ventricular systolic dysfunction. The clinical diagnosis 
from echocardiograms was not included in this risk function, due to the limitation of 
using echocardiograms in the period prior to this study (Wang, Massaro and Levy 2003).
Several systematic reviews have been undertaken to verify the validity and 
accuracy of the Framingham’s equation (Brindle et al. 2006, Eichler et al. 2007). The 
reviews tend to demonstrate similar comparable results. Brindle et al (2006) studied the 
accuracy and impact of the Framingham risk score for assessing the primary prevention 
of CVD. This study included 2 systematic reviews. First, a review of the external 
validity of the Framingham, Anderson and Wilson's equation, to observe the ratio 
predictions in the different cohort studies, for the 10 years risk prediction. Second, the 
review of the effectiveness of the CVD risk score in a randomised control trial by health 
care professionals. The former results suggested that there were heterogeneity 
considerations across the population.
The Framingham equation underestimated the risk of CVD 0.43 (95%CI, 0.27- 
0.67) in the high-risk population, for example: patients with diabetes and patients with a 
family history of CVD. Conversely, it over predicted the risk of CVD 2.87 (95%CI, 
1.91-4.31) in the lower-risk population. The latter review found only 4 randomized 
control trials which investigated the risk score of CVD. It was concluded that there was 
no strong evidence for the performance of risk assessment in improving health 
outcomes, and there was insufficient information to conclude accurately the 
effectiveness of the risk assessment in clinical practice (Brindle et al. 2006). Beswick
(2006) suggested that the risk scoring was variably accurate when transferred to a 
different ethnicity and social context. However, the recalibration method was required 
specifically to relate to the population (Beswick and Brindle 2006). Eichler Klans, et.al
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(2007) conducted a systematic review of the Framingham score in 25 cohort studies in 
US and Non-US population. The review concluded that the Framingham score 
performed well in terms of predicting for a first coronary event, and was well calibrated 
for use in the US, Australia and New Zealand. However, it overestimated the 
cardiovascular risk in European cohorts (Eichler et al. 2007). Table 2.2 shows the 
summary of the Framingham's risk algorithms.
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2.3.2 The Asia Pacific Cohort Studies (APCS) Collaboration
The Asia Pacific Cohort Studies (APCS) Collaboration is the largest cohort 
collaborative project in Asia, which includes over 650,00 participants, in 44 setting 
within China, Hong Kong, Taiwan, Japan, South Korea, Singapore, Thailand and 
Australia (Asia Pacific Cohort Studies Collaboration 2007). The APCS developed a 
CVD risk equation which was adjusted and reestimated with the Framingham’s 
equations for the Asia population, with a limitation of risk factors data (only age, 
systolic blood pressure, total cholesterol and smoking status). This equation was derived 
from 172,077 Asia cohorts, 25,682 Chinese cohorts and 6,053 Framingham cohorts, 
during the 8 years of the follow-up period. The outcomes for this equation were any 
CVD event, such as cardiovascular death, non-fatal MI or non-fatal cerebrovascular 
event. This study derived both the Asia cohort cardiovascular risk prediction equation 
and the Framingham cohort equations for men and women. This prediction equation has 
been used to calculate the future cardiovascular events in the Thai cohort study data. 
When comparing the Asia cohort equation to the Framingham equation, it was found 
that the recalibrated Framingham equation overestimated the risk of CVD. Although 
the Asia cohort equations have used fewer parameters to estimate the risk of CVD, the 
Asia cohorts risk prediction equation is likely to provide the most reliable prediction 
tool for Asian populations. When compared to the recalibrated Framingham’s equation, 
it was explained that there were broadly similar associations of most risk factors and 
systolic blood pressure showed the strongest association to cerebrovascular disease in 
the Asia cohort, than Framingham cohort. Another explanation was related to the CVD 
and background risk factors that were similar across APCS cohorts. The missing 
variables of the recalibrated Framingham equation might not effect to the overall risk 
prediction.
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2.3.3 CVD risk assessment in Thailand
There have been few prospective cohort studies undertaken in Thailand. 
The only longitudinal study for CVD was established to explore the association of the 
modifiable risk factors. The setting was the Electricity Generating Authority of 
Thailand (EGAT) study, Bangkok, Thailand. This study was set up by a group of 
cardiologists from the Faculty of Medicine, Ramathibodi Hospital, Mahidol University. 
The EGAT study followed-up the 3,499 participants who were aged 35-54 years, since 
1985 (EGAT1) and continuously recruited an additional cohort later in 1998 (EGAT2) 
and 2009 (EGAT3) (Vathesatogkit et al. 2012). The RAMA-EGAT heart score was 
developed by using the Cox-proportional hazard model. There were 3 versions of the 
RAMA-EGAT heart score which were: a risk score for use in the clinical assessment; 
a risk score for the general population with included the serum lipid variable and 
a simplified version of the risk score without any requirement of the laboratory 
variables. The outcome prediction was the 10-year risk for Coronary Artery Disease 
(CAD). The traditional risk factors included in the RAMA-EGAT score were, age, 
gender, serum total cholesterol, cigarette smoking status, diabetes mellitus, hypertension 
and waist circumference. This risk score was validated by comparing the actual number 
of observed clinical diagnosis by medical doctors and the estimated number from the 
RAMA-EGAT heart score and Framingham risk score. The finding showed the 
precision of the RAMA-EGAT risk score compared to the Framingham risk score. 
Overall, the Framingham risk score was 243.14% overestimated. The clinical diagnosis 
by medical doctors was overestimated by 21.44% and the RAMA-EGAT risk score for 
the general population was over predicted by 55.86%. There were some limitations of 
using this risk score. The participants in the EGAT cohort were mainly men, only 22% 
of participants were women (Yamwong 2005).
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There were some limitations of the RAMA-EGAT heart score. Firstly, the risk 
score for use in the clinical assessment was developed based only on male data. 
However, a risk score for use in the general population was derived based on both men 
and women. It included gender as one of the prediction parameters of the risk score. 
Secondly, the RAMA-EGAT score was derived using middle-class participants who 
lived in urban areas. It was necessary to understand this constraint when applying the 
equation across different regions and socio-economic statuses. The finding suggested 
applying this risk score with the other Thai dataset to evaluate the performance of this 
risk score. However, the RAMA-EGAT score is the only available risk score based on 
the Thai population.
The validation of this risk score was evaluated in several studies in Thailand.
The RAMA-EGAT score was applied to the 1,224 patients with moderate to high risk of
CAD in Thailand. The risk score was evaluated against the CT angiography coronary
for diagnosing the coronary stenosis. It was found that the RAMA-EGAT heart score
was a good predictor for the CVD event, with a significant correlation between the
clinical diagnosis and the estimation from the risk score (Pattanapichakul et al. 2007).
The RAMA-EGAT risk score was also evaluated using the case-control study of the
ACS patients at Siriraj hospital, Thailand. The case group was comprised 163 patients
with CHD and a control group of 314 patients without CHD. The 3 versions of RAMA-
EGAT score were applied to estimate the risk to ACS. It was found that the risk
RAMA-EGAT for the general population, with serum lipid variables, was more
accurate that the version than that developed for use in clinical practice and the risk
score for general population without the lipid profile. The positive predictive value in
the general population version was 82% in males and 93% in females. This finding
suggested that the RAMA-EGAT score was an accurate predictor for screening for the
risk of ACS in the Thai population. Another study was evaluated in the HIV
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Netherlands, Australia, Thailand Collaboration (HIV-NAT) cohort study. This study 
followed 785 HIV-infected participants from 1996 to 2009. The Framingham’s equation, 
RAMA-EGAT and Data Collection on Adverse Effects of Anti-HIV Drugs (D:A:D) 
risk equations were applied to this cohort. The D:A:D risk equation was derived from 
the HIV-infected in 20 countries across Europe and Australia. All three equations were 
used to estimate the 10-year risk of CHD. The comparison results showed a similar 
agreement between RAMA-EGAT equation and D:A:D risk equations. This study 
indicated the suitability of using the RAMA-EGAT or D:A:D equation in this cohort, 
rather than using the Framingham equation (Edwards-Jackson et al. 2011).
In terms of the recalibrated Framingham equation in Thailand, Khonputsa et.al
(2011) has derived the recalibrated version of the Framingham equation which was
applicable for the Thai population. The two equations were developed to project the risk,
separately, for ischemic heart disease (IHD) and stroke within a specific time period for
both men and women. The Weibull accelerator model had been used to derive the
equations in the Framingham’s original and offspring cohorts and provided the
constants and regression coefficient, for each risk factor (Khonputsa, et al. 2011).
The risk predictors in this equation were age, systolic blood pressure, total cholesterol,
diabetes mellitus and cigarette smoking status. The equations were derived by
incorporating those constants and risk factors separately by gender. The equations were
then applied and compared to the average 10 year CVD observed risk ratio and the
estimated ten-years risk calculated from the Framingham equation. This equation was
applied to the 3rd National Health Examination Survey Dataset (2004), in participants
who were aged 30 years and over, to calculate the individual probability of getting IHD
or Stroke. It was found that the recalibrated Framingham equations decreased the CVD
risk predicted by 10% in Thai women and by 97% in Thai men. The performance of this
equation was tested by comparison with the Framingham’s APCS equations. Both
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recalibrated Framingham equations and the APCS equation were applied to the EGAT 
cohort study data set and projected the CVD risk over 8 years, in Thai men aged 30 
years and over. The equations showed a similar estimation of the 8 years CVD risk. 
This study suggested using the recalibrated Framingham equation rather than using the 
APCSC equations, because it was more feasible when estimating the risks separately for 
IHD and stroke (Khonputsa, et al. 2011). However, there were some limitations in the 
recalibrated Framingham equation because the equation was recalibrated with the 
cumulative risks and CVD incidence. The incidence of non-fatal IHD or stroke was 
estimated by using the national hospitalization database in 2004. The proportion of first- 
ever IHD or Stroke came from a study in UK (Rothwell et al. 2005) and applied to the 
dataset by age and gender. There was an absent of up to date information on the 
proportion of the first ever IHD and stroke specifically for Asia.
2.3.4 The other global CVD risk equations
2.3.4.1 The QRISK equation
The QRISK algorithm was the first and largest algorithm to have been 
developed to predict the CVD events in the United Kingdom. The QRESERCH 
database has been used as a prospective open cohort study. The participants, aged 35 to 
74 years were divided into two groups. These included 1.28 million participants, for 
derivation cohort, from 318 UK general practices and 0.61 million participants for the 
validation cohort, from 160 UK general practices. The outcomes that are of interest 
being CVD, including myocardial infarction, CHD, stroke and TIA or death from CVD, 
occurring within a 27 month period (Jan 1995 to April 2007). The risk factors included 
in the analysis were, age, gender, cigarette smoking status, systolic blood pressure, and 
ratio of total serum cholesterol (TC) to high density lipoprotein (HDL), left ventricular 
hypertrophy, family history of CVD, Townsend deprivation score and current
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prescription of at least one anti-hypertensive drug. The Cox proportional hazards model 
was performed to estimate the coefficients of the association between risk factors and 
CVD in both males and females. The QRISK algorithm was performed and validated 
with the Framingham's equation and the ASSIGN equation, for the population in UK. It 
was found that the QRISK equation was extremely accurate in predicting CVD in the 
UK population (over-predicted CVD by 0.4%), whereas the Framingham's equation was 
over-predicted by 35% and the ASSIGN by 36% (Hippisley-Cox et al. 2007). The 
QRISK algorithm has been validated in The Health Improvement Network (THIN) 
cohort database (Hippisley-Cox et al. 2008). It also showed that the QRISK algorithm 
was more suitable to the UK population than the Framingham's algorithm, which over­
estimated the risk by 23%.
In 2008, the QRISK2 algorithm was developed and validated, to estimate the
risk of CVD in England and Wales across different ethnic groups. The 10 years follow-
up opened cohort from the QRESEARCH database has been used to derive the QRISK2
equation, which included 2.3 million people and included the white population, south
Asian, black African, black Caribbean, Chinese, other Asian and other ethnic groups.
The outcomes were a prediction of CVD (CHDs, stroke and TIA).The risk factors
which were incoiporated in the risk algorithm were, self-assigned ethnicity, age, gender,
cigarette smoking status, systolic blood pressure, ratio of total serum cholesterol / high
density lipoprotein cholesterol, body mass index, family history of CHDs, Townsend
deprivation score, treated hypertension, rheumatoid arthritis, chronic renal disease, type
2 diabetes and atrial fibrillation. The differences between the QRISK 1 and QRISK2
algorithms were that the QRISK2 included more risk factor parameters, such as
ethnicity, deprivation and clinical conditions. When comparing the QRISK2 to the
modified Framingham equation, it was found that the QRISK2 was better at classifying
the higher risk groups of cardiovascular events, than the modified Framingham's
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equation, which was recommended by NICE (Hippisley-Cox et al. 2008). The QRISK2 
has been evaluated in a 10 year prediction performance, in an independent UK cohort 
study. Comparing the QRISK1 to the QRISK1 and the Framingham's equation, QRISK2 
demonstrated more accuracy in identifying the high risk CVD groups. However, the 
limitation of QRISK2 was the incompleteness of data for the total serum cholesterol and 
high density lipoprotein in the study population, which might introduce a bias in the 
analysis (Collins and Altman 2010).
The QRISK life time CVD risk function was developed further to estimate the 
lifetime risk of developing CVD which included stroke, TIA, angina or heart attack. 
The common risk factors with QRISK2 were included in this risk function, such as 
cigarette smoking status, ethnicity group, systolic blood pressure, ratio of total 
cholesterol and HDL-C, BMI, family history of CVD, Townsend deprivation score, 
treated hypertension, rheumatoid arthritis, chronic renal disease, diabetes mellitus and 
atrial fibrillation. There was some difference between QRISK2 and QRISK lifetime. 
The QRISK life time took into account the age and the risk of dying from the other 
causes. The smoking variable was classified to 5 categories according to the level of 
smoking habit; non-smoker, ex-smoker, light smoker (<10 a day), moderate smoker 
(10-19/day) and heavy smoker (>20/day). The advantage of QRISK life time was the 
capacity of the risk identification in the younger population, which was difficult to 
identify in the 10-year risk function (Hippisley-Cox et al. 2010).
Dent (2010) reviewed the prediction equations for CHD which are: the 
Framingham’s equation, SCORE, QRISK, PROCAM and ASSIGN. The review 
compared the strengths and limitations across the different algorithms. It was suggested 
that the recent development of the QRISK equation might be appropriate for the UK 
population, as the QRISK2 has good calibration predicting, when compare to the
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observed number of the cardiovascular events. In addition, the model also comprises 
ethnicity and socio-economic deprivation, which has not been included in the 
Framingham’s equation (Dent 2010).
2.3.4.2 The ASSIGN CVD risk score
The Scottish Heart Health Extended cohort (SHHEC) (Woodward, Brindle and 
Tunstall-Pedoe 2007) derived the ASSIGN score for predicting the risk of developing 
CVD. The cohorts were randomly selected from the Scottish MONICA project and the 
Scottish Heart Health study. A total of 13,297 participants aged between 30 to 74 years 
old were recruited to this study. The risk factors used including in the ASSIGN score 
were, age, gender, Scottish index of Multiple Deprivation, family history, cigarette 
smokers, the number of cigarettes smoked per day, systolic blood pressure, total 
cholesterol and HDL cholesterol. The main differences between the ASSIGN score and 
the Framingham equation are the addition of the social deprivation data, family history, 
and the quantity of cigarettes smoked. The outcomes of interest were death from the 
cardiovascular cause or discharging for CHD, cerebrovascular disease or for coronary 
artery intervention. The Cox proportional hazard model has been used to derive the 
ASSIGN risk score and then compare the number of observed and expected events to 
the Framingham’s equation. The ASSIGN score showed a similar estimation to the 
Framingham equation (Woodward, Brindle and Tunstall-Pedoe 2007). However, it 
found that the ASSIGN score and the Framingham score were likely to overestimate the 
risk of CVD. When the ASSIGN score was validated to the Framingham equation with 
the THIN database, it was found that both algorithms overestimated the risk, especially 
in the higher risk population. The ASSIGN over predicted by 20%, whereas the 
Framingham equation over predicted by 16% (De la Iglesia et al. 2010).
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2.3.4.3 The UKPDS risk engine
Because people with Type II diabetes have a significantly higher risk of 
developing CHD than the general population and there was no specific equation for 
predicting the risk in Type II diabetes patients, the UK Prospective Diabetes Study 
(UKPDS) (Stevens et al. 2001) derived the UKPDS risk engine to estimate the 
probability of getting CHD in Type II diabetes patients. Age, gender, ethnicity, cigarette 
smoking status, HbAlc, body mass index, systolic blood pressure, total cholesterol and 
duration of diagnosis to diabetes has been used in a parametric model. This risk engine 
was applicable for health care planning especially for diabetes patients.
2.3.4.4 The SCORE project
The SCORE project was a collaborative cohort study between 12 countries in 
Europe, (Finland, Russia, Norway, UK (England), Scotland, Denmark, Sweden, 
Belgium, Germany, Italy, France and Spain). The outcome of interest was the 10-year 
risk of death from CVD. This project focused on the mortality event as an outcome, 
because of the inconsistency of the end-point definition for morbidity in the other risk 
assessments. It also aimed to develop the comparable risk score for national level across 
Europe. The SCORE project derived the risk chart for identifying the high risk and low 
risk groups for the CVD according to age, gender, total cholesterol level, systolic blood 
pressure and cigarette smoking status. The risk score has been tested for the sensitivity 
and specificity under the ROC curve, which showed the area range from 0.71 to 0.84. 
However, the SCORE equation was limited to the principal risk factors and there are 
some associated risk factors which were not incorporated in the project, such as 
triglyceride, family histoiy and the impaired glucose level (Conroy et al. 2003). The 
fourth joint task force of the European Society of Cardiology and other societies on 
CVD prevention in clinical practice, suggested using SCORE as the standard risk
assessment for the population in Europe (Graham et al. 2007).
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2.3.4.5 The FINRISK function
The FINRISK function was developed for estimating the risk of coronary events 
and stroke for the population in Finland. The risk function was derived from the 
FINRISK CVD factors survey dataset, which was conducted in 1982, 1987 and 1992 in 
the population aged between 30-64 years. The logistic regression was used to derive the 
risk functions after 10-year of follow-up periods. The prediction outcomes were 
coronary risk, stroke risk, and all CVD risk. The risk factors incoiporated in the 
FINRISK function were age, gender, smoking status, serum cholesterol, systolic blood 
pressure, HDL-c, diabetes mellitus and the family history of infarction or stroke 
(Vartiainen et al. 2007).
2.3.4.6 ASCORE
A recent CVD risk score had been developed from the randomized clinical trial 
Anglo Scandinavian Cardiac Outcome Trial BPLA (ASCOT-BPLA). The ASCORE 
risk score was derived especially for the hypertensive patient. The study population was 
15,995 the hypertensive patients who were initially free from CVD and never received 
any CVD preventive intervention. The Cox proportional hazard model derived the 5 
year-risk function included age, gender, smoking, diabetes, blood pressure treatment 
history, systolic blood pressure, total cholesterol, HDL-C, fasting plasma glucose and 
creatinine. The ASCORE projected a 5-year risk of the first CVD event which was 
CVD death, myocardial infarction or stroke. The ASCORE performed a better 
prediction than the Framingham risk score which may overestimate the CVD risk in the 
hypertensive patients (Prieto-Merino et al. 2013).
2.3.4.7 PROCAM risk score
Prospective Cardiovascular Munster (PROCAM) study derived the PROCAM 
risk score for projecting the 10-year risk to the acute coronary event. This study was the
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prospective cohort study which followed 5,389 men who aged 35-65 years in Germany. 
The Cox-proportional hazard model was used to produce the risk function. The risk 
predictors were age, LDL-c, smoking, HDL-c, systolic blood pressure, family history of 
premature MI, diabetes and triglyceride. However, this version of risk score was 
suitable to use in men, middle age, white population (Assmann, Cullen and Schulte 
2002). The PROCAM study was developed further risk function to project the risk of 
MI and stroke based on the data from 18,460 men and 8,515 women in the north-west, 
Germany. The risk score for MI was derived by using the Weibull model. The risk 
predictors for MI were LDL-c, HDL-c, systolic blood pressure, smoking status, 
triglyceride and diabetes mellitus. The risk score for stroke was derive from the Cox 
proportional hazard model which included age, gender, diabetes status, smoking status 
and systolic blood pressure as the risk predictors (Assmann, et al. 2007).
2.3.4.8 The INTERHEART modifiable risk score (IHMR)
A new risk score for acute MI was developed from the INTERHEART study. 
This study was a large standardized case-control study in 52 countries which included 
19,470 participants in the analysis. The risk score was developed by using the multiple 
logistic regressions model. The risk predictors were, Apo lipoprotein, smoking, second­
hand smoke exposure, hypertension and diabetes. The strength of this risk score was 
more generalizable than the other risk scores, because the IHMR risk score was derived 
from data across the different ethnicities and global geographic regions. The case- 
control procedure allowed the recruitment of a larger number of participants than the 
prospective cohort study. However, it was argued that the case-control study, was not 
the ideal risk score for predicting the future instances of MI, because the case-control 
study did not allow to calculate the incidence or the absolute risk of disease, as risk 
functions that derived from the prospective study (McGorrian et al. 2011).
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2.3.5 The CVD risk assessment in Asia
Several studies have applied the global CVD risk assessment algorithm to the 
Asia population. The Framingham risk score, JBS2 and QRISK2 have all been applied 
to calculate the 10-years risk of CVD, in the south Asian samples (Gujarati Indian 
origin), in the UK. It was found that all the three risk scores presented the moderate risk 
in agreement but QRJSK2 estimated the proportion of participants who had 10-year 
risk >20% higher than the Framingham risk score (Rao et al. 2012). The Newcastle 
heart project also explored the CVD-risk engines by comparing Framingham risk score 
(1991), FINRISK and SCORE in the south Asian population (Bangladeshi, Pakistani 
and Indian). Those risk scores had calculated the risk of CVD mortality. 
The Framingham risk score and FINRISK showed similar results, while the SCORE 
presented lower 10-year risk estimations. The performance of SCORE was difference 
than the others, because it did not included HDL and diabetes as part of the predictors 
(Bhopal et al. 2005). The Singapore cardiovascular cohort study compared the 
predictability of the Framingham risk score, with the metabolic syndrome for estimating 
CVD mortality. By comparing the area under the ROC curve, the Framingham risk 
scores (Wilson et al. 1998) performed better in predicting CVD mortality than the 
metabolic syndrome, in healthy Chinese, Malays and Asian Indians (Lee et al. 2008).
2.3.5.1 The Chinese Multi-provincial Cohort Study (CMCS)
The Chinese Multi-provincial cohort study (CMCS) was a longitudinal study in 
11 provinces in China (Liu, Hong and D'Agostino 2004). This study followed 30,121 
participants aged between 35 to 64 years, from 1992 to 2002. This study derived
the 10-year risk prediction equation for the ‘Hard CHD’, which referred to acute MI, 
sudden death or other coronary death. This study derived 2 versions of the CHD risk 
functions which were, the CMCS risk functions and the recalibrated Framingham’s
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equation for the population in China. The Cox-proportional hazard model had been used 
to derive the risk functions. It was found that the CMCS risk factor categories 
associated with the Hard CHD were similar to the Framingham risk function. Those risk 
factors were, age, smoking status, diabetes status, blood pressure, total cholesterol and 
HDL-C. When comparing the predictive capacity of the original Framingham equation 
with the CMCS equation, the original Framingham equation overestimated the absolute 
CHD risk. However, the recalibrated Framingham version, which was taken into 
account for the mean value of the risk factors and mean CHD incidence rate, enhanced 
the performance of the equation (Liu, Hong and D'Agostino 2004). Another risk 
algorithm for the population in China was derived from the USA-PRC, (USA -People's 
Republic of China) Collaborative Study of Cardiovascular Epidemiology cohort, that 
followed up 9,903 participants in China for 17 years and followed-up the participants 
every 2 years. The 10-year risk equation estimated the Ischemic Cardiovascular Disease 
(ICVD) such as ischemic stroke and coronary event. The simply 10 year risk score for 
ICVD had been derived. The Cox proportional hazard model showed statistically 
relationship of age, systolic blood pressure, total cholesterol, BMI, smoking status and 
diabetes mellitus. This risk algorithm was applied to the CMCS data set and compared 
with the recalibrated Framingham equations. The ICVD equation performed well in 
terms of the discrimination power, which considered the area under ROC was 
approximately 0.79 in both men and women. It also showed accuracy and precision 
when compared to the number of observed and estimated of CVD. Although, the 
recalibrated Framingham’s equation showed the better prediction in the previous study, 
it demonstrated an overestimate in both Chinese men and women in this study. This 
result was controversial with Lui et.al (2004) arguing that the recalibrated Framingham 
risk function may not be applicable for the Chinese population because it projected the
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CHD alone. The CVD risk function should include both stroke and CHD together, 
because stroke was a predominant cause of death in China (Wu et al. 2006).
2.3.5.2 The JMS Cohort Study
The JMS cohort study was a community-based longitudinal study in 12 rural 
districts in Japan, which followed 12,276 participants aged 19-93 years. The 10-year 
risk score for stroke was derived by using the Cox proportional hazards model. The 
prediction outcomes were 10-year risk score for all stroke risk, cerebral haemorrhage 
and cerebral infarction. The risk factors associated in the risk function were gender, age, 
smoking status, diabetes mellitus and systolic blood pressure. Those risk factors were 
common between cerebral haemorrhage and cerebral infarction. Although the JMS risk 
score was suitable for the Japanese population, the setting of this cohort was in the rural 
districts. Therefore, it should be used with caution when applying this risk score to 
populations in urban areas (Ishikawa et al. 2009).
2.3.5.3 WHO/ISH Risk prediction charts
In 2007 WHO provided the CVD risk prediction chart for 14 WHO 
epidemiological sub-regions (World Health Organization 2007), which included Africa, 
the Americas, Eastern Mediterranean, Europe, South East Asia and Western Pacific 
regions. The charts are used to estimate the 10-years risk of fatal or non-fatal, major 
CVD events such as MI or stroke for men and women who are aged 40 years and above. 
The risk charts are specifically used for each sub-region. Age, gender, systolic blood 
pressure, total cholesterol and cigarette smoking are used to estimate the individual risk 
of getting CVD in the next 10-years. However, there were 2 sets of the risk charts for 
use, one where the blood cholesterol measure data is available and the other set for 
when this data is unavailable. However, the risk equations were not published. 
Otgontuya et.al (2013) applied the WHO/ISH risk charts (World Health Organization
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2007) to a cross-sectional survey conducted in Cambodia, Malaysia and Mongolia 
during 2005 to 2010 and estimated the prevalence of CVD over 10-years period 
(Otgontuya et al. 2013). It was found that using this risk assessment may underestimate 
the prevalence of CVD in people who are in the high risk group. Additionally, it also 
underestimated the treatment need in the high risk group, because it did not take into 
account the treatment effect in such instances as drug treatment for 
hypercholesterolemia and hypertension.
Table 2.3 presents the comparison of the CVD risk equations. The strengths and 
limitations in each equation are presented as follow;
Table 2.3 Comparison of the risk equations
Risk functions Target
populations
Outcome
prediction
Strengths Limitations
Framingham US, white 
population
10 years 
risk to 
CVD, 
maximum 
projection 
is a 30 
years CVD 
risk
1) Well-known 
equations
2)Feasible to 
calculate the risk 
of the different 
CVD outcomes
3)Recommended 
as the standard 
guideline
1) Not
generalizable 
with other 
ethnicities
2) Needs a 
calibration 
when applying 
to specific 
populations.
QRISK2 UK population 
and across 
different ethnic 
groups
10 years 
risk to 
CVD 
(CHD, 
stroke and 
transient 
ischaemic 
attack)
New and up to 
date risk score 
with the accurate 
validation among 
UK population 
and some other 
ethnicities
The equations 
were not 
revealing in 
the research 
article.
However, the 
risk calculation 
engine was 
available 
online.
QRISK lifetime UK population 
and across 
different ethnic 
groups
Life time 
risk of 
CVD
First ever risk 
assessment 
equation that is 
capable to 
calculate the life
The same 
limitation as 
QRISK2
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Risk functions Target
populations
Outcome
prediction
Strengths Limitations
time risk
ASSIGN Scottish
population
10 years 
CVD risk
Specific risk score 
for Scottish 
population and 
included the social 
deprivation 
variables
Over predict in 
the high risk 
population
UKPDS risk 
engine
UK diabetics 
patients
Risk to 
CHD
Risk engine 
specific for 
diabetic patients
Population
specific
SCORE European
population
10 year risk 
of death 
from CVD
Use as the 
standard risk 
assessment for the 
European 
population
Predict only 
the death from 
CVD
FINRISK Finland
population
10 year risk 
of all CVD, 
CHD and 
stroke
Accurate among 
the population in 
Finland
Risk function 
derived from 
the cross- 
sectional data
ASCORE Scandinavian
cohort
5 year risk 
of CVD
Valid for the
Scandinavian
population
Population
specific
PROCAM German
population
10 year risk 
of acute 
coronary 
events
Valid for the
German
population
Population
specific
INTERHEART International 
based on 52 
countries 
worldwide
Risk for 
acute stroke
New risk score for 
predicting stroke 
in the international 
level
Based on the
case-control
studies
Chinese multi 
provincial 
cohort study 
(CMCS)
Chinese
population
10 year risk 
of the Hard 
CVD
Valid for Chinese 
population
Population
specific
JMS cohort 
study
Japanese
population
10 year risk 
for stoke
Valid for Japanese 
population
Population
specific
APCS cohort 
study
Asia population 8 year risk 
of CVD
Generalizable for 
the Asia 
population
Capable to 
project the risk 
only for CVD 
overall
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Risk functions Target
populations
Outcome
prediction
Strengths Limitations
WHO/ISH risk
prediction
charts
14 WHO
epidemiological
sub-regions
10 year risk 
of fatal or 
non-fatal, 
major CVD 
events
The risk chart has 
been specifically 
used for each sub- 
region.
The equations 
were not 
published.
RAMA-EGAT 
risk score
Thailand
population
10 year risk 
of CVD
First ever CVD 
risk specific for 
Thai population
1)RAMA- 
EGAT
Published the 
risk score but 
not published 
the equation
2)RAMA- 
EGAT mostly 
base on Thai 
men, middle 
age and living 
in Urban area
2.3.6 Summary
This section presented the concept of the classical prediction model for CVD,
which mostly use the risk equations or the risk score that have been derived from
regression models such as the multiple logistic regressions, Cox proportional hazard
model and Weibull model. Those risk functions were used widely to assess the risk of
getting CVD events, such as total CVD, CHD or stroke, in both fatal and non-fatal
events. The risk function was used as a standard guideline for assessing the risk of the
individual in many countries and also assessing the risk to identify the high risk
population for prevention and control. However, there were some limitations when
applying the risk equation to a diverse population. The Framingham’s equations
overestimate the risk of CVD in the low risks population and under estimates in the high
risk populations for several reasons. First, the Framingham equation was derived during
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the high prevalence and high risk factors level in the US middle-aged white population, 
while some risk factors in other countries tend to decrease, for example with the decline 
of cigarette smoking. Secondly, the improvement of CVD treatment and medication has 
reduced the incidence and mortality of CVD in the population. Thirdly, the 
Framingham’s equation has not included some associated risk factors, such as the socio­
economic deprivation and ethnicity.
Although the prediction equation is not capable of calculating the exact number 
of future CVD events, it is an effective tool for assessing the risk of developing CVD in 
the future. Those equations had been used in routine CVD risk assessment, which was 
more accurate than the assessment by using only a single risk factor. This thesis will use 
the equation from the calibrated Framingham version for the Thai population and the 
APCSC cohort study as it represents CVD in the Asia/Pacific region and has been 
applied in the Thai population. Additinally, these equations was available in the 
publication and the list of independent risk factors in the equations are applicable to 
apply in the Thai data. The selection criteria of the CVD risk equation has explained in 
chapter 3. However, as discussed, the APCSC equation uses fewer parameters than the 
Framingham equation and it is possible to overestimate the CVD event. Therefore, it 
will be necessary to adjust with the Framingham algorithm.
2.4 Health economic modelling for CVD
This section reviews the application of the health decision modelling techniques 
related to the CVD, which have been conducted in many studies. The various types of 
model which have been applied to estimate the Future CVD events are, decision tree 
model, Markov model, Discrete event simulation or micro-simulation, cell-based 
simulation and system dynamic simulation. The impact of the primary prevention of the 
CVD risk has been estimated in terms of mortality saving, morbidity saving, life year
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saving and economic saving. This review presents the up to date literature of CVD 
decision modelling, which has been used for the health economic evaluation and policy 
implication.
Modelling for economic evaluation has been used widely in public health in 
many countries and is increasingly used in the UK (Brennan, Chick and Davies 2006, 
Barton, Bryan and Robinson 2004). The increase in the variation of health care 
interventions and new technologies such as pharmaceuticals, surgery, diagnostic tests 
and primary prevention interventions, leads to increased consideration for the policy 
planner, to manage and allocate budgets and resources which are limited in availability. 
Drummond et.al (2005) defines economic evaluation as “the comparative analysis of the 
alternative courses of action in terms of their cost and consequence” (Drummond, et al. 
2005). The decision analytic model was developed by performing the mathematical 
algorithm, to capture the relationship between the series of consequences and the 
evaluation of the alternative options. The consequences address the probability or a 
chance of getting to events and it can calculate the cost and outcome of each 
consequence. For example, Mar et.al (2008) developed the Markov model for 
calculating the stroke prevalence and economic impact of thrombolytic treatment (Mar, 
Sainz-Ezkerra and Miranda-Serrano 2008). The expected cost and expected outcome 
can be estimated by the decision model; however the variability and uncertainty should 
be taken into account (Briggs, Sculpher and Buxton 1994). The decision modelling, 
such as the cost-effectiveness modelling, provides the information for a decision maker 
to prioritise and select the most suitable interventions for a health problem (Briggs, 
Claxton and Sculpher 2006). In addition, it is able to estimate costs, effectiveness or 
benefits and evaluate treatment decisions.
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The following section provides an overview of the decision modelling 
techniques which have been used in health economic evaluations. The aim of the review 
is to address which type of economic decision model will be most appropriate to use 
within the study. The review focuses on the decision trees model, the Markov Model, 
the discrete event simulation model and the other types of health economic modelling, 
which are most often used for the health economic evaluation (Briggs, Claxton and 
Sculpher 2006). The review includes the theoretical concepts of modelling, the 
comparison of strengths and limitations of the model, and the previous studies of health 
economic modelling which relate to the estimation of the future burden of CVD and the 
primary prevention intervention.
2.4.1 The Decision tree model (DTM)
The decision tree model is the most commonly used model for economic 
evaluation (Briggs, Claxton and Sculpher 2006). The model illustrates the health 
situation as a tree like diagram. The expected costs and outcomes are calculated by 
summation of the pathway weight by the probability of each pathway.
Whitfield et al (2006) developed the cost offset model which was a spreadsheet 
based decision tree model. The model applied the Framingham algorithm and the 
UKPDS risk engine, to estimate the economic impact of CVD risk reduction strategies. 
The findings found that a 2-4% risk reduction in CVD would save the cost, in acute 
admission rates, of about £5.4 million over 5 years and prevent approximately 4,000 
people from having cardiovascular events from a population base of 185,000 (Whitfield 
et al. 2006).
Liew et.al (2006) demonstrated the health effect from the hypothetical
intervention of primary prevention strategies for CVD by conducting a decision-
analysis tree and underpinning life-course analysis and Markov processes. Uncertainty
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and sensitivity analyses were undertaken by Monte Carlo simulation (Liew et al. 2006). 
This study showed the strength of the models in terms of its generic nature and is 
applicable to any population which has data available. The model included both CHD 
and Stroke which have shared risk factors and treatment. The model was also shown to 
be capable of simulating temporary factors, such as lag-time and discontinued therapy, 
and allowed for uncertainty analysis.
The decision tree model draws the explicit picture of the relationship and the 
progression of each pathway. However, the limitation of the decision tree model is that 
it does not take into account the outcome over time. (Drummond, et al. 2005, Briggs, 
Claxton and Sculpher 2006).
2.4.2 Markov Model
The Markov Model is more complex than the decision tree model. It is 
commonly used in decision analysis when the progression of diseases and risk are 
dynamic, when time is involved and with possible recurrence of events occurring over 
time. The Markov model moves forward by using the transition probability of the 
beginning stage to the next stage. The Markov chain model is used widely for health 
economic evaluations (Briggs, Claxton and Sculpher 2006).
The CHD policy model (Weinstein et al. 1987) was a Markov state transitional
model, which was originally developed for projecting the CHD event in the US
population. The CHD policy model consisted of three sub-models: the demographic
epidemiologic sub-model, the bridge sub-model and the disease history sub-model. The
demographic-epidemiologic sub-model simulated the distribution of risk factors and the
incidence of CHD in a general population. The bridge sub-model simulated the events
in the first CHD patients. The disease history sub-model simulated the event for people
who previously got CHD. The model was built up based on the number of the US
61
population in 1980 and estimated the risk by using the data from the national health and 
nutrition examination survey (NHANSII). The Framingham’s equation was applied to 
calculate the probability of getting CHD event in the population. The outcomes of the 
projection were the number and rate of fatal and non-fatal CHD, number of people who 
survived until age 85 years old with and without CHD; number of CHD events 
including cardiac arrest, MI, angina pectoris and the cost of intervention including both 
therapeutic intervention and prevention intervention up to 30 years period. However, the 
CHD policy model assumed that the CVD risk factors would remain stable, even as the 
time changed (Weinstein et al. 1987). This model also estimated the impact of coronary 
risk factors reduction and the change in CHD events among the US population between 
1980 and 1990. It was found that the decline of CHD prevalence was substantially 
related to the risk reduction interventions, such as changing life styles and habits, which 
resulted in life saving and health care cost saving of approximately $5400 per year of 
life save (Goldman et al. 2001).
The CHD policy model (Moran et al. 2008) was applied to project the change of 
the Future CHD in China and the impact due to the change of demographics. The CHD 
policy model, which was calibrated for China, was applied to estimate the future 
prevalence of CHD. The CHD event, CHD mortality and DALY were calculated. 
The results from the model showed a continuously increase of CHD events in the 
Chinese population during 2010 to 2029, because of the growing age of the population 
(Moran et al. 2008). This result was confirmed by the further development of the CHD 
policy model. The model simulated the CHD event at a national scale, which projected 
the CHD event in China’s population aged 35-84 years (Moran et al. 2010). This has 
allowed the projection of trends for stroke and CHD from 2010 to 2030. The finding 
reported a 23% increase in a cardiovascular event during a 20 year period. It
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demonstrated that although the level of risk factors remains, CVD will possibly increase 
with the effects of an ageing population and a continuous population growth.
The Rotterdam ischemic heart disease and stroke computer simulation (RISC) 
model was developed by using the Monte Carlo Markov model in the Netherlands 
(Kempen et al. 2012). This model aimed to estimate the effect of the modifying risk 
factors on the burden of CVD, as well as performing the internal validation with the 
Rotterdam 5-years of follow-up study. The model simulated the 13-years risk of getting 
CHD, stroke, CVD death and non-CVD death, in the Rotterdam cohort. The Monte 
Carlo Markov model was performed with six states: 1) the CVD death state; 2) non- 
CVD death state; 3) CHD state; 4) Stroke state; 5) CHD and stroke state; and 6) the well 
state (alive without any CVD conditions). The probability of changing the health state 
was calculated from the Cox-proportional hazard model. It was found that the risk of 
CVD event was increase from year 5 to year 12. In terms of the validation, the model 
performed well when comparing the number of observed and expected occurrences 
within 5-10 years period.
The Markov’s model for projecting the burden of stroke was conducted in South 
Korea (Kang et al. 2011). The Markov state transitional included the post primary 
stroke event, alive post stroke and dead. The model simulated the life time stroke by 
using the transitional probability, based on the epidemiological study in South Korea 
and the literature review. The life time cost of stroke was calculated and included both 
the health care aspect and economic aspect, such as the cost of treatment and cost of the 
loss of productivity. It was estimated that people who start getting stroke at age 45 years 
have the year of life lost from stroke was 15.5 years for men and 17.62 years for women. 
The life time cost for stroke also depended on the age of onset, which means that the
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younger the age of getting the first stroke, the more life time costs to pay (Kang et al. 
2011).
The evaluation of the effectiveness of the primary prevention and the risk 
reduction strategies to reduce the CVD events was studied in some previous studies 
using the Markov’s state transitional model. Pletcher et.al (2009) estimated the impact 
of the primary prevention strategies on lowering cholesterol level, to the reduction of 
CHD risk. The CHD policy model was applied to the US population aged 35 -  85 years. 
The input parameters were the risk factors from the National Health Survey during 1999 
to 2004, vital statistics, cost of treatment for statin and other publish data. 
The Framingham risk function was used to calculate the probability of getting CHD. 
The model projected the number of CHD events between 2010 to 2014 and the impact 
of lowering serum cholesterol based on the public health impact of adult treatment panel 
III (ATPIII) guideline. The ATPIII guideline recommended treatment for the serum 
cholesterol lowering based on the cholesterol level and the calculation of the individual 
CHD risk. It was found that lowering the cholesterol level, according to the ATPIII 
guideline, with statin would prevent 20,000 events of MI and 10,000 CHD deaths per 
year and the incremental cost effectiveness of statin contributed to $42,000 per quality 
adjusted life year (QALY).
Martin et.al (2004) developed the Markov’s model for projecting the 20 year 
survival from CVD in the UK cohort aged 35 to 65 years. The Whickham cohort was 
used as the baseline data. The transitional probability was derived from the 
Framingham’s equation. The model evaluated the accuracy with the number of 
observed events in this cohort. The impact of changing the coronary risk factors, such as 
cigarette smoking, has been evaluated. It was found that the model’s performance 
closely estimated the actual survival events. The elimination of CVD risk factors would
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gain an increased life expectancy of 4 years for all 35 year old men and 1.8 years for all 
35 year old women. It was concluded that the model performed an accurate prediction 
in the CVD free people, who had systolic blood pressure below 180mmHg and 
underestimated for people who had systolic blood pressure over 180 mmHg (Martin, 
Vanderpump and French 2004). Mistry et.al (2012) investigated the cost-effectiveness 
of the primary prevention intervention for CVD by using the Markov’s modelling 
approach in the EUROACTION study across 6 countries in Europe. The purpose of 
modelling was to compare the cost-effectiveness of the CVD primary prevention 
intervention, to the usual care, after implementing the intervention for 1 year in the high 
risk group. The intervention group received the lifestyle changing intervention and 
management for controlling blood pressure and lipids. At an individual level, Markov’s 
model was used to simulate the CVD events over an 11 years period, in both the 
intervention group and the usual care group. The transitional probability came from the 
published literature, expert opinion and the Framingham equation. The incremental cost 
per QALY gain was calculated, to compare the cost-effectiveness of the intervention 
group against the usual care group. It was found that changing the lifestyle intervention 
was more costly and more effective over the usual care approach (Mistry et al. 2012).
Another study in Sweden also estimated the effects of a primary prevention
program, to reduce the CHD in the elderly population, using Markov’s model (Lindgren
et al. 2003). The primary intervention focused on the dietary program, exercise and
combining both dietary and exercise. The Markov’s model was developed with the
CHD states, such as without CHD, first year of MI, second year of CHD events, the
following year of disease and death. The Framingham equation was used to calculate
the risk of CHD. The model predicted the effect of the primary intervention and
presented the cost-effectiveness of the intervention, life year gain and the cost per life
year gain. It was found that the most cost-effective intervention was a dietary program
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which contributed to save 0.0228 life years compare to no intervention (Lindgren et al. 
2003).
Cobiac et.al (2012) identified the most cost-effectiveness intervention for 
primary prevention in Australia by developing a discrete time Markov model. 
The model projected the ischemic heart disease and stroke event over the life time, in 
the general population aged 35 to 84 years, and estimated the impact of the mix-primary 
prevention programs such as lifestyle change, pharmaceutical intervention and the 
population wide primary prevention intervention. There were four health states in the 
Markov model, which were: fatal or non-fatal IHD, and fatal or no-fatal stroke. The 
cost-effectiveness analysis was presented in both cost per QALY and cost per DALY. 
The finding from this study suggested that the most cost-effective invention was the 
limitation of salt in the manufactured food product, which would produce more impact 
than the pharmaceutical intervention. However, changing the lifestyle intervention and 
exercise did not produce a strong impact in this study (Cobiac et al. 2012).
The Markov model is more flexible than the decision tree model but the 
restriction of the Markov model is the assumption that the model has no memory for the 
previous states. For example, once patients move to the next state, the model has no 
memory of which state they came from and will treat all patient as homogenous. 
Therefore, it might be difficult to model more complex prognoses using the Markov 
model (Drummond, et al. 2005, Briggs, Claxton and Sculpher 2006).
2.4.3 Discrete event simulation (DES)
The discrete event simulation is sometimes referred to as micro-simulation or
individual sampling models. It performs the advance simulation at the patient-level by
tracking the individual’s progression to each stage, instead of using aggregated data.
The discrete event simulation allows simulating the events of an individual, when the
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state can occur more than once. The model is transited by the probability of the 
individual. The variation of time of the individual throughout the process is included in 
the analysis, which allows more complexity and flexibility such as the time. It is 
suitable for modelling complicated disease conditions or specific health problems 
(Briggs, Claxton and Sculpher 2006).
The CVD policy model was the microsimulation model in Australia. This model 
projects the incidence of CHD and hospitalization (Mui 1999). The model found a 
decline of 13% and 24% in the incidence of CHD in the male and female population 
respectively. However, the model projected an increase in the number of 
hospitalisations by 40%, this largely being due to the increasing aging population. This 
study suggested that the micro-simulation model is advantageous for projecting and 
planning in the future health problem, however, the availability of data required is a 
concern. Battes et.al (2013) discussed the benefits of the microsimulation technique 
over the classical regression model and Markov’s model. The microsimulation was 
more feasible in calculating the lifetime risk and incorporated the change of some risk 
factors over time, such as patient age. It allowed estimating the multiple outcomes of 
the individual patients with the time dependent or the repeated outcomes which might 
occur in the patients. These were the strengths of micro simulation when compared to 
the regression analysis, which just calculates single events over a certain period of time 
and Markov’s model which has no memory of the previous health state (Battes et al. 
2013).
The PREVENT model(Gunning-Schepers 1989) was a microsimulation model 
which was originally developed for predicting the effects of changes in risk factor 
prevalence and the health effects in the population levels in the Netherlands. 
The results from the PREVENT model provided suggestions to use in policy making to
67
help determine the target population and compare scenarios with and without 
intervention, on the change of the future prevalence of events (Gunning-Schepers 1989). 
The PREVENT model showed a reasonable estimation when testing the model validity 
against other models. The model was applied to predict the mortality of IE1D in the 
Danish population, with the effect of reducing the CVD risk factors, such as 
hypertension, hypercholesterolemia, cigarette smoking and physical activity (Bronnum- 
Hansen and Juel 2000). The PREVENT model took into account the change of risk 
factors over time. The input parameters in the model were the population size during 
1993 from Statistics Denmark, the cause-specific mortality rate for the year of the 
model start, the all causes mortality and the relative risk of each individual risk factors. 
The risk factors data came from the various sources such as: the prevalence of 
hypertension and hypercholesterolemia from part of the MONICA study, the prevalence 
of smoking from the nationwide survey, and the physical activity data from the Danish 
Health and Morbidity Survey. All those risk parameters came from the same period of 
the year onset in the model. It was showed that the most effective intervention on the 
reduction of IHD mortality was the reduction of smoking. The IHD would be reduced 
by one-third within 10 years from reduction of the prevalence of smoking, to be 10% 
lower for men and 15% lower for women. The other risk reduction interventions which 
affected the IHD mortality, was the reduction of the prevalence of hypercholesterolemia 
by 25%, and undertaking gentle exercise of at least 4 hours a week, would reduce death 
from IHD by 3-6%, at ages below 65 years (Bronnum-Hansen 2002).
The Canadian’s Population Health Model (POHEM) (Will et al. 2001) was a 
dynamic microsimulation model which was developed by Statistic Canada. The model 
was designed based on the interaction between the set of risk factors and specific 
chronic diseases. The individual-level data on health care cost, the health-related quality
of life and the Health Utility Index Mark 3 (HUB) were included in the analysis.
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The POHEM model is currently developing a sub-model for specific chronic diseases. 
The common risk factors such as smoking, BMI, total cholesterol and blood pressure 
were incorporated into the model. There are four disease specific sub-models which are: 
a heart diseases model, a diabetes model, an osteoarthritis model and a cancer model. 
The dynamic model was allowed to simulate the continuous-time, the population age 
change, the co-morbidities, the change in risk factors and the progression of disease. It 
provided a lifetime projection for a large population representative for Canada (Statistic 
Canada 2010, Will et al. 2001).
Babad et al. (2002) described the development of a new CHD Policy Model
which uses the discrete event simulation technique. This study was a collaborative
project between the Department of Health at the London School of Hygiene and
Tropical Medicine (LSH andTM) and the University of Southampton and the University
of Birmingham (Babad et al. 2002). The model was purposed to estimate the impact of
the primary prevention strategies to prevent CHD for the UK population. A discrete
event simulation model was created to simulate the CHD events of the individual, with
their CHD risk profile. The CHD events were simulated for each individual by sampling
from the probability distribution. It allowed the change in risk factors, disease status and
event rates by taking into account new distribution parameters and the sample of
discrete event time. A number of data were required to conduct this model. The health
survey for England (HSE) was used as the baseline data for the population characteristic
and coronary risk factors. The Framingham study was used to derive the time-to-
disease-event distribution and provided information on the natural history of CHD, with
the capability to distinguish between the CHD states, to stable or unstable angina, MI or
Stroke. The Framingham equation was considered for use for the risk calculation. The
British Regional Heart Study (BRHS) was used to calibrate the results with the
Framingham study. The model contained the modifiable risk factors such as age, gender,
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systolic blood pressure, total cholesterol and smoking. The outcome events were: stable 
or unstable angina, MI (heart attack), sudden cardiac death, stroke death, other CVD 
death, cancer death, and death from the other causes. The effect of primary prevention 
programs were evaluated in the model, such as the reduction in blood pressure, 
cholesterol and smoking. The treatment parameters were determined to further analyse 
such changes as the uptake rate, compliance rate and the effectiveness. The model was 
running the PASCAL simulation, which was known as POST (Patient Oriented 
Simulation Techniques). The data from the health survey for England was manipulated 
to generate a population size factor in the database. The model will run for the life-time 
of each individual. This model was under the development process. However, there was 
no published literature to date about the results from the model.
The World Health Organization (WHO) and the Organization Economic Co­
operation and Development (ODEC), developed the chronic disease prevention model 
named the CDP model (Sassi 2010). The CDP model is a dynamic micro-simulation 
model, which is capable of estimating the impact of health investment on the 
intervention to prevent chronic diseases. The web of causation was used to link the 
causal relationship between the modifiable risk factors and the occurrence of chronic 
diseases. The CDP model individually estimated the health outcome by age, gender and 
socio-economic status. The strength of the CDP model was that it is unique from the 
other exiting models. The simulation was designed for the dynamic risk factors and the 
environmental factors, with the continuously interaction and capability to simulate the 
complexity of the reality. It was the first and only model too date, which simulates the 
health behaviour and obesity to chronic diseases, with the pooled data analysis from 
individuals across 30 countries (Sassi 2010). Cecchini et.al (2010) used the CDP model 
to investigate the health effect due to the unhealthy behaviour such as unhealthy diet,
physical inactivity and obesity, in 6 low-middle income countries: Brazil, China, India,
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Mexico, Russia, and South Africa. It was found that increasing the price of the 
unhealthy diet and reducing the price of a healthy diet, had the largest effect on the 
heath gain from chronic diseases in the short term. The intervention that targeted on 
child obesity, such as the restriction of food advertising, was more effective than the 
school-based intervention (Cecchini et al. 2010).
The discrete event simulation has some limitation with regard to data availability 
and the computational burden. The model requires individual data, such as patient 
characteristics, remission and recurrent experience, type of intervention undertaken and 
the time the individual remained in each stage. The model provides a precise evaluation 
when all data are available. The computational burden is discussed in terms of the 
complexity of the model, which requires time for development, especially in a large 
cohort data set. Furthermore, there is difficulty when performing, in terms of the 
uncertainty of the expected cost and outcome, because the sensitivity analysis has to run 
all uncertainties of every parameter in the model. It also requires specialist software and 
hardware to perform the analysis (Briggs, Claxton and Sculpher 2006).
2.4.4 The other types of CVD modelling
Other types of CVD modelling include the mathematic model which have been 
developed for specific purposes of different studies.
The IMPACT model was developed to estimate the CHD death in England and
Wales betweenl 981-2000 (Unal, Critchley and Capewell 2005). This IMPACT model
was a cell-based mortality model, which was developed in a Microsoft Excel
spreadsheet. The detail of the IMPACT model was described elsewhere in an online
website (www.healthimpact.org.uk). The IMPACT model was validated to estimate the
change in CHD mortality in several countries such as UK, USA and China (Critchley et
al. 2004, Unal, Critchley and Capewell 2004, Ford et al. 2007). The IMPACT model
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was used to investigate whether the primary prevention in a healthy population, was 
more effective than the secondary prevention, (Unal, Critchley and Capewell 2005). 
This model estimated the numbers of CHD patients, treatment, trends of CVD risk 
factors and mortality saving, due to the reduction of specific risk factor changes in a 
healthy population and in patients with CHD. The model used a 35.5 million population 
base, aged between 25 to 84 years. The estimation of change in risk factors and 
mortality in the general population, was calculated from the regression equation from 
the systematic review of the MONICA study. The impacts of risk factors change 
involved smoking, total cholesterol and blood pressure. Patients in this model were 
divided into group categories which were: an acute MI, survival of MI, 
revascularization patients, patients with unstable angina, chronic angina and chronic 
heart failure. Statin and other treatment interventions were taken into account as the 
impact of secondary prevention in patients. This study estimated that reduction in 
primary prevention had a fourfold impact on the larger reduction in the mortality of 
CHD, when compared to the secondary intervention. The decline of 35% in smoking 
effected the reduction of around 29,715 deaths in the UK population. The fall of serum 
total cholesterol of 4.2% contributed to 5,770 fewer deaths. Blood pressure reduction by 
7% resulted in saving approximately 5,870 deaths. Overall the reduction in those three 
major risk factors resulted in 81% fewer deaths in a health population and 19% fewer 
deaths in CHD patients.
2.4.5 Selection of the appropriate modeling approach
Selection of the appropriate modeling approach is a crucial step for the model 
developer to construct an effective model which can identify the whole picture of health 
problems according to the objectives and the characteristic of the data. Several studies 
have been reviewed in order to select the most appropriate health economics modeling 
for this study.
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Kamon and Brown (1998) showed the difference approach of the decision tree, 
Markov model and the discrete event simulation model by demonstrating the breast 
cancer scenario and comparing the strengths and limitations of each method. These 
authors suggested that the decision tree was suitable to model an event and intervention 
in a short-time period. The Markov chain models are suggested as being most 
appropriate when events occur over a long period. The discrete event simulation was 
modeled by shifting the probability of the individual in each stage which showed more 
flexibility than the decision trees and Markov model. If using adequate and reliable data, 
it can provide confidential information. However, it requires time and specialist 
software to conduct the model (Kamon and Brown 1998). Kamon (2003) also compared 
the Markov model to the discrete event simulation by demonstrating the calculation of 
the cost-effectiveness in the alternative adjuvant therapies for breast cancer. Even 
though the discrete event simulation was more flexible and more complex than the 
Markov model, both models showed similar results. Therefore, the discrete event 
simulation is appropriate to use when the available data points out specific characteristic. 
This is due to the time and resources required to build up the complex model while the 
simpler analytic modeling can answer the same questions (Kamon 2003).
Barton (2004) suggested the model selecting approach which is illustrated in the
diagram below (Figure 2.4). When selecting the type of model, it need to consider the
potential interaction between the individual, the level of modeling need (cohort or
individual), path way structure and the number of the extensive stages. For example, if
the health problem address the interaction between the individuals or having a complex
number of stages the discrete event simulation is more appropriate to use than the
decision tree or Markov model (Barton, Bryan & Robinson 2004). Brennan (2006)
described the model structural and the selection criteria which is classified by a
taxonomy of the models. The taxonomy classified the economic evaluation model by
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the modeling level (cohort or individual), the interaction allowance and time 
consideration. Brennan provided the checklist for selecting the model which 
emphasized the need to consider the timing for cost and health outcome, whether or not 
heterogeneity population, the population size, the interaction between individual and the 
need of the sensitivity analysis (Brennan, Chick & Davies 2006).
No
Is individual-level 
modeling needed?
Yes
No Yes
Can patient pathways be^ 
represented adequately by 
Nv\  p robab ility trees?/^
Yes
No
"Can a Markov model bh- 
built without needing an 
\excessive number 
states? 
^ V ' N o
Yes
Is interaction between 
individuals important?
Decision tree
Markov model
Modeling problem
Discrete event simulation
System dynamics model
Individual sampling model
Figure 2.4 Diagram for selecting an appropriate model (Barton, Bryan and 
Robinson 2004)
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Table 2.4 Comparison of the health economic decision modelling techniques
Content Decision Tree Markov
Model
Discrete-event
simulation
Other types 
of modelling
Key
Methodology
To determine
the optimal
strategies
when it has
decision
alternative
under
conditions of 
uncertainty
To model the 
health state 
and the effect 
of
intervention 
over the state 
transition by 
time of an 
evaluation 
into cycles.
To simulate the 
patient-level for 
the specific 
events
experienced for 
each individual. 
It usually uses 
Monte-Carlo 
simulation 
method.
To estimate 
the future 
health
problems and 
the impact of 
the
interventions
Use for 1)Any 
decision 
process which 
can be
classified into 
the tree-like 
structure
2)Event occur 
over a short 
time period
1)The
progression of 
disease
2) The 
ongoing risk 
which occur 
more than 
once, 
(recurrent 
event)
3) The 
progression 
through the 
different state
1) Modelling 
the specific 
events which 
are experienced 
by the 
individual.
2) Event 
oriented based 
on each 
individuals.
3) Simulate the 
time to event
1) Estimating 
the future 
events and 
the impact of 
the
intervention.
2)Specific 
purposed of 
study or 
specific 
population
Structure Tree-like
structure
Cycle of the 
transition state 
depend on the 
disease
Pathways are 
tracked 
independently 
by the
individual data 
over time
Various
Move state by Probability Probability of 
transition 
(assume that it 
is constant 
over time)
Transition 
probabilities 
vary by time of 
the individual in 
each state.
Various
Timing Untimed Timed Discrete or 
continuous 
timed
Untimed
Interaction No No Allowed No
Benefit 1) Capable to 
project the 
outcomes and 
evaluate the 
optimal 
alternative.
2)Develop the 
clinical
1) Possible to 
model the 
repeated set of 
the outcome 
over time.
2) Allow to 
model for 
long time
1 )Allow more 
complexity of 
the model 
2) Incorporate 
each individual 
history and the 
interaction 
between the
1)Capable to 
project the 
health 
outcome 
events.
2) Reflect a 
large
population
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Content Decision Tree Markov
Model
Discrete-event
simulation
Other types 
of modelling
guideline
3)Clearly and 
exactly for 
explaining and 
criticizing
4) Capable to 
measure the 
variability of 
the number of 
individual in 
each state.
5)Reflecting 
to a large 
population 
assumption
period. individual 
which is 
suitable for 
modelling the 
infectious 
diseases.
3) More 
Flexible and 
confidential.
assumption
3)Capable to 
design for the 
specific 
population
4) Capable to 
apply when 
the data is 
limited.
Limitation 1) not able to 
calculate the 
recurrent of 
diseases and 
looping
2)suitable 
only for a 
short period of 
time
1) When 
moving to the 
next state, the 
model will not 
memorize the 
previous state. 
It focuses 
only on the 
current cycle.
2) Has a fixed 
length of the 
operation 
cycle.
1)Require 
specific 
software to 
construct
2) Cannot 
perform without 
the adequate 
data.
3) Require the 
specialist 
analysis, control 
and validation, 
or else it will be 
lead to the miss- 
interpretation.
4) Demand for 
time to develop 
model
5) Concern for 
the over 
complexity.
1) The model 
is static and 
not taking 
into account 
the time or 
the change 
over time.
2) May not 
capture all 
complexity of 
the event as 
in the reality
2.4.6 Summary
In summary, this section reviewed the principal concepts of decision modelling 
techniques, which are widely used in health economic evaluation in many countries 
(Brennan, Chick and Davies 2006, Barton, Bryan and Robinson 2004). Table 2.4 
Comparison of the health economic decision modelling techniques provides a summary 
of each type of model in terms of the key methodology, advantages, timing, interaction,
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benefits and limitations. Overall, the decision tree and Markov model use the 
aggregated data while the discrete simulation uses the individual level data.
According to Barton (2004) and Brennen (2006) criteria for selecting modeling 
approch, this study will focus on modeling data at population level with no interaction 
between the individual and the population aggregated data of risk factors. So, the 
discrete event simulation are not considered in this study. Hence, during the period of 
study, there are lack of the information on the CVD probability, particularly in Thailand 
such as the transitional probability of the disease progression, the probability of the 
severity of disease, the remission rate, the recurrence rate and information related to the 
time to event of CVD patients. This is why we can not consider the Markov model or 
the Simulation model for the analysis. In this end, this study will develop a CVD model 
for Thailand, which adapted the concept of the cost offset model. The model was mainly 
to focus to incorporate the risk assessment algorithm to estimate the number of CVD 
events (such as a number of hospital admission and death from CVD) over 5 to 10 years 
period if population level risk factors such as smoking, systolic blood pressure and 
cholesterol level can be reduced or contain.
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2.5 Disability Adjusted Life Years (DALYs)
2.5.1 The concept of summary measures of population health
Health indicators are used for comparing the health status between populations 
or between times, studying on the inequality of the health status, such as the difference 
between gender and the socioeconomic status, measuring the size of the health problems, 
prioritizing the health problems, planning for the health investment and assessing the 
health outcome (Global Forum for Health Research et al. 2006). In the past, single 
health indicators such as the mortality rate or morbidity rate were widely used to reflect 
the health problems in the population, by measuring the mortality event or the mortality 
event and disability (Murray, Salomon and Mathers 2000). However, using the single 
health indicator captures the health situation in only one dimension. The summary 
measures of population health are the composite health indicators, which are combined 
of both fatal and non-fatal health outcomes, to measure the health status in the 
population. They are divided into two concepts: the health expectancies and the health 
gaps (Robine, Romieu and Cambois 1999), which are explained below;
1) The health expectancy is the years of living with full health or the healthy life 
year span, which is adjusted for the year of living with disability or year of living with 
illness. It demonstrates the quality of life and is mostly used in cost-effectiveness 
analysis. Some indicators are adjusted for the disability free or healthy life year such as 
the Disability Free Life Expectancy (DFLE), Disability Adjusted Life Expectancy 
(DALE) or Health Adjusted Life Expectancy (HALE).
2) The health gaps present the difference between the ideal health status and the 
actual health status. It calculates the gap between the years of premature death, illness or 
disability and the year of living with full health. For example, the DALYs are the
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indicator that measures the health gaps between the year of life lost and the year of 
living with disability.
2.5.2 Disability adjusted life years (DALYs)
DALYs are one type of the health indicator to measure the overall health status 
in the population, which combines mortality, morbidity and disability and use it as one 
indicator to compare with the different health problems. This indicator had been 
developed by researchers at Harvard University, World Bank and the World Health 
Organization (WHO) in 1993 (Lopez, et al. 2006) . It was widely used in prioritizing 
health problems, planning for health investment and assessing the health outcome. To 
calculate DALYs, it requires various data sources, such as the number of death by ages 
and gender, size of the population, the epidemiological data, such as the prevalence rate, 
incidence rate, remission rate, case-fatality rates or the relative risks, duration of 
diseases and the age at onset of the diseases (Murray 1994, Devleesschauwer et al. 2014, 
Rushby and Hanson 2001).
The DALY calculation formulas are as follows:
DALY = YLL + YLD (2.1)
YLL = N x L (2.2)
Where, N is the number of deaths, L is the age-specific life expectancy
YLD = I x D W x L  (2.3)
Where, I is number of new cases or the incident case in the period of time, DW 
is the disability weight and L is the duration of illness
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2.5.3 Years of Life Lost (YLL)
The Years of Life Lost (YLL) is one of the components of DALYs. It measures 
the number of years of the life that are lost from premature death and compares thi to an 
average life expectancy of the individual in each age group, based on the underlying 
assumption that the life years lost are different in each age groups. The life table is used 
to calculate YLL and the unit of measurement is life years (Mathers et al. 2005). There 
are four methods that are used to calculate YLL, based on the different patterns of death 
and the type of life tables (Murray 1994) which are: 1) Potential Years of Life Lost 
(PYLL), 2) Period Expected Year of Life Lost (PEYLL), 3) Cohort Expected Year of 
Life Lost (CEYLL) and 4) Standard Expected Year of Life Lost (SEYLL). Each method 
is described below.
1) Potential Years of Life Lost (PYLL) is the measurement of the years of life 
lost due to the premature death prior to the referenced age. The number of life years are 
compared with the life years lost at the specific age, e.g., PYLL(70) refers to year of life 
lost compared to the death at age 70. The data from the death registration system and 
the case fatality data from the Ministry of Public Health are used in the calculation. The 
benefit of using PYLL is it presents the loss from premature death and has the capability 
to be compared across the different populations. However, the limitation of PYLL is 
that people who die at ages beyond the reference age are not included in the calculation 
and there are no standards for detennining the reference age. PYLL is calculated by 
using the formula below.
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PYLL= YJdx{ L - x ) (2.4)
x=0
Where, L is the highest age which expects everybody will dead , d x is the
number of deaths in each age group and x is the Age at death.
2) Period Expected Year of Life Lost (PEYLL) is the number of years of life lost 
from premature death which is calculated by using the period life table. The data 
sources that are used in this method are: the number of deaths by age and gender from 
the death registration system, case fatality data and the national life table. The benefit of 
using PEYLL is that it uses the period life table, which can be used to calculate the life 
years lost in a specific age group.
PYLL = Y^dxex (2.5)
x=0
Where, ex is the expected age of living in each age group, dx is the number of 
deaths in each age group and L is the highest expected age of death.
3) Cohort Expected Year of Life Lost (CEYLL) is the number of life years lost 
from premature death which is calculated by using the cohort life table in each 
generation. The data from death registration, number of case fatalities by age group and 
the cohort life table are used in the calculation. CEYLL is well suited to present the life 
years lost in the cohort but it cannot be used to compare over long periods of time 
because the cohort life table changes. It is a generation and country specific formula. In 
the case of Thailand, there are no cohort life tables available to perform this calculation.
L
CEYLL = '£Jdxecx (2.6)
, v = 0
Where, ex is the age interval of living in each age group from the cohort life 
table, dx is the number of deaths in each age group and L is the highest age of death.
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4) Standard Expected Year of Life Lost (SEYLL) is the number of life years lost 
due to premature death which use the standard life table (West level 26) in the 
calculation. Using the standard life table in calculating SEYLL allows the comparison 
of the number of life years lost across countries and over time. However, SEYLL is not 
suitable for some countries which have high life expectancy, such as Japan, Sweden, 
Australia and Switzerland, because their populations live longer than the highest age in 
the standard life table. The data required to calculate SEYLL are from the death 
registration, case fatality data and the standard life table (West level 26). The burden of 
diseases and injury, (BOD) studied in Thailand also used the SEYLL to calculate the 
number of years of life lost because of the availability of mortality data and using the 
standard life table (West level 26) for the life expectancy by age and gender.
SEYLL = f jdxesx (2.7)
x=0
Where, esx is the expected age of living in each age group from the standard life 
table, dx is the number of deaths in each age group and L is the highest age of death.
2.5.4 Years of life lost due to disability (YLD)
YLD is one of the components of DALY s. It presents the number of years of life 
lost during the disability from health problems. It requires data from the disability 
incidence, the disability duration and the age onset of the disability. The disability 
weights are used in the calculation according to the level of severity of disease (Vos et 
al. 2013).
YLD = I x DW x L (2.8)
Where, I is the number of new cases or the incident case in the period of time, 
DW is the disability weight and L is the duration of illness.
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2.5.5 Disability Weights (DW)
The disability weights are the valuations of the health status and the severity of 
disease, based on the social perspective of the health problems or disability compare to 
the ideal health status. The maximum value of disability weights is 1 which refers to 
death and the minimum is 0, equivalent to the perfect health. The disability weight is 
used to calculate the years lost due to disability, (YLD), by multiplying it with the 
number of cases and duration of illness. In this study the disability weights of the 
cardiovascular and circulatory disease from the global burden of disease study in 2010 
are used (Murray et al. 2012a).
2.5.6 Discounting
Discounting is the method used for adjusting the future value to the present 
value. The present value means the value of cost, utility and benefit at the present time, 
which is adjusted for the changing of value in the future. When implementing the 
interventions in the health care system, discounting is involved in both the monetary 
benefit and the health benefit. In terms of the monetary benefit, the discounting will be 
taken into account with the opportunity cost and the time preference. For example, if 
one deposits a £1000 in the bank for 1 year, it will earn interest at a value of £2.50 per 
year. However, if one spends a £1000 on investment, there may be more benefit than 
saving the money in the bank. The time preference referred to the uncertainty of the 
value and the declining of marginal utility. This assumed that the present value is more 
valuable than the value of money in future. If personal income is increasing in the future, 
the value of £1 in the present will be more than £1 in the future. In terms of the health 
benefits, there is the uncertainly of the health problems in each individual age group and 
the opportunity to die from the disease. The discounting will determine the value of 
death in different age groups; therefore the value of years of death in younger people is
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different from an older age group. WHO and the World Bank Health Sectors use the 
discounting rate at 3% to transfer the value of a year in the future to the current year. 
For example, when using 3% of the discount rate, it means 1 healthy year in the next 10 
years is less than 24% of the current year. Therefore, if there is a gain of 1 healthy year 
in the next 10 years, it will equal to 0.76 of the current year.
Discounting formulas
1) Present value
Costpv = Cost 
(1 + r)‘
(2.9)
Where, Costpv is the present value of cost, Cost is the future number of money
that must be discount, r is the discounting rate, t and the number of time (in year) where 
the discount rate has been applied ( r and t have to be in the same range of time)
2) Discounting continuous streams of life
2.1) Discrete formula
‘PV = (l + r ) 0'5 x —x r
1
n
1 -
1 +  r
(2 .10)
2.2) Continuous formula
y i p y  — — xe  
r
(2 . 11)
Where, nPV is the present value of the number of years, n is the number of
years that must be discount, r  is the discounting rate , 0.5 is the weighting value and 
e is the exponential function.
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2.5.7 Age weighting
The age weighting is used to value the year of life according to the age 
preferences. If there are 2 patients who are aged 20 years old and 3 years old are 
admitted to the emergency unit at the same time, most people may decide to save the 
life of 20  years old patient because of the external factors, such as the family 
relationship, family bonding and social prospective. The age weighting will focus only 
on the age difference and will not consider the external factors. However, there are 
some arguments for using the age weighting to value the life of people. In terms of the 
human capital approach, it is assumed that the value of years of life is difference 
between different ages. Labour age gains more productivity than children and the 
elderly. They have the potential to produce more than they consume and can support the 
other age groups. Therefore, saving the life of a labour age person will gain more 
benefit than saving the life of a child. On the other hand, when considering the life lost 
approach, most people will choose to save the life of younger age groups over older age 
groups, because more life years can be saved in children than in the elderly. In addition, 
rather than considering the benefit in a static time, it should take into account the future 
benefit. When the government implements the intervention for children, such as health 
care or education, they will gain more benefit in the future and increase the future 
productivity. In terms of the cost-of-illness approach, it will focus only the differential 
of age groups but does not include any other factors. Children and elderly are both 
considered as the dependency age groups, which require the support of the labour force 
age group. The mathematical formulation of differential age weights is shown below.
85
Age weight = Cxe^x (2.12)
Where, p is the relative age weight function, which determines the important value of 
each age groups. C is the adjustment constant, WHO using c= 0.1658 in the global 
burden of disease study.
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Figure 2.5 The age weight functions (p)
Source: (Murray 1994)
2.5.8 Summary
DALYs are the combination of the measurement which can present the health 
status of the population in both morbidity and mortality. It is capable of comparing the 
health status in different populations and over different periods of time. In addition, 
DALYs presents the burden of disease for the non-fatal health outcomes. It can be used 
in prioritizing health problems for the health policy because it presents the health 
problem in the same unit of measurement. These are the benefit of DALYs over the 
other single health indicators, such as the mortality rate, incidence or prevalence rate.
For example, when using the only the mortality rate, prioritising the health problem in 
Thailand in 2000, the top 5 health problems were cancer, road traffic injury, CHD, 
hypertension and stroke. On the other hand, when using DALYs to prioritise the health 
problems in the same years, the top 5 health problems were AIDS, road traffic injury, 
CVD, cancer and suicide. Furthermore, it also widely used in the cost-effectiveness 
analysis of health intervention. However, there are some limitations of using DALYs. 
First, it needs various data sources to calculate the DALYs. Furthermore, there are some 
arguments in the method of calculation, such as using the disability weight from the 
expert opinions, using age weight, which values the year of life in younger people more 
than the older people. Moreover, the definition of the cause of death and disability uses 
a single cause, so it may not cover the complication of diseases and the multiple causes 
of death and disability.
2.6 The public health risk reduction strategies for CVD
This section reviews the public health risk reduction strategies to reduce the 
prevalence of CVD in the population. The reviews focus on both global target risk 
reduction goals and the national goals specifically for Thailand.
2.6.1 The global target risk reduction strategies for CVD
In 2011, The United Nations (UN) General Assembly declared the 25 x 25
millennium goal, to reduce the global mortality of four non-communicable diseases by
25% by 2025 (United Nations General Assembly 2011). Those four non-communicable
diseases (NCD) are CVD, chronic respiratory diseases, cancer and diabetes. The six risk
factors were targeted, which were: 1) reduction of 30% in prevalence of tobacco
smoking, 2) reduction of 10% in alcohol consumption per person, 3) reduction of 30%
of salt intake in average the population, 4) Stop the rising in the prevalence of obesity, 5)
reduction of 25% of the prevalence of high blood pressure and 6) Stop the rising in
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prevalence of diabetes (The NCDs alliances 2014). Furthermore, WHO also set the 
additional goals of treating the NCD patients which are providing 80% coverage of the 
NCD medicine and technologies and 50% coverage of the drug therapy and counselling 
(World Health Organization 2014). Kontis et.al (2014) estimated the impact of 
reducing risk factors, according to the UN 25 x 25 millennium goal by conducting the 
systematic analysis and meta-analyses (Kontis et al. 2014). It was found that if all six 
risk factors are reached in a population who are between 30 to 70 years old, the 
probability of dying from those 4 non-communicable diseases will decline by 22% in 
men and 19% in women, between 2010 and 2025. Additionally, it will also save a 
number of premature deaths by approximately 37 million worldwide.
Table 2.5 The UN millennium goal target risk reduction in the population
Risk factors Target risk reduction in the 
population
(UN millennium goal by 2025)
Smoking Reduce 30% in prevalence of tobacco 
smoking
Alcohol use Reduce 10% of alcohol use per person 
consumption
Salt intake Reduce 30% in average population 
intake
Obesity Stop rising in prevalence
Blood pressure Reduce 25% of the prevalence of high 
blood pressure
Blood glucose and Diabetes Stop rising in the prevalence of 
diabetes
2.6.2 The target risk reduction strategies for CVD in Thailand
The 11th National Health Development Plan in Thailand (2012-2016), states that:
“All Thai citizens are healthy and take part in creating a sufficient health system 
with equity, leading to social wellbeing” (Ministry of Public Health 2012).
The goals of the 11th National Health Development Plan are targets to reduce 
morbidity from preventable diseases and unhealthy lifestyles, improve the quality of the 
health care system and health care service providers, improve the disaster monitoring 
system and put in place an active health promotion and disease prevention plan. The 10 
years targets of this plan are to increase the life expectancy at birth of Thai people to 80 
years of age and state that the healthy life expectancy should be at least 72 years. For 
the target strategies related to CVD in Thailand, It was stated that within 3-5 years, the 
mortality rate for CVD (included both MI and stroke), should be less than 20 per 
100,000 population and 90% of Thai people who are aged 15 years and over receive 
screening for diabetes and hypertension. Every single year, at least 50% of the diabetes 
patients who are identified are capable of controlling their blood sugar levels. At least 
40% of newly identified hypertension patients could control their blood pressure and 
100% of diabetes and hypertension patients, who have these disease complications, are 
treated and have access to the health care services, (Bureau of Non-Communicable 
Disease,Department of Disease Control,Ministry of Public health 2013).
According to the Thailand healthy lifestyle strategic plan (2011-2020), the aims
are to reduce the non-communicable diseases due to an unhealthy life style, namely:
diabetes, hypertension, heart disease, cerebrovascular disease and cancers (Ministry of
Public Health 2011). The risk reduction strategies are promoting the sufficiency life
styles, which are having a balanced diet, undertaking adequate physical exercise and
having suitable emotional management. This strategy is divided into three phases, short
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term (1-3 years, 2011-2013), medium term (5 years, 2011-2015) and long teim (10 
years, 2011-2020). The main development goals of the short-term strategies are: 
emphasize the collaborative policies on the healthy diet, advocate physical activity and 
healthy environment for all target populations at central, regional and provincial level. 
Increase the satisfaction with the health policy in the target population and improve 
their health behaviours to prevent the occurrence of chronic disease due to lifestyle. 
Increase fruit and vegetable consumption and decrease the sweet, salty, fatty, 
chemically contaminated food intake and decrease alcohol consumption and tobacco 
smoking. The medium-term goals are targeting on the metabolic risk factors, which are 
decreasing obesity among children younger than 15 years old and obesity in adults who 
are aged 15 years and older, increasing an active physical lifestyle, decreasing blood 
cholesterol and the prevalence of metabolic syndrome among population age 15 years 
and older, increasing the skill of emotional management amongst the population age 15 
years and older and reducing the proportion of the disease complication among the 
patients who have the chronic diseases. The ultimate long-term goals of this plan are 
increased disease-free, and disability free life expectancy of the Thai population, a 
decrease in the mortality rate of the lifestyle diseases, a decrease in the health care 
expenditure of treatment of the lifestyle diseases and no increase in the prevalence of 
the lifestyle diseases.
2.6.3 The target CVD risk reduction for the individual in Thailand
According to the national guideline for reducing CVD risk factors in the Thai 
population, there are three groups in the target population, diabetes mellitus patients, 
hypertension patients and the general population (Bureau of Non-Communicable 
Disease,Department of Disease Control,Ministry of Public health 2013). The general 
population’s level of risk of CVD is classified by the probability of 10-years risk to
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CVD events of the individual, calculated by using the CVD risk assessment from 
WHO/ISH (Otgontuya et al. 2013). The low risk group of CVD refers to people who 
have 10-years risk lower than 10%, the medium risk group are 10% to <2 0 %, the high 
risk group are 20% to <30% and the severe risk group are more than 30% of 10-years 
CVD risk. The multiple CVD risk factors are targeting on blood pressure, blood glucose, 
total cholesterol, LDL, HDL, Triglycerides, cigarette smoking, weight, waist 
circumference, physical activities and food consumption. For blood pressure control in 
diabetes patients, the target risk reduction strategy is using the suggestions from an 
evidence-based guideline report, from the panel members appointed to the 8th Joint 
National Committee, 2014 (JNC8) (James et al. 2014), for the management of high 
blood pressure in adults. The following table summarizes the target of reducing CVD 
risk factors for the individual in Thailand.
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Table 2.6 The target CVD risk reduction for the individual who aged 40 years and
over in Thailand
Target DM patients HT patients General population 
(no DM and HT 
conditions)
Blood pressure 
(mmHg)
<140/90* <140/90 <140/90
(age<60years) and 
<150/90 (age>60 
years)
Blood glucose
FPG(mg/dL) 70-130 60-100
HbAlc(%) 6-7
Lipid Profiles
Total Cholesterol 
(TC)mg/dL
<280 (for medium risk group**)
<200 (for high and severe risk group***)
Low Density 
Lipoprotien (LDL) 
mg/dL
<160 (for medium risk group) 
< 100 (for high risk group) 
<70 (for severe risk group)
HDL (mg/dL) >40 (men) 
>50 (women)
Triglyceride <150 (mg/dL)
Cigaratte smoking Smoking cessation
BMI 1 8 .5 -2 4 .9  kg/m2
Waist circumference < hight/2 (cm)
Physical activity Moderate physical activity, at least 30 minutes/time and 5 times/week
Food consumption Reducing sweet, fatty and salty food consumption
Increasing fruit and vegetable consumption
Source: (Bureau of Non-Communicable Disease,Department of Disease 
Control,Ministry of Public health 2012)
*The JNC 8th guideline (James et al. 2014)
**Medium risk group refer to 10-years risk probability o f CVD events 10-<20%
***High risk group refer to 10-year risk probability o f CVD events 20-<30% and Severe risk group refer 
to 10-year risk probability o f CVD events >30%
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2.6.4 Summary
The public health risk reduction strategies have been reviewed at both global 
and national level. The global level is the UN millenniums goal for reducing the 
mortality rate from NCDs, which targets six modifiable risk factors. For the national 
policy level in Thailand, there are two plans of health development stated by the 
Ministry of Public Health. The 11th health development plan and the Thailand healthy 
style strategies plans which are both aims to reduce the number of deaths from the 
lifestyle diseases in the general population and improve the health care coverage for 
people with the CVD complication. However, it was not stated clearly in the Thailand 
healthy life style strategies plan, by what percentage of reducing the risk factors among 
population it wanted to achieve. It stated only “increase”, “decrease” or maintains the 
level of risk factors at the same state. For the individual risk reduction goal in Thailand, 
it has been focused on the population at the high risk age of 40 years old.
The study target risk reduction will be assessed according to the national 
guidelines. The UN mellenium development goal will also be used as the target risk 
reduction scenario in this study.
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Chapter 3 : Method
3.1 Introduction
Obesity, hypertension, hypercholesterolemia and cigarette smoking are common 
risk factors for CVD. These classical risk factors, apart from smoking, have 
continuously increased in Thailand over a decade, which has led to an increase in the 
prevalence of CHD and stroke among the Thai population (Aekplakom, et al. 2010). 
Although the Ministry of Public Health has implemented many primary prevention 
programs, the effects of reducing these multiple risk factors in the population, in terms 
of health benefit and health care cost savings, are still unclear, because the number of 
health economic and decision models in Thailand are limited. This study will obtain a 
mathematical model which can be used to estimate the future prevalence and the 
impacts of reducing risk factors through the public health strategies. The model will 
calculate the future possible events of CVD, such as MI, stroke and mortality, for 
people who have those multiple risk factor profiles. In addition, it will also estimate the 
expected cost for hospital admissions, the expected burden in terms of the DALYs, as 
well as simulating the potential impacts of the prevention interventions strategies, such 
as DALYs saving and hospitalisation cost saving. The purpose of this chapter is to 
address the aims, objectives and the two main key questions about this study. This 
research will focus on two main areas. First is the CVD modelling for Thailand, by 
applying mathematical models to estimate the 8 to 10 years prevalence and the DALYs 
of CVD. Secondly, an exploration of the cost of CVD hospital admissions in Thailand 
and to estimate the impact of reducing CVD risk factors in the population level on the 
health care cost and DALYs. This section will outline the research methodology to be 
adopted in this study.
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3.2 Research methods
This study has used the concept of the cost offset model approach, which 
previously developed for estimating the possible clinical and potential financial impact 
of the population-level health risk reduction program in the UK over a 5 year period 
(Whitfield et al. 2006). Whitfield's model estimated the impact of reducing population 
level CVD risk factors on the acute hospital admissions avoided, premature death 
avoided and potential revenue cost saving.
This study will develop the model further by not only estimated the impact in 
terms of the number of hospital admisssion and cost, but also estimated the future 
burden of CVD in term of DALYs. The model using individual risk data for estimating 
the probability of future CVD events, and then apply those probabilities to the data held 
on the Thai population in 2009. The model is used to estimate the number of hospital 
admissions and calculate the consequences of the risk reduction strategies, in terms of 
the burden of diseases (DALYs). A spreadsheet cost offset model has been developed, 
based on the risk factors data from the 4th National Health Examination Survey (2008- 
2009) (NHESIV) Thailand. The CVD risk profiles of the individuals included BMI, 
systolic blood pressure, total cholesterol and regular cigarette smoking. These risk 
factors data were entered into the spreadsheet to calculate the probability of all fatal and 
non-fatal CVD events, MI or stroke and the number of acute hospital admissions over 8 
to 10 year period. The model will integrate the background knowledge of epidemiology 
and health economics. The model will also combine various data sources to address the 
study research questions, for example population level data, the demographic data, the 
epidemiology, risk factor level, health services and health care cost analysis. The 
methods, data set and data analysis are explained in the following stages diagram of 
developing CVD cost offset model.
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Stages of developing CVD cost offset model
Stages Data requirements
1. Descriptive analysis of the baseline 
CVD risk factors data to describe the 
data set and explore the association of 
the risk factors and CVD (Chapter 4)
2. Calculate the probability o f CVD 
events over next 5-10 years for Thai 
population
Outcome: 10-years CVD probability by 
age& gender (Chapter 5)
_______________V_______________
3. Estimate the number o f CVD events 
base on the calculated probability 
(Chapter 5)
CVD risk factors data in Thailand such 
as BMI, cholesterol, blood pressure, 
cigarette smoking
Data source: National Health 
Examination Survey 2009-2010
CVD prediction equation o f Asia
• Framingham's equation
• Asia pacific cohort study equation
• Framingham's Asia equation
_______________________________
Number of population in Thailand 
classify by age and gender in 2009 
Data source: Ministry o f Interiors, 
Thailand
4. Validation of the CVD estimated 
events by comparison with the actual 
CVD events in Thailand (Chapter 5)
• Number o f hospitalization from 
CVD in Thailand by age and gender
• Prevalence o f CVD (IHD, stroke) 
by age & gender
Data source:
1) Chronic disease surveillance system 
in Thailand
2) Health insurance system research 
office
Deduction
Outcome of interests
< --------------------— •  Background mortality rate by age &
1) Number o f CVD events gender
•  CVD (IHD & Stroke) mortality rate
2) Number of people who are by age & gender
alive with CVD Data source:
1) The NationalDdeath Registration,
2) Number o f cases of mortality Ministry of Interior, Thailand
(Chapter 5) 2) Ministry o f Public Health
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Stages Data requirements
5. Calculate the cost o f hospitalisation 
(Chapter 6)
 Y____________
6. Calculate the disability adjusted 
life year (DALYs) (Chapter 7)
DALY = YLL + YLD
YLL = N x L
YLD = I x DW x L
7. Calculate the risk reduction 
scenario (Chapter 7)
Standard life expectancy 
Disability weight
1) Number o f CVD (IHD, stroke) 
patients
2) Number o f case mortality
Outcome of interests from No.4
Average cost o f hospital admission. 
The cost o f treatment and type of 
CVDs events were classified and 
explored by the International 
Classification o f Diseases (ICD-10) 
code which is used in the health 
information system in Thailand. The 
ICD-10 codes 120-125 are used for 
IHD and codes 160-169 are used for 
stroke.
Outcome of interests
1) Burden o f disease in terms of 
DALYs
-Years o f life lost due to 
premature death from CVD (YLL)
- Years o f living with disability 
(YLD)
2) Number of hospitalisation avoided
3) Cost of hospitalization avoided
4) DALYs saving 
(Chapter 7)
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3.2.1 Stagel. The descriptive analysis of the baseline CVD risk factors 
data to describe the data set and explore the association of the 
risk factors and CVD. (Chapter 4)
3.2.1.1 Study population
The 4th National Health Examination Survey (2008-2009) (NHESIV) dataset 
(Aekplakom, et al. 2010), has been used as the baseline population and provided the 
risk factors profile of the Thai population. This survey is the most up to date and the 
largest national representative cross-sectional survey currently available in Thailand. 
This survey presents the health status, the prevalence of health problems and potential 
CVD risk factors among the Thai population. This survey sampled 20,450 individuals 
who were aged > 15 years old in 2009, classified by age and gender in 5 geographical 
regions; northern, central, north eastern, southern and Bangkok. This data was input to 
the model as the base population. The sampling procedure of the NHESIV has been 
described elsewhere (Aekplakom et al. 2011). The data collection included the health 
behaviour risk factors that were collected on the questionnaires by the interviewers and 
a blood sample was taken from each participant to examine for lipid profiles (total 
cholesterol, HDL, Triglyceride, LDL), fasting blood sugar, haemoglobin, haematocrit 
and red blood cell morphology. In addition the anthropometry (such as body weight, 
height, waist and hip circumference, arm span), and physical examination (such as 
blood pressure, near vision test, walk test and hand grip strength test), were performed 
in each individual participant. The following are inclusion and exclusion criteria for the 
data analysis.
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1) Inclusion criteria
NHES participants who were aged 15 years and over and had completed the full 
data collection on the CVD risk factors, such as the lipid profiles, fasting blood sugar, 
BMI, blood pressure and cigarette smoking status. Of 20,450 participants who were 
aged 15 years and above, 19,342 participants have been included in the analysis.
2) Exclusion criteria
1,108 participants have been excluded in this analysis because there were some 
incomplete data of the CVD risk factors.
3.2.1.2 Data analysis
The descriptive analysis of the baseline data from NHESIV was performed to 
explore the distribution of CVD risk factors. Descriptive statistics are used to explore 
the characteristics of the study sample, such as mean, percentage and standard 
deviations. The bivariate and multiple logistic regressions have been performed to 
explore the association to the CHD and stroke by using the statistical software package, 
STATA version 12 (StataCorp LP 2011).
3.2.1.3 Outcome of interests
1) The mean level of CVD risk factors by age and gender.
2) The prevalence of CHD and stroke in the NHESIV data set.
3) The mean level of risk factors by CVD conditions (CHD or stroke).
4) The factors that are associated with CHD or stroke in the Thai population 
based on the national health examination survey data.
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3.2.2 Stage 2. Calculate the probability of CVD events over next 5-10 
years for the Thai population (Chapter 5)
3.2.2.1 Selecting CVD risk assessment equations for Thai population
CVD risk equations have been critically reviewed through the literature review. 
There are 5 criteria for selecting the CVD risk equations which are suitable for the Thai 
population.
1) Setting of studies: The CVD risk prediction equations were derived from the 
cohort studies which were set in the Asia Pacific regions or Thailand. CVD risk 
equations, where the population characteristics of the studies were closely matched to 
the Thai population, were selected. The other well-known equations from the 
Framingham cohort study, where the characteristics of the study population are different 
to Thai population, have been selected to compare the performance of the CVD risk 
equations.
2) Availability of the equations: The CVD risk assessment equations are 
available in the publications reviewed and clearly described how the equations have 
been derived and how to apply to the population.
3) Applicability of the equations: The independent variables in the risk 
assessment equations are applicable to the risk factors data that are available in Thailand.
4) Period of the risk estimations: The risk assessment equations are capable of 
estimating the CVD risk in the next 5 to 10 year period.
5) Outcome of the estimation: The outcomes are 5 to 10 years probability of 
getting fatal or non-fatal CVD, IHD, MI or stroke.
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According to the selection criteria above, three equations have been selected in 
the model. First, the Asia-Pacific Collaborative Cohort Study equations (AJPCS 
equation), which uses the concept of the Cox's proportional hazard model, which had 
been derived from 177,077 participants of the cohort studies around Asia and 25,682 
Chinese cohorts. The Electricity Generating Authority of Thailand ( EGAT) cohort 
studies also included in this APCS (Asia Pacific Cohort Studies Collaboration et al. 
2007). Second, the recalibrated Framingham’s equation or the low information 
Framingham’s equation (Framingham Asia), which has applied the Cox's proportional 
hazard model concept derived from 6,053 participants of the Framingham studies and 
adjusted for the Asian population, where some risk data is not available (Asia Pacific 
Cohort Studies Collaboration et al. 2007). Third, the Framingham’s equation 
(Framingham original), using the concept of the Weibull accelerated failure-time 
models, which have been applied to the Thai population (Khonputsa, et al. 2011). 
Table 3.1 shows the summary of CVD risk assessment equations which has been 
selected to estimate the risk of CVD in 8 to 10 year period.
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Table 3.1 The selected CVD risk assessment equations
Equations APCS equation Framingham
Asia
Framingham original
Type of 
model
Cox's
proportional 
hazard model
Cox's
proportional 
hazard model
Weibull accelerated failure-time 
models
Follow-up
years
8 8 10
Study
populations
172,077
participants from 
the Asian 
cohorts; 25,682 
participants from 
Chinese cohorts.
6,053
participants from 
the Framingham 
Study.
9,373 men and 11,198 women 
free of previous stroke were 
included in the risk prediction 
equation for first-ever stroke, 
and 8,754 men and 10,783 
women free of previous IHD 
were included in the risk 
prediction equation for first-ever 
IHD
Independent
factors
Age, gender, 
systolic blood 
pressure, total 
cholesterol, 
smoking
Age, gender, 
systolic blood 
pressure, total 
cholesterol, 
smoking
Age, gender, total cholesterol, 
systolic blood pressure, 
smoking, diabetes
Outcomes Fatal and non- 
fatal CVD events
Fatal and non- 
fatal CVD events
IHD, Stroke and Overall CVD 
(IHDandStroke)
3.2.2.2 Data analysis
Calculation of the CVD probability
The NHESIV individual data and the individual risk factor variables were 
entered into a Microsoft Excel spreadsheet to use as the baseline population. The 
Framingham’s equations (Konputsa et.al 2010), the APCSC equations and the Asia 
Framingham’s equations (Asia Pacific Cohorts Studies Collaboration 2011), were 
applied to calculate the risk of the population who might be likely to contract CVD. The 
main outcome prediction is the of probabilities of CVD related events, such as stroke, 
heart attacks and heart failure. The details of the equations are described below.
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1) The APCS equation. The Asia cohort CVD risk prediction equations (Asia 
Pacific Cohorts Studies Collaboration 2011)
The probability of getting a cardiovascular event within 8 years
For Asian men is:
f0.065(age, - a g e ) +  0.027(sBR - S B P )  ) 
M 8)„„=l-Sm,„exp I ‘ (3-D
| + 0.095(rc;. -T C )+ 0 3 2 > [s m o k e i -  sm o k e jj
For Asian women is:
.... . f0.072fflgel -a g e )+ 0 .m  1^(8)w<,TO„ = l-S ( 8 )WOTO„ejg)^ , (3.2)
[+0.027((7’C1 -TC)+03\\smoke, -smoke))
2) The Framingham’s Asia equation for estimating the probability of getting a 
cardiovascular event within 8 years
For men is:
l0.068(age,.-age)+0.0\2(sBP.- SBP) ] 
P ( 8 ) „ = l - S ( 8 ) _ e x p  _ _ \ 7 ‘ t i  _ }  _ 2 _ ,  (3.3)
+ 0.01ii'I'C -2"c)+0.37
For women is:
f0.078(tf«?,-age)+0.0n(sBP.-SBp) ) 
p(S)mma= exp Y '  —P  (3.4)| + 0.14(rc;. -T C j+ 0 .55[smokei -  smoke)l|
Where, S(8) is the survival free from the cardiovascular event (in the 8 years 
average), age is the mean age of the NHESIV participants, agej is the age of the
individual, SBP is the mean systolic blood pressure of the NHESIV participants, 
SBPi is the systolic blood pressure of the individual, TC is the mean of total cholesterol
of the NHESIV participants, TCi is the total cholesterol of the individual, smokeis the
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prevalence of regular smoking of the NHESIV participants, smoke, is the smoking 
status of the individual (l=being a regular smoker, 0=not smoking).
3) The Framingham original equation for estimating 10 year probability of CVD event.
Using the Framingham's equation for Thai population from Weibull accelerated 
failure-time model regression coefficients (Khonputsa P, et.al 2011)
i=n
m = Constant 1+^pjX ; (3.5)
i=l
u _ logCOj-m (3 g)
constant2
p =  1 -  e (3.7)
CVD risk = 1 - ( l - P ,,,,,/1 ~ p s.roke) (3.8)
Where, m is the interim variables, Xj are the risk factors, p are coefficients 
estimated from the Framingham study , u is the interim variables for calculating p, t is 
the time of follow-up in years, and p is the predicted probability of IHD/Stroke by time t. 
The further information about the constants and the p coefficients of the original 
Framingham equation shows in (appendix B).
3.2.2.3 Outcome of interests
8 to 10 years probability of getting CVD, IHD or Stroke of the individuals and 
the 8 to 10 years probability of getting CVD, IHD or Stroke events by age groups and 
gender.
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3.2.3 Stage 3. Estimate the number of CVD event base on the 
calculated probability (Chapter 5)
Stage 3 estimates the number of CVD events at the national level according to 
the outcome from stage 2. The study population, data collection and data analysis at this 
stage are described below.
3.2.3.1 Study population
The Thai population who were aged 15 years and above in 2009.
Table 3.2 Number of the mid-year Thai population in 2009 by age groups and 
gender
Age groups Men Women
15-24 4,683,981 4,532,018
25-34 5,149,508 5,130,746
35-44 5,154,963 5,408,488
45-54 4,058,120 4,388,770
55-64 2,399,309 2,694,633
65-74 1,362,752 1,655,159
>75 749,125 1,086,374
Total 23,557,758 24,896,188
3.2.3.2 Data requirement and data sources
1) The number of mid-year population in Thailand in 2009 has been collected 
from the Ministry of Interior.
2) The CVD mortality data, the number of CVD deaths by age groups and 
gender has been collected from the Thailand national health statistic report over the 
past 10 year period, to calculate an average 10-year probability of dying from CVD by
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age groups and gender. The mortality data available to calculate the mortality rate by 
age groups and gender in Thailand are from 1996 to 2006.
3.2.3.3 Data analysis
The mean of a probability of getting CVD, IHD or Stroke which has been 
calculated in stage 2 were used at this stage. The underlying assumption at this stage 
was that the NHESIV data represents the health status of the Thai population during 
2008-2009. Thus, the mean probability of getting any CVD event in the NHESIV 
sample can reflect the probability of getting CVD in the general population, by age 
groups and gender. The number of Thai population who are aged 15 years and over was 
used to estimate the number of future CVD events. When multiplying the number of 
Thai population, with the probability of getting CVD events by age groups and gender, 
the result was an estimate of the number of people who are likely to have CVD events 
over 8-10 year periods. The probability of CVD events will include both fatal and non- 
fatal occurrences. Therefore, the model deduced the number of people who are likely to 
die before admission to the hospital, which will estimate the number of CVD acute 
admission events over the next 10 years. Moreover, the model was also adjusted for the 
different proportion of the population structures between NHESIV and the general 
population, by age groups and gender.
3.2.3.4 Outcomes of interest
1) The estimated number of CVD patients in Thailand over the next 10 years.
2) The estimated number of the Case-fatality in Thailand over the next 10 years.
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3.2.4 Stage 4. Validation of the CVD estimated events by comparison
with the actual CVD events in Thailand (Chapter 5)
The estimated number of CVD events using the CVD risk assessment equations 
was validated for accuracy by comparison with the actual CVD events that occurred in 
Thailand.
3.2.4.1 Data requirement and data sources
1) The number of inpatient hospitalisation in Thailand
The number of inpatient hospital admissions due to CVD by age and gender 
during 2007 to 2011 from the national hospitalisation database of the Universal Health 
Care Coverage (UC) (Supachutikul 1996). The UC is the main health insurance system 
in Thailand, which covered 75% of the population, approximately 47 million people. 
This health care scheme is financed by tax revenue to UC cover in and out-patients, 
health care expenditure, denture, pharmaceuticals, medical equipment, food, hospital 
admission (common room) and maternal delivery of mainly public health care services 
(National Health Security office 2008). The number of inpatient admissions from CVD 
is collected from the National Health Security Office (NHSO). The inpatient cases are 
classified by ICD-10 which was 100-199 referred to all CVD, 120-125 referred to IHD 
and 160-169 regard to stroke.
3.2.4.2 Data analysis
The model validation has been performed on the Microsoft Excel spreadsheets. 
The average of the estimated number of hospital admission per year has been compare 
with the actual number of hospital admission in 2009. The validation classified by the 
same age group and gender to make it comparable.
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3.2.5 Stage 5. Calculate the cost of hospitalisation due to CVD 
(Chapter 6)
The average cost of hospital admission for CVD in Thailand were estimated and 
calculated by using the costing data from the National Health Security Office (NHSO). 
These analyses were limited to the health care service provider perspective and not 
include the patients and other indirect expenditure. The cost of treatment and type of 
CVD events were classified and explored by the International Classification of Diseases 
(ICD-10th ) code, which is used in the health information system in Thailand. 
The ICD-10th codes 120-125 are used for CHD and codes 160-169 are used for stroke 
and 100 -199 for all CVD events.
3.2.5.1 Data requirement and data sources
1) The national inpatient cost of hospitalisation data in 2009, Thailand, which 
included the universal coverage health care schemes from the National Health 
Security Office (NHSO), Thailand
2) The estimated number of CVD patients.
3.2.5.2 Data analysis
An average cost of hospitalisation and the standard deviations are calculated. 
The unit of hospitalisation cost were presented in Thai currency. The cost of hospital 
admission were calculated by multiplying the estimated number of CVD patients with 
an average cost of hospital admission.
3.2.5.3 Outcomes of interest
The estimated of cost of hospitalisation over an 8 to 10 year period.
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3.2.6 Stage 6. Estimation of the burden of CVD (Chapter 7)
Once the model has estimated the CVD events, stage 5 will estimate the burden 
of CVD in terms of the DALYs.
3.2.6.1 Data requirement and data sources
1) Standard life table west level 26 (World Health Organization 2000) is used to 
calculate YLL
2) The estimated number of CVD events from stage 3
3) The estimated number of CVD mortality from stage 3
4) The disability weight of the Global Burden of Diseases (GBD) study (Murray et 
al. 2012a)
5) The number of mid-year population by age and gender in 2009
3.2.6.2 Data analysis 
Calculate the disability adjusted life year (DALYs)
DALYs were calculated to estimate the burden of CVD in Thailand. DALYs are 
the summation of years of potential life lost (YLL) due to premature death and the years 
of productive life lost due to disability (YLD). The calculation formula for DALY is 
described below:
DALY = YLL + YLD (3.9)
Where, YLL is the Year of Life Lost measure the lost years of life due to premature 
death, calculated by the number of deaths (N) multiplied by the standard life expectancy 
at of death occur in years (L).
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YLL = N x L (3.10)
YLD is the Year of Life with Disability corresponds to the number of the lost 
years of living with disability. It is calculated by multiplying the number of incident 
cases in that period (I), the average duration of disease (L) and the disability weight 
(DW) which indicate the severity of the disease from perfect health = 0 to death = 1. 
The YLD is calculated by:
YLD = I x DW x L (3.11)
To calculate the DALYs, the prevalence of CVD were estimated from the model 
by the number of hospital admissions. The mortality rate and remission rate will come 
from the literature reviews. Incident and average duration were derived from the 
Dismod Software (Barendregt et al. 2003). The disability weights were applied from the 
Global Burden of Diseases (GBD) study (Murray et al. 2012a).
3.2.6.3 Outcomes of interests
1) Burden of disease in terms of DALYs
2) Year of life lost due to premature death from CVD or IHD or Stroke (YLL)
3) Year of living with disability (YLD)
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3.2.7 Stage 7. The risk reduction scenario (Chapter 7)
The targets of the CVD risk reduction were determined from the literature 
reviews of previous studies, regarding the level of reduction in the potential multiple 
risk factors such as hypertension, hypercholesterolemia and regular smoker. The model 
will compare the CVD in 4 different scenarios: the do nothing scenario, the optimistic 
scenario, achieve the UN millennium development goal scenario and the worst case 
scenario.
3.2.7.1 Data analysis
The scenario of the percentage of effective reduction were used to calculate the 
avoidable CVD admission rate, CVD deaths avoided, the average cost of hospital 
admission saved and DALYs saved. The risk reduction scenario were calculated on the 
Microsoft Excel spreadsheet.
3.2.7.2 Outcomes of interest
1) Number of hospitalisations avoided
2) The number of deaths avoided
3) Cost of hospitalisation avoided
4) DALYs saving
3.3 Data sources
This section summarises all data requirements and data sources that are used in 
this study.
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3.3.1 List of all data requirements and data sources
The data requirements and data sources for populating the model are shown in. 
Table 3.3 Data requirement and data sources
Data requirement Data sources
1. Baseline population data sampling from 
the National Health Survey in Thailand in 
2009
The National Health Examination Survey 
2008-2009 from the National Health 
Examination Survey Office, Health 
System Research Institute, Thailand
2. Risk factor data
1) Baseline variables
• Age
• Gender
• Geographical regions
2) Risk factor variables
• Height (cm)
• Body Mass Index (BMI)
• Diabetes status (yes/no)
• Fasting Blood Sugar (mg/dL)
• Total Cholesterol (mmol/L)
• HDL (mmol/L)
• LDL (mmol/L)
• Triglyceride (mmol/L)
• Systolic blood pressure (mmHg)
• Diastolic blood pressure (mmHg)
• HypertensionStatus (yes/no)
• Regular smoking status (yes/no)
The National Health Examination Survey 
2008-2009 from the National Health 
Examination Survey Office, Health 
System Research Institute, Thailand
3. The admission rate and cost of hospital 
admissions
The National Health Security Office, 
Thailand.
4. The mortality rate by age and gender The national death registration, Ministry 
of Interior, Thailand and the national 
health statistic, Ministry of Public Health
5. The mortality rate from CVD or MI or 
stroke
The national health statistic, Ministry of 
Public Health
6. Probability of CVD events Calculated by using the risk assessment 
equations.
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3.4 Data collection
3.4.1 Phase I: The national health examination survey data
The secondary anonymous population data have been collected for the analysis 
from the National Health Examination Survey Office (NHESO). A letter outlining the 
proposed research, showing the detailed research proposal and the analysis plan were 
submitted to the NHESO during January 2011, in order to seek access to use their data. 
The use of the secondary data is followed by the criteria of the data sharing policy from 
the Health System Research Institute (HSRI), Thailand. Permission to access and use 
the data was granted by the National Health Examination Survey Office Thailand 
(NHESO) in January 2011. (See Appendix C).
3.4.2 Phase II: the number of hospital admissions and the cost of 
hospitalisation due to CVD
The number of hospital admissions and the cost of hospitalisation has been 
collected from the National Health Security Office (NHSO). A letter outlining the study 
including the research protocols, dummy tables, plans for data analysis and the data 
requested form, was submitted to NHSO during September 2013. The data permission 
was approved and granted in May 2014. The use of the anonymous hospitalisation data 
is defined under the criteria of the data sharing policy from NHSO, Thailand (See 
Appendix C).
3.5 Overall of outcomes of interests
The CVD cost off-set model estimated the various outputs which are:
1) Number of hospitalisations for non-fatal CVD events;
2) Number of DALY lost due to CVD;
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3) Cost of hospitalisation;
4) Number of hospitalisation savings due to the reduction of CVD risk factors;
5) Number of DALY savings due to the reduction of CVD risk factors;
6) Health care cost savings due to the reduction of CVD risk factors.
3.6 Other information
3.6.1 Data management procedures
The National Health Examination Survey Office Thailand (NHESO) has agreed to 
provide anonymous population data in the STATA file format (*. data). This data were 
kept confidentially on a researcher’s computer which is kept secured and is password 
protected. Only the researcher and the lead supervisor will have access to the data. The 
data were initially analysed for the general characteristics and risk factor information 
categorized by age, gender and geographical region. The statistical analysis were 
performed by using the percentages, mean, standard deviation and 95% confidence 
interval. The initial results were presented in an aggregate of the population level before 
being entered into the modelling process.
3.6.2 Ethical considerations
The study does not include UK NHS participants or services, therefore ethics 
approval from the UK NHS is not required. However, ethical considerations were taken 
into account to ensure that the well-being of individuals is not compromised. The 
ethical issues considered are as described below:
1) Recruitment -  The data collected is secondary anonymous population data 
from Thailand. Full pennission to access this data has been granted by the 
National Health Examination Survey Office (NHESO), Thailand and the
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National Health Security Office (NHSO), to use for the purposes of 
secondary data analysis (modelling).
2) Confidentiality -  All records of the secondary data were kept confidential 
and it is strictly anonymous. The name and the identity of the individuals are 
not associated with the research finding in any way. The data were kept 
securely and only use by the researcher. The data usage is restricted to the 
data sharing policy of the Health System Research Institute, Thailand.
3) Consent -  This project does not collect data from the individuals, so a 
consent form is not applicable.
4) Risks and benefits -  There are no known risks, harmful and/or discomforts 
to the individuals associated with this project.
The study was submitted to the Sheffield Hallam University, Faculty of Health 
and Wellbeing Research Ethics Committee during April 2011 and subsequently 
received ethics approval during April 2011 (See approval letter Appendix C).
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Chapter 4 : Risk factors associated with CVD in 
Thailand from the 4th National Health Examination 
Survey 2008-2009
Abstract
Coronary heart disease (CHD) and stroke are ranked in the top five causes 
of death, in both males and females, as well as a cause of premature death and 
disability in Thailand. The aim of this chapter is to describe the current situation of 
CVD and to explore the association of the modifiable risk factors with CHD and 
stroke in Thailand.
The 4th National Health Examination Survey (NHESIV) dataset has been 
used in this study. 19,342 participants aged >15 years who have completed the data 
gathering process on CVD risk factors, have been included in the analysis, which 
comprise 9,246 men and 10,096 women. The descriptive statistic, the bivariate 
analysis and the multiple logistic regression have been performed to describe and 
explore the association among CVD risk factors, CHD and stroke. The modifiable 
risk factors included in the analysis are age, BMI, total cholesterol, triglyceride, 
high density lipoprotein cholesterol (HDL-C), systolic blood pressure(SBP), 
diabetes and regular smoking.
The mean age of the participants is 52.7 years. The prevalence of CHD was 
2.5% in men and 2.3% in women and the prevalence of stroke was 2.5% in men 
and 1.6% in women. The overall prevalence of diabetes was 10.1% and regular 
smoking was 17.9%. When exploring the association of the modifiable risk factors 
with CHD and stroke, using the bivariate and multivariate analysis, the results 
show that factors associated with both CHD and stroke are being aged 55 and over, 
high blood pressure and diabetes. Obesity, high triglyceride level and low HDL-C, 
only showed association with CHD but does not show any significant association 
to stroke. Having a high triglyceride level was related to stroke only in women but 
does not show any association in men. The factors that do not show significant 
association in both CHD and stroke are high total cholesterol and being a regular 
smoker.
Although the analysis of the cross-sectional data was not able to identify 
the cause and effect of the factors relating to CHD or stroke, it showed some 
association of these modifiable risk factors for CVD. The modifiable risk factors, 
such as high blood pressure, obesity and diabetes need to be of concern in 
considering the CVD prevention strategies in Thailand.
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4.1 Introduction
CVD has become the leading causes of death and disability in Thailand 
(International Health Policy Program 2012). The number of patients who were admitted 
to hospital with CVD conditions has increased year on year (Bureau of Non- 
Communicable Disease,Department of Disease Control,Ministry of Public health 2010). 
Over the past decade, the modifiable risk factors, such as obesity, dyslipidemia, systolic 
blood pressure, diabetes and regular smoking, have been proved to be associated with 
the cause of CVD in many studies(Hubert et al. 1983, Asia Pacific Cohort Studies 
Collaboration 2003, Ezzati et al. 2002, Huxley, Barzi and Woodward 2006, Lee et al. 
2008, Anand et al. 2008). The increase of CVD patients in Thailand may be caused by 
changes in lifestyles, such as being less physically active and having an unhealthy diet, 
which leads to an increase in the level of metabolic risk factors of the individual 
(Aekplakom, et al. 2010). The EGAT study, which was a CVD cohort study in Thailand, 
found that the trend of the mean level of CVD risk factors such as SBP, BMI, total 
cholesterol, HDL-C and the prevalence of diabetes, increased over a 12-year follow-up 
period (Sritara et al. 2003), whereas the prevalence of regular smoking declined (World 
Health Organization, Regional Office for South East Asia 2009). Although it is well 
known that these modifiable risk factors are related to CVD conditions, the metabolic 
risk factors may change over time.
This chapter presents the results from the descriptive analysis of the risk factors 
for CVD. This study aims to describe the current situation of CVD and explore the risk 
factors that are associated with the CVD conditions, such as CHD and stroke, 
especially in Thailand. The CVD conditions referred to in this chapter are CHD and 
stroke.
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4.2 Dataset and method
4.2.1 Dataset
The 4th National Health Examination Survey (NHESIV) Thailand is a cross- 
sectional, population based survey which was conducted in 2008-2009. The main 
objective of this survey is to present the prevalence of chronic diseases and the potential 
health risk factors to the Thai population. This survey is a national representative of the 
Thai health status by age, gender, administrative area (urban/rural) and geographic 
regions. Stratified four stage random sampling has been applied to the sampling in the 
Thai population, at the age of 1 year and above, in 20 provinces and the Bangkok 
metropolitan area. The survey sampling was divided into 3 age groups, 1-14 years, 15- 
59 years old and 60 years old and above for both sexes. This survey recruited 20,450 
adults who were aged 15-59 years and 60 years and above to represent the health status 
in both the labour force and the elderly. The sampling method has been described 
elsewhere (Aekplakom, et al. 2010). The data has been collected by interview using a 
questionnaire, physical examination, blood examination and urine examination.
4.2.2 Method
The secondary anonymous dataset has been collected from the National Health 
Examination survey office, National Health System Research institute, Thailand. Full 
permission was granted including ethical approval to allow access to data to use in this 
study. Of 20,450 participants aged 15 years and above, 19,342 participants have been 
included in the analysis. 1,108 participants have been excluded from this analysis 
because the data was incomplete. The descriptive analysis has been performed on the 4 
main classical risk factors for CVD, such as body mass index (BMI), lipid profiles (total 
cholesterol, triglyceride, HDL and LDL), systolic blood pressure and regular smoking.
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It has been descriptively analysed for CVD related conditions that have been reported in 
participants in the survey, such as hypertension, diabetes mellitus, CHD and stroke. 
Multiple logistic regressions have been performed to explore the association between 
these risk factors and CVD conditions.
4.3 The outcome variables
The definition of the outcome variables use a similar definition as that of the 
National Health Examination Survey IV. The outcome variables are CHD and stroke. 
For the further information see (Terms and definitions page xiv) of the Thesis.
4.4 Results
Table 4.1 shows the general characteristic of the NHESIV participants aged >15 
years. There were 9,246 men and 10,096 women included in the analysis. 20.8% of 
participants are at age 55 to 64 years. Although 60.4% of men and 50.6% of women had 
normal BMI levels (BMI 18.5 to <25 kg/m2), 22.2% of men and 29.2% of women were 
overweight (BMI 25 to <30 kg/m2). Additionally, 5.6% of men and 11.4% of women 
were obese (BMI > 30 kg/m2).
In terms of the lipid profile, 51.1% of men and 60.5% of women had high total 
cholesterol levels. 38.9% of men and 33.9% of women had high triglyceride level. 
Furthermore, 35 % of men and 57.7% of women had low levels of the HDL-C which is 
considered as a risk for CVD.
Moreover, 33.3% of men and 31.9% of women had high blood pressure. 9.3% of 
men and 10.9% of women had diabetes. 34.4% of men were current regular smokers, 
whereas, 2.7% of women were regular smokers.
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Table 4.1 The general characteristic of the NHESIV participants aged >15 years 
classified by risk factors of CVD and gender
Risk factors Men Women Total
(n=9,246) (n=10,096) (n=19,342)
Age groups (years)
15-24 9.9%(919) 8.3%(834) 9.1 %(1,753)
25-34 9.6%(889) 9.5%(962) 9.6%(1,851)
35-44 13.9%(1,287) 15.7%(1,581) 14.8%(2,868)
45-54 13.6%(1,256) 15.9%(1,600) 14.8%(2,856)
55-64 20.8%(1,920) 20.8%(2,096) 20.8%(4,016)
65-74 21.4%(1,975) 19.5%(1,969) 20.4%(3,944)
>75 10.8%(1,000) 10.44(1,054) 10.6%(2,054)
BMI categories (kg/m2)
<18.5 11.8%(1,090) 8.8%(885) 10.2%(1,975)
18.5-<25 60.4%(5,584) 50.6%(5,106) 55.3%(10,690)
25 - <30 22.2%(2,054) 29.2%(2,952) 25.9%(5,006)
>30 5.6%(518) 11.4%( 1,153) 8.6%(1,671)
High total cholesterol
(TC>200mg/dL)
No 48.9%(4,519) 39.5%(3,989) 44.0%(8,508)
Yes 51.1 %(4,727) 60.5%(6,107) 56.0%(10,834)
High triglyceride
(TG>150mg/dL)
No 61.2%(5,654) 66.1%(6,669) 63.7%(12,323)
Yes 38.9%(3,592) 33.9%(3,427) 36.3%(7,019)
Low HDL-C (<40mg/dL in male
and <50 mg/dL in female)
No 65.0%(6,014) 42.3%(4,273) 53.2%(10,287)
Yes 35.0%(3,232) 57.7%(5,823) 46.8%(9,055)
High blood pressure
No 66.7%(6,168) 68.1 %(6,873) 67.4%(13,041)
Yes 33.3%(3,078) 31.9%(3,223) 32.6%(6,301)
Diabetes mellitus
No 90.7%(8,384) 89.1%(9,000) 89.9%(17,384)
Yes 9.3%(862) 10.9%( 1,096) 10.1 %(1,958)
Regular smoking
No 65.6%(6,062) 97.3%(9,820) 82.1 %(15,882)
Yes 34.4%(3,184) 2.7%(276) 17.9%(3,460)
120
Table 4.2 presents the prevalence of CHD and Stroke in the NHESIV for 
participants aged 15 years and over, classified by risk factors of CVD. The modified 
risk factors are the gender, age groups, BMI categories, high total cholesterol, high 
triglyceride, low HDL-C, high blood pressure, diabetes and regular smoking.
For CHD, the prevalence of this in men is 2.5% and in women is 2.3%. The 
prevalence increases respectively with an increase of the age groups. The highest 
prevalence of CHD is 5.3% in participants who are aged over 75 years old. The lowest 
prevalence of CHD is 0.2% in ages 15-24 years and 25-34 years.
The prevalence of CHD also increases, according to an increase of the BMI 
categories, the highest prevalence of CHD occurs in 3.7% of participants who had an 
obesity condition (BMI >30 kg/m2). The second highest prevalence of CHD is 3.2% of 
participants who had been classified as overweight (BMI between 25 and <30 kg/m2). 
The prevalence of CHD is lower in BMI lower than 18.5 kg/m2 (1.8%) and BMI 
between 18.5 and < 25 kg/m2 (2.0%).
In terms of the lipid profile, the prevalence of CHD in participants with high 
total cholesterol (>200 mg/dL) is less than those who had normal levels of total 
cholesterol (2.2% vs. 2.7%). In addition, the prevalence of CHD in participants who had 
a high triglyceride level was higher than those who had a normal triglyceride level 
(2.8% vs. 2.2%). Furthermore, the prevalence of CHD in people in the population with 
low HDL-C was higher than in those who had high levels of HDL-C (2.7% vs. 2.1%).
Moreover, the prevalence of CHD in participants with diabetes mellitus are 5 
times higher than those who did not have diabetes (6.5% vs. 1.9%). On the other hand, 
the prevalence of CHD in regular smokers was lower than in nonsmokers (1.3% vs. 
2.6%).
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In terms of stroke, the prevalence of stroke in men is 2.5% and 1.6% in women. 
The prevalence of stroke also arises with an increase in age groups. Therefore, the 
highest prevalence of stroke was in participants who were aged 75 years and over. 
The second high prevalence of stroke was in participants aged between 65 and 74 years 
old and the third highest prevalence in ages between 55 and 64 years old. The 
prevalence of stroke was less than 1 % of participants who are aged lower than 45 years 
old.
When looking at the prevalence of stroke by BMI categories, it was found that 
the prevalence of stroke was higher in participants who have a BMI lower than 18.5 
kg/m2 and second highest in those who were overweight, (BMI between 25 and less 
than 30 kg/m2). In the total cholesterol level, there was not difference in the prevalence 
of stroke. 2.1% of participants who had high total cholesterol had a stroke condition and 
2.0% of those who had normal levels of total cholesterol had a stroke. In terms of the 
triglyceride level, the prevalence of stroke in participants who had a high triglyceride 
level were higher than those who had a normal triglyceride level (2.6% vs. 1.7%). 
Additionally, the prevalence of stroke in participants who had a low HDL-C level was 
higher than those who had the highest level of HDL-C (2.2% vs. 1.9%).
In terms of blood pressure, 3.6% of participants with high blood pressure had 
stroke conditions, whereas 1.3% of participants with normal blood pressure had strokes. 
The prevalence of stroke in participants with diabetes was higher than those who did not 
have diabetes (4.4% VS. 1.8%). Conversely, the prevalence of stroke in the regular 
smoking group was lower than in the non-smoking group (1.6% VS.2.1%).
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Table 4.2 The prevalence of CHD and Stroke (%) classified by risk factors in the 
NHESIV participants aged >15 years
Risk factors N
(N=19,342)
CHD
(n=466)
STROKE
(n=395)
Gender
Men 9,246 2.5% (233) 2.5% (234)
Women 10,096 2.3% (233) 1.6%(161)
Age groups (years)
15-24 1,753 0.2%(4) 0.3%(6)
25-34 1,851 0.2%(4) 0.4%(8)
35-44 2,868 0.5%(13) 0.8%(24)
45-54 2,856 1.4%(39) 1.2%(33)
55-64 4,016 3.4%(136) 2.7%(110)
65-74 3,944 4.1 %(161) 3.5%( 139)
>75 2,054 5.3%(109) 3.7%(75)
BMI categories (kg/m2)
<18.5 1,975 1.8%(36) 2.6%(51)
18.5-<25 10,690 2%(209) 1.9%(199)
25 - <30 5,006 3.2%(160) 2.3%(115)
>30 1,671 3.7%(61) 1.8% (30)
High total cholesterol (TC>200mg/dL)
No 8,508 2.7%(228) 2%(170)
Yes 10,834 2.2%(238) 2.1%(225)
High triglyceride (TG>150mg/dL)
No 12,323 2.2%(271) 1.7%(214)
Yes 7,019 2.8%(195) 2.6%(181)
Low HDL-C (<40mg/dL in men and
<50 mg/dL in women)
No 10,287 2.1 %(215) 1.9%(198)
Yes 9,055 2.7%(251) 2.2%(197)
High blood pressure
No 13,041 1.3%( 170) 1.3%(169)
Yes 6,301 4.7%(296) 3.6%(226)
Diabetes mellitus
No 17,384 1.9%(338) 1.8%(308)
Yes 1,958 6.5%(128) 4.4%(87)
Regular smoking
No 15,882 2.6%(420) 2.1 %(341)
Yes 3,460 1.3%(46) 1.6%(54)
123
Table 4.3 shows the unadjusted odds ratio and adjusted odds ratio of the 
association of the individual risk factors and CVD conditions. The bivariate analysis 
and multiple logistic regression has been performed in the NHESIV participants aged 
15 years and over. The risk factors that had significant association with CHD are 
described as follows.
The middle and elderly age groups were associated with CHD and the advancing 
of age also increases the risk of getting CHD. When compared with the unadjusted odds 
ratio to the younger age group (15-24 years old), being in age group 55-64 years is 1.6 
times increased risk of CHD (OR=l. 6. 95% Cl 1.3-1.9), age group 65 -  74 years is 2.1 
times increased risk of CHD (OR=2. 1. 95% Cl 1.7-2.6) and age group 75 years and 
over is 2.7 times increased risk of CHD (OR=2. 7. 95% Cl 2.1-3.3) than the younger 
age group. In terms of stroke, the risk factors that presented the most significant 
association with stroke were similar to the risk factors of CHD. People in the middle 
age group and the elderly were more likely to have stroke than people in younger age 
group. People at age 55-64 years were 1.48 times more likely to suffer a stroke than 
those who were aged 15-24 years (OR=1.48. 95% Cl 1.18-1.85). The risk of stroke 
increased to 2.16 times at age 65-74 years (OR=2. 16.95% 0=1.75-2.66). At age 75 
years and over, the risk of stroke were 2.09 times greater than people in the younger age 
group. When modified for the effects of the other variables, the adjusted odds ratio 
showed that the middle age groups of 45-54 years, 55-64 years and elderly age groups 
65-74 years and 75 years and above had significant association with both CHD and 
stroke.
For the lipid profile, the bivariate analysis showed that participants who had 
high triglyceride level were 1.3 times more likely to have CHD than those who had a 
normal triglyceride level (OR=1.3, 95% Cl 1.1-1.5). The low level of the good lipid
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profile such as HDL-C was also associated with CHD. People who had low HDL-C 
were 1.3 times more likely to have CHD than those who had the high level of HDL-C 
(OR=1.3, 95% Cl 1.1-1.6). For stroke, the high triglyceride level was associated with 
stroke. However, the high level of total cholesterol and low level of HDL-C showed no 
association with stroke. The un-adjusted odds ratio showed that people with high 
triglyceride level were 1.49 times more likely to suffer stroke than those who had a 
normal triglyceride level (OR=l. 49, 95% 0=1.22-1.82). However, the adjusted odds 
ratio of the lipid profiles, such as high total cholesterol, high triglyceride and low HDL- 
C, did not show association with both CHD and stroke, when controlling the effects of 
the other variables.
Obesity (BMI>25 kg/m2) showed significant association with CHD in both 
unadjusted and adjusted odds ratio. The bivariate analysis showed that people with the 
obesity condition (>25 kg/m2) were 1.7 times more likely to experience CHD than those 
who had BMI at the normal level (0R=1.7, 95% Cl 1.4-2.1). In addition, the adjusted 
odds ratio of BMI showed that people who were obese were 1.6 times more likely to 
experience CHD than those who had a normal BMI level (OR=l. 6, 95% Cl 1.31-1.96). 
On the other hand, there was no association between obesity and stroke.
High blood pressure was significantly associated with both CHD and stroke in 
both bivariate and multivariate analysis. The unadjusted odds ratio showed that people 
with high blood pressure had 3.7 times the risk of CHD, than those who had normal 
blood pressure (OR=3.7, 95% CI=3.1-4.5) and were 2.83 times more likely to suffer 
stroke (OR=2.83, 95% 0=2.31-3.46). Furthermore, the adjusted odds ratio showed that 
people who had high blood pressure were 1.81 times at greater risk of experiencing 
CHD (0R=1. 81, 95% Cl 1.47-2.22) and 1.63 times more likely to suffer a stroke 
(OR=l. 63, 95% Cl 1.31-2.03) than those who had normal blood pressure.
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Additionally, diabetes also showed a significant association with both CHD and 
stroke. The unadjusted odds ratio showed that people who had diabetes were 3.5 times 
more likely to experience CHD than those who did not have diabetes (OR=3.5, 95% 
CI=2.9-4.3) and 2.57 times more likely to get stroke (OR=2.57, 95% Cl = 2.02 -  3.28). 
Whenthe multivariated analysis was performed , people who had the diabetes condition 
were 1.85 times more likely to get CHD (OR=1.85, 95% Cl 1.49-2.31) and 1.59 times 
more likely to get stroke (OR=1.59, 95% Cl 1.23-2.05).
However, there were some risk factors which did not show any significant 
association of being a risk to CHD and stroke, such as being women, having high 
cholesterol and regular smoking.
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Table 4.4 presents the association between risk factors and CVD conditions in 
male participants aged 15 years and over, by using the multiple logistic regression. 
When controlling for the effects of the other variables, the factors associated with CHD 
in both men and women were being in the middle and elderly age groups (aged 55 and 
above), being obeses, having high blood pressure and diabetes.
The risk of getting CHD in men and women increased with an advance in age. 
Men aged 55-64 years had 8.49 times higher risk of CHD (OR=8.49, 95% Cl 2.62- 
27.46) and men aged 65-74 years were 9.44 times more likely to have a risk of CHD, 
than those who were aged 15-24 years (OR=9.44, 95% Cl 2.92-30.49). The risk of CHD 
was highest at age 75 years and above which was 13.67 times higher than those who 
were aged 15-24 years (OR=13. 67, 95% Cl 4.19-44.61). In addition, women who were 
in the middle age and elderly age groups were more likely to get both CHD and stroke 
and the risk increased with an advance in age. Women aged 55-64 years had 16.8 times 
the risk (OR=16. 8, 95% Cl 2.3-123.0), at age 65-74 years had 20.5 times the risk 
(OR=20. 5, 95%CI 2.81-149.43) and at age 75 years and over had 26.45 times the risk 
(OR=26. 45,95% Cl 3.59-194.5) of getting CHD than women aged 15-24 years.
Furthermore, men who had an obesity condition (BMI> 25 kg/m2) were 1.74 
times more likely to experience CHD than those who had a normal BMI (OR=l. 74, 
95% Cl 1.30-2.32). Women who were obese (BMI>25 kg/m2) were 1.49 times more 
likely to experience CHD than those who had a normal BMI (OR=l. 49, 95% Cl 1.12- 
1.97).
Men who had high blood pressure were 1.72 times more likely to experience 
CHD than those who had normal blood pressure (OR=l. 72, 95% Cl 1.29 - 2.30). 
Women who had high blood pressure were 1.89 times more likely to experience CHD 
than those who had nonnal blood pressure (OR=1.89, 95% 0=1.42-2.54).
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Additionally, men who had diabetes were 1.68 times more likely to get CHD 
than those who did not have diabetes. Women who had diabetes were 2.02 times more 
likely to experience CHD than those who did not have diabetes.
However, dyslipidemia and being regular smokers did not show any significant 
association with CHD in both men and women.
The factors associated with stroke in both men and women were being in the 
middle and elderly age groups, having high blood pressure and diabetes. The middle 
and elderly age groups showed significant association to stroke in men as well as CHD. 
Men aged 55-64 years had 4.78 times the risk of experiencing CHD (OR=4. 78, 95% Cl 
1.88-12.11) than men in the younger age group (15-24 years). The risk of stroke in men 
was highest at age 65-74 years, which is 6 times higher than the younger age group 
(OR=6. 00, 95% Cl 2.38-15.12). For women, the age group that showed association 
with stroke were being aged 55-64 years, 65-74 years and 75 years and above. The 
adjusted odds ratio were presented as follow 55-64 years (OR=12. 22, 95% Cl 1.65- 
90.22), 65-74 years (OR=13. 72, 95% Cl 1.86-101.29) and 75 years and above (OR=15. 
59, 95% Cl 2.08-116.76).
In addition, men who had high blood pressure were 1.52 times more likely to 
experience a stroke than those who had normal blood pressure (OR=1.52, 95% Cl 1.15- 
2.03). Women who had high blood pressure were 1.8 times more likely to experience a 
stroke than those who had normal blood pressure (OR=1.8, 95% Cl 1.27-2.55).
Men who had a diabetic condition also had a 1.56 times greater risk of 
experiencing stroke than those who did not have diabetes (OR=1.56, 95% Cl 1.11-2.21). 
Women with a diabetic condition were 1.59 times more likely to experience stroke than 
those who did not have diabetes (OR=1.59, 95% Cl 1.09-2.32).
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Furthermore, the factor that showed a significant association with stroke only in 
women was a high triglyceride level. Women who had a high triglyceride level were 
1.51 times more likely to experience a stroke than those who had a normal triglyceride 
level (OR=l. 51, 95% Cl 1.07-2.13).
On the other hand, dyslipidemia, obesity and regular smoker factors were not 
associated with stroke, when controlled against the effects of the other variables in men. 
Furthermore there were no associations found between high total cholesterol, low HDL- 
C, being obese, being a regular smoker and stroke in women.
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4.5 Discussion
This chapter has showed the analyses of the national cross-sectional data which 
was collected during 2008-2009. The strength of the NHESIV is that it is the largest 
national representative cross-sectional survey, which can present the health status of the 
general Thai population during that period. However, there are some limitations. 
Although the bivariate analysis and multivariate analysis present the associations 
between the risk factors and the CVD conditions, it is not able to present the causal 
relationship between these risk factors and CVD. Therefore, the results do not show the 
cause and effect of risk factors to CVD.
The risk factors that show no association with CHD or stroke in both bivariate 
analysis and multivariate analysis are high total cholesterol and regular smoking (Table 
4.3 and 4.4).This might be because people who already had CHD or stroke had received 
treatment to control their blood total cholesterol, such as receiving a cholesterol 
lowering drug. Additionally, once they had been diagnosed that they had CHD or stroke, 
they also changed their unhealthy lifestyle and stopped smoking.
When adjusted for an effect of the other variables in both men and women 
(Table 4.4), the risk factors that are associated with CHD, in both genders, are being in 
the middle and elderly age groups, having high triglyceride levels, having low HDL-C, 
being obese (BMI > 25 kg/m2), having high blood pressure and diabetes. The analysis 
did not show significant associations with higher total cholesterol and regular smoking 
and the result also showed no association in the bivariate analysis. However, when 
analysing the association with gender, all lipid profiles were not related to CHD. This 
might be due to the limited number of CHD cases, when performing the analysis by 
gender, which was not a large enough sample to show any significant association.
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Furthermore, the factors associated with stroke were being in the middle age and 
elderly age groups, having high blood pressure and diabetes. There was no association 
between all lipid profiles, obesity and regular smoking, when performing the 
multivariate analysis in both genders. However, having high triglyceride level showed 
significant association with stroke but only in women.
Although the middle age and elderly age groups show a significant association 
with both CHD and stroke in women, the 95% confidence interval among women was 
very wide across the age groups factor (Table 4.4). This was because there are very few 
numbers of stroke cases in the reference age groups of 15-24 years and the number of 
stroke cases in women aged 55 years and over, was higher than in the other age groups. 
Another reason was the NHESIV randomly selected the sampling in the general 
population, there are few numbers of CHD and stroke cases found in the survey. If there 
were a larger number of cases, it may have showed a more precise association in 95% 
confidence interval.
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Chapter 5 Application of CVD risk assessment 
equations to the Thai population
Abstract
The CVD risk assessment equations have been developed in many studies in 
order to estimate the risk of getting CVD in asymptomatic people. However, those 
CVD risk equations have been deemed suitable for the specific target population and 
there are a limited number of CVD risk equations in Thailand. The objectives of this 
chapter are 1) To calculate the probability of CVD events by applying 3 different 
equations, which are: the APCS equation, the Framingham-Asia equation and the 
original Framingham equation, to the individual risk factors data from the NHESIV, 
Thailand. 2) To estimate the number of 8-10 years CVD events. 3) To validate and 
identify the most suitable CVD risk equations for the Thai population.
The individual risk factors from the NHESIV dataset has been entered into a 
Microsoft excel spreadsheet as the baseline population. The APCS equation, the 
Framingham-Asia equation and the original Framingham equation, are applied to 
calculate the probability of 8 to 10 years CVD events by age groups and gender. 
The CVD events in this analysis refer to all fatal and non-fatal CVD events (ICD10, 
100-199), which include IHD (ICD10, 120-125) and stroke (ICD10, 160-169). The 
individual CVD probability from the NHESIV participants, will calculate the average 
probability of CVD by age groups and gender. Then, it will be applied to the national 
population to estimate the number of future CVD events in Thailand. The average 
CVD mortality rates over a 10-year period are used to calculate the 10-year 
probability of dying from CVD and estimate the number of CVD deaths. The number 
of CVD deaths has been deduced in the estimated CVD events, to estimate the number 
of people who are alive with CVD condition. The estimated number of CVD events 
has been validated against the actual events in Thailand. The national hospitalisation 
database has been used to validate the mathematical model.
The following results were recorded when the APCS, the Framingham-Asia 
and the original Framingham equations, were applied to the NHESIV dataset. 
The APCS equation calculated the average 8-years probability of getting CVD as 
8.3% in men and 7.8% in women. The 8-year probability of CVD in the Framingham- 
Asia equation were 7.2% in men and 8.1% in women. The original Framingham 
equation showed the highest probability of 10-years CVD which were 18.8% in men 
and 11.1% in women.Over the next 8 years, the APCS equation estimated overall 5.0 
million CVD cases and the Framingham-Asia estimated 4.8 million CVD cases. 
While, the original Framingham estimated 8.3 million CVD cases in the next 10 years. 
Through the validation, we found that all CVD equations overestimated the risk of 
CVD in the elderly age groups. The original Framingham equation overestimated the 
risk of CVD in the Thai population in all age groups.
The APCS and the Framingham-Asia equation both performed a better 
estimation than the original Framingham equation in both men and women.
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5.1 Introduction
CVD risk prediction models have been developed in many studies, as a tool to 
predict the levels of CVD in the future. The most influential prediction models, using 
statistical multivariate analysis equations, were derived from the Framingham Study 
(Sritara et al. 2003, Wilson et al. 1998, Cui 2009, Wu et al. 2006). Many studies found 
that the Framingham's function was suitable for predicting future CVD in the middle 
aged, US white population and others with similar profiles of CVD risks 
(Diverse Populations Collaborative Group 2002, Liao et al. 1999). However, some 
studies showed an overestimated prediction for groups which have different risk profiles 
and ethnicity such as Asian and some EU populations (Liu, Hong and DAgostino 2004, 
Thomsen et al. 2002, Haq et al. 1999, Brindle et al. 2003).
Nevertheless, the Framingham equation gives a generalized prediction, in terms 
of the biomarker risk factors, such as blood pressure and cholesterol level. Several 
studies have developed adjustments to the Framingham CVD risk prediction equation, 
to adapt it for use in specific populations. For example: the QRISK risk score in the 
United Kingdom and the Asia Pacific Cohort Studies Collaboration (APCSC) 
(Hippisley-Cox et al. 2007, Asia Pacific Cohort Studies Collaboration et al. 2007).
In Thailand, to date, there is only one CVD risk score, which has been derived 
from the EGAT cohort study (Vathesatogkit et al. 2012). This study has followed-up 
3,499 participants aged 35 to 54 years since 1985. Several studies found that RAMA- 
EGAT risk score provided a better prediction of CVD than the Framingham equation 
(Pattanapichakul et al. 2007). Although the CVD risk score was derived specifically for 
the Thai population, this cohort study was well representative only for Thai middle- 
class men aged 35 years and over but it was not well representative in women (Sritara et 
al. 2003).
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The objectives of this study are: 1) To calculate the probability of CVD events 
by applying the three difference equations, which are APCS equation, the Framingham- 
Asia equation and the original Framingham equation, to the individual risk factors data 
from the NHESIV, Thailand; 2) To estimate the number of 8-10 years CVD events; 
3) To validate and identify the most suitable CVD risk equations for the Thai population.
This chapter presents the results of the application of the CVD risk assessment 
equations to the Thai populations. The details of the analysis and CVD risk assessment 
equations has been described in chapter 3, at stage 2 to stage 4. The outcome of interest 
in this chapter were the probability of CVD events using the three different equations, 
the estimated number of non-fatal CVD events in the Thai population and the validation 
of the mathematic model.
5.2 Methods
5.2.1 Selecting CVD risk assessment equations for Thai population
The available CVD risk equations have been critically reviewed through the 
literature. The APCS, Framingham- Asia and the original Framingham equations have 
been applied. For more information about the selection criteria of the CVD risk 
equations see (chapter 3, page 101). The APCS and the Framingham-Asia equations 
both have been applied to the Asia Pacific cohort study collaboration. The original 
Framingham equation has also been applied to the Thai population. The APCS and the 
Framingham-Asia equations both use the same independent factors such as age, gender, 
systolic blood pressure, total cholesterol and smoking status. The original Framingham 
equation also included the diabetes status as one of the independents factors. The 
outcome of the estimation are fatal and non-fatal CVD events. Hence, the original
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Framingham equation is able to calculate the risk of getting IHD or stroke seperately. 
The period of CVD estimation are 8 to 10 years.
5.2.2 Calculation of the CVD probability
The NHESIV dataset has been used as the study population. The individual data 
and risk factors profile have been entered to an Excel spreadsheet. The APCS, 
Framingham-Asia and the original-Framingham equations have been applied to the data 
to calculate the probability of getting CVD in each individual. Then, the mean of 8-10 
years probablity has been calculated by age groups and gender. The main outcomes are 
the probablity of IHD, stroke and all CVD events.
5.2.3 Estimated number of CVD events
The number of CVD events at the national level are estimated by multiplying the 
CVD probability to the number of the mid-year population in 2009, by age groups and 
gender, to obtain the number of all CVD events over the next 8 to 10 year period. The 
probablity of CVD events includes both fatal and non fatal CVD. The analysis excluded 
those who died based on the statistical information. The average 10-years probability of 
dying from CVD conditions has been calculated based on the Thailand Health Statistic 
Report during 1996 to 2006 (appendix H). The 10-years probability of dying from CVD 
has been multiplied with the population in 2009 (mid-year population) to get the 
number of people who are likely to die from CVD over the next 10 years . The number 
of people who are likely to die from CVD has been deducted from the estimated number 
of CVD events, in order to estimate the number of people who are alive with the CVD 
conditions over the next 10 years. The number of current CVD cases in 2009 has been 
statistically estimated from the NHESIV by age groups and gender. Then, the number of 
current CVD cases in 2009 has been added to the estimated number of people who are
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alive with CVD over the next 10 years, to get the number of future prevalence cases of 
CVD.
5.2.4 Validation of the CVD estimated events
The estimated number of CVD events are validated with the actual number of 
CVD hospital admissions in Thailand in 2009. The number of CVD cases will be 
classified by the ICD-10 code in which 10-199 refers to all CVD events, 120-125 refers 
to IHD and 160-169 refers to stroke. The actual number of CVD admissions come from 
the National health Security Office, Thailand (NHSO) which covers 75% of all hospital 
admissions in Thailand and includes the patients who were in the universal coverage 
health care scheme.
5.3 Results
5.3.1 The probability of CVD events
Table 5.1 shows the comparison of mean probability of CVD, which has been 
calculated by using the APCS equation, the Framingham-Asia equation and the original 
Framingham equation in the NHESIV dataset. The mean probability of CVD has been 
calculated by age groups and gender.
When applying the APCS equation, the overall mean of 8-year CVD probability 
are 8.3% in men and 7.8% in women. The trend of 8-year probability increased 
according to age groups in both men and women. The probability of CVD is lowest at 
age 15-24 years. The probability of CVD starts to increase from the 45-54 years age 
group The CVD probability in men is higher than in women from the ages 15 to 74 
years. Whereas, women have CVD probability higher than men at age 75 years and over.
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The mean 8-year probabilities of CVD when using the Framingham-Asia 
equation are 7.2% in men and 8.1% in women. The minimum CVD probability is at age 
15-24 year. At age 45-54 years, the CVD probability in men is 3.2% and 2.6% in 
women. The CVD probability is equal to 6.7% in both men and women at age 55-64 
years. The CVD probability increases with an increase of age groups. Although the 
trends of CVD probability of the Framingham-Asia equation are similar to the CVD 
probability that are calculated with APCS equation, the Framingham-Asia calculated the 
CVD probability in women as higher than in men from age 65 years and over. 
The 8-year probability of CVD is highest at age 75 years and over.
In terms of the 10-year original Framingham equation, the overall mean of 10- 
year CVD probability is 18.8% in men and 11.1% in women. The CVD probability in 
men is higher than in women in all age groups. The lowest CVD probabilities are 1.9% 
in men and 0.8% in women at age 15-24 years. The CVD probability continuously 
increases when age increases, in both men and women. The CVD probability is 2 times 
higher in men than in women at the age 35-44 and 45-54 years. In elderly age groups, 
the 10-year CVD probability is higher than in the younger age groups and the highest 
probability of CVD is at age 75 years and over, which are 47.6% in men and 30.8% in 
women.
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Table 5.1 The mean probability of CVD events by age groups and gender amongs 
APCS equation, the Framingham-Asia equation and the Framingham original 
equation
Age
(years)
8 years-probability of CVD (%) 10-year probability of CVD
(%)
APCS F ramingham-Asia Framingham original
Men Women Men Women Men Women
15-24 0.3 0.2 0.3 0.2 1.9 0.8
25-34 0.8 0.5 0.8 0.4 4.1 1.6
35-44 1.7 1.1 1.6 1.0 6.8 2.8
45-54 3.6 2.7 3.2 2.6 11.5 5.8
55-64 7.8 6.6 6.7 6.7 19.5 11.8
65-74 14.4 13.9 12.1 14.4 30.5 19.6
>75 26.0 29.5 22.4 30.9 47.6 30.8
Total 8.3 7.8 7.2 8.1 18.8 11.1
Table 5.2 shows the 10-year probabilities of CVD, which are calculated by the 
Framingham original equation in the NHESIV data set. This equation is capable of 
calculating three events, which are IHD, stroke, and all CVD events. Table 5.2 presents 
the mean 10-year probability, by CVD condition, age groups and gender.
The overall mean of 10-year IHD probability is 14.5% in men and 8.0% in 
women. The trend of IHD probability rises with an increase in age groups. Men have 
more probability of getting IHD than women in all age groups. The IHD probability is 
lowest at age 15-24, which are 1.9% in men and 0.7% in women. The probability of 
IHD at age 25-34 is 3.9% in men and 1.4% in women. The IHD probability in men 
continually increases in the middle age and elderly age groups. At age 35-44 years, the 
IHD probability in men is nearly triple that in women, which is 6.3% in men and 2.4% 
in women. The IHD probability is twice as high in men than in women at age 45-54 
years, which is 10.2% in men and 4.8% in women. At age 55-64, the IHD probability in 
men is 15.9% and 9.1% in women. The IHD probability in elderly age groups, 65-74
years and 75 years and above is higher than the IHD probability in younger age groups.
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At age 65-74 years, there are 22.8% of men and 14.0% of women who have a chance of 
getting IHD. The IHD probability reaches the highest at age 75 years and over, which is 
32.4% in men and 20.15 in women.
The average 10-years probability of stroke is 6.2% in men and 3.8% in women. 
The graph shows that the stroke probability is below 1 % from age 15 to 44 years in both 
men and women. At age 45 -  54 years, there is 1.5% probability in men and 1.2% of 
women who suffer a stroke. The trend of stroke probability increase from the age of 55 
years and men are more likely to have a chance of suffering a stroke than women. 
The stroke probability is 4.5% in men and 3.1% in women at age 55-64 years. 
Then, the stroke probability increases in the elderly age groups, which is 10.6% in men 
and 6.8% in women at age 65-74 years. The stroke probability reaches 24.7% in men 
and 14.6% in women at age 75 years and above. Compared to figure 5.3, the mean of 
10-year probability of stroke is lower than the probability of IHD, in both men and 
women in all age groups. The overall mean of stroke probability is twice as high than 
the mean of IHD probability. In men, the probability of IHD is 14.5% and stroke 6.2%. 
In women, the probability of IHD is 8.0%, while the probability of stroke is 3.8%.
Table 5.2 The mean probability of CVD events by age groups, gender and CVD 
conditions using the original Framingham equations
Age 10-years probability (%)
(years) IHD Stroke CVD
Men Women Men Women Men Women
15-24 1.9 0.7 0.1 0.1 1.9 0.8
25-34 3.9 1.4 0.2 0.2 4.1 1.6
35-44 6.3 2.4 0.5 0.5 6.8 2.8
45-54 10.2 4.8 1.5 1.2 11.5 5.8
55-64 15.9 9.1 4.5 3.1 19.5 11.8
65-74 22.8 14.0 10.6 6.8 30.5 19.6
>75 32.4 20.1 24.7 14.6 47.6 30.8
total 14.5 8.0 6.2 3.8 18.8 11.1
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The graph that compare the probability of CVD when applying the the three 
differences equation shows in (appendix F).
5.3.2 The estimated number of CVD events in the Thai population 
over 8 to 10 year periods.
This section presents the estimated number of CVD events when multiplying the 
probability of CVD in an 8-year and 10-year period, to the number of the national mid­
year populuation in Thailand in 2009. The number of CVD events, which have been 
calculated using three different equations, are the number of total CVD events which 
included both fatal and non-fatal events of IHD and stroke. Therefore, the number of 
estimated CVD events will deduct the number of people who are dead from CVD, to 
obtain the number of people who are alive with CVD. The number of deaths from CVD 
are estimated by appling the average of 10-year CVD mortality probability, which has 
been calculated from the national CVD mortality rate in Thailand over 10-year period 
(1996-2006).
Table 5.3 shows the estimated number of people who are alive with CVD in 
Thailand in the next 8 to 10 years. In men, the APCS equation estimated 2.5 million, the 
Framingham Asia equationestimated 2.2 million and the original Framingham equation 
estimated 5 million, of men who are alive with CVD. The table shows that the original 
Framingham equation estimated a higher number of CVD events than either the APCS 
or the Framingham-Asia equations in all age group. The number of estimated CVD 
patients increase according to age groups. The APCS equation estimated the number of 
CVD cases as nearly the same at ages 15 to 44 years. However, at age 45 year and 
above, the APCS equation estimated number of CVD cases higher than the 
Framingham-Asia equation. The lowest number of CVD cases are at at age 15 to 24
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years. The number of CVD cases increases at age 45 years and above. The highest 
number of CVD cases are at ages 65 to 74.
The estimated number of CVD cases in women in Thailand in the next 8 to 10 
years, when applying the 8-year and 10-year probability of CVD from the APCS 
equation, the Framingham-Asia equation and the original Framingham equation. 
The total number of estimated CVD cases in women are 3.3 million when applied the 
10-year probability of CVD from the original Framingham equation, whilst, the 
Framingham-Asia equation estimated 2.6 million cases and the APCS equation 
estimated 2.5 million cases overall in an 8-year period. The table shows that the original 
Framingham equation estimated a higher number of CVD cases in women than either 
the APCS equation or the Framingham-Asia equation in most age groups, except at age 
75 and over. The lowest number of estimated CVD cases are at age 15 to 74 years. The 
APCS equation estimates the number of CVD cases in women higher than the 
Framingham-Asia equation from age 15 to 54 years. On the other hand, the 
Framingham-Asia equation estimated the number of CVD cases higher than the APCS 
equation at age 55 years and above. The original Framingham equations estimated the 
highest number of CVD cases at age 65 to 74 years. However, at age 75 years and 
above the Framingham-Asia equation estimated the higher number of CVD cases than 
the original Framingham equation or the APCS equations.
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Table 5.3 The estimated number of people who are alive with CVD in Thailand 
during the next 8-10 years by age groups and gender amongs APCS equation, the 
Framingham-Asia equation and the Framingham original equation
Men Estimated number of people who are alive with CVD
Age APCS Framingham Asia Framingham original
8-years 8-years 10-years
15-24 24,711 24,403 62,084
25-34 22,065 21 ,794 96,848
35-44 139,848 137,442 308,877
45-54 248,721 237,687 501,574
55-64 566,300 510,851 1,139,557
65-74 818,176 703,639 1,627,409
>75 722,779 630,331 1,273,257
Total 2,542 ,599 2 ,266,147 5,009,607
Women Estimated number of people who are alive with CVD
Age APCS Framingham Asia Framingham original
8-years 8-years 10-years
15-24 12,512 11,869 25,354
25-34 53,255 52,135 79,660
35-44 93,754 90,281 160,900
45-54 253,433 250,647 377,651
55-64 536,927 544,755 807,650
65-74 761,026 782,969 1,034,955
>75 827,332 862,479 860,526
Total 2,538,238 2,595,135 3 ,346 ,695
The graphs of the estimated number of people who are alive with CVD in 
Thailand during the next 8-10 years by gender shows in (appendix F).
5.3.3 The validation of the mathemetic model
This section presents the validation of the mathemetic model. The estimated 
number of people who are alive with CVD calculated from the APCS, the 
Framingham-Asia and the original Framingham equations have been validated against 
the actual number of CVD events in Thailand.
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The national hospitalisation data in 2009 from NHSO, Thailand, have been used 
to validate the model which covers the in-patients hospital admissions for the whole 
country. The in-patients admissions from the Universal Coverage Health Care Scheme 
(UCS), which accounts for 75% coverage of the all hospitalisation data in Thailand. The 
average number of the estimated CVD patients per year, has been calculated to make it 
comparable with the 1-year hospital admissions in Thailand and is compared by age 
groups and gender. The CVD conditions have been indentified by using the ICD-10 
code, which 100-199 refers to all CVD, 120-125 refers to IHD and 160-169 refers to 
stroke.
Table 5.4 shows the validation of the estimated number of CVD patients which 
has been calculated from the APCS equation, Framinham-Asia equation and the original 
Framingham equation. The actual number of CVD patients who were admitted to 
hospitals in 2009 in has been used to validate the estimated number of CVD patients 
using each equation. In men, The APCS and the Framingham-Asia equations estimated 
the total number of patients closer to the actual number, than the original Framinham 
equation. The original Framingham equation overestimated the number of CVD patients 
by a factor of two.
When comparing across age groups in men, the APCS equation and the 
Framingham-Asia equation both slightly over-estimated the number of CVD patients at 
age 15 to 24 years but under-estimated the number of patients from age 25 to 34 years. 
Both APCS and the Framingham-Asia equations over-estimated the number of patients 
at age 55 years and over. The APCS equation and the Framingham-Asia equation 
performed a close estimation at age 35 to 44 years and 45 to 54 years. The original 
Framingham equation over-estimated the number of CVD patients in almost all age
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groups, with estimates at double the actual number at age 25 to 54 years and triple the 
actual number at age 15 to 24 years and 55 years and over.
Overall, the three equations overestimated the number of CVD patients in 
women. When comparing across age groups, the APCS and the Framingham-Asia 
equations both under estimated the number of CVD patients at age 15 to 24 years, 
whereas, the original Framingham performed a close estimation in this age group. In 
addition, at age 35 to 44 years and 45 to 54 years the APCS equation and the 
Framingham-Asia equation both closely estimate the actual number of CVD patients. 
Whereas, the original Framingham equation overestimated the number of CVD events. 
In the elderly age groups, all three equations have overestimated the number of CVD 
patients. The validation graph is shown in (appendix F).
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Table 5.4 Comparing the actual number of CVD hospital admissions with the 
estimated number of CVD patients per year in the three different equations 
amongst Thai men by age groups, in 2009
Men Observed number 
of CVD patients in 
2009 (only UC)
The average of estimated number of people who 
are alive with per year
Age APCS
Framingham
Asia
Framingham
original
15-24 2 ,479 3,089 3,050 6,208
25-34 4,661 2,758 2,724 9,685
35-44 13,135 17,481 17,180 30,888
45-54 27,217 31,090 29,711 50,157
55-64 37,721 70,788 63,856 113,956
65-74 40,861 102,272 87,955 162,741
>75 32,122 90,347 78,791 127,326
Total 158,196 317,825 283,268 500,961
Women Observed number 
of CVD patients in 
2009 (only UC)
The average of estimated number of people who 
are alive with CVD per year
Age APCS
Framingham
Asia
Framingham
original
15-24 2,227 1,564 1,484 2,535
25-34 3,768 6,657 6,517 7,966
35-44 11,459 11,719 11,285 16,090
45-54 25,308 31,679 31,331 37,765
55-64 36,352 67,116 68,094 80,765
65-74 45,637 95,128 97,871 103,495
>75 44,488 103,417 107,810 86,053
Total 169,239 317,280 324,392 334,670
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5.4 Discussion
The probability of CVD events, which are calculated by the APCS equation, the 
Framingham-Asia equation, and the original Framingham equation, increases 
accordingly with an increase in the age groups, in both men and women (Table 5.1 and 
5.2). However, the original Framingham equation projects a higher CVD probability 
than either the APCS equation or the Framingham-Asia equation, in both men and 
women at all age groups. This might be because the original Framingham equation was 
derived from the Framingham cohort, who have different characteristics of CVD risk 
factors and ethnicity, compare to the Asian population. Many studies have found that 
the Framingham's function was suitable for predicting future CVD in middle aged US 
white populations, and others with similar profiles of CVD risks (Liao et al. 1999, 
Diverse Populations Collaborative Group 2002). However, some studies showed an 
overestimated prediction for groups which have different risk profiles and ethnicity, 
such as Asian and some EU populations (Liu, Hong and D'Agostino 2004, Thomsen et 
al. 2002, Haq et al. 1999, Brindle et al. 2006). The APCS equation was derived from 
the pooled data of the cohort studies around Asia and included the EGAT cohort study 
in Thailand. Hence, the Framingham-Asia equation was also recalibrated with the 
APCS cohort. Therefore, the APCS equation and the Framingham-Asia equation are 
more suitable than the original Framingham equation, when applied to the Thai 
population.
When comparing genders, the original Framingham equation calculated the 
higher probability of CVD in men than in women. Conversely, the probability of CVD 
in women is higher than in men in the Framingham Asia equation (Table 5.1). This 
might because the Framingham Asia equation was reported to overestimated the risk of 
CVD by an average 4% in women and underestimate the CVD risk by an average 2% in
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men, in the non-chinese cohorts (Asia Pacific Cohort Studies Collaboration et al. 2007). 
In addition the prevalence of regular smoking in women is lower than in men, which 
might have an impact and affect the calculations.There are some metabolic risk factors 
in women which are higher than men. For example, the mean of BMI in women is 24.36 
kg/m2 but in men is 23 kg/m2. The mean of total cholesterol in women is 5.58 mmol but 
in men is 5.27 mmol. Hence, the prevalence of diabetes in women is 10.9% but in men 
is 9.3%.
In terms of the mathematical equations, there are some limitations of using the 
APCS equation, the Framingham-Asia equation and the original Framingham equation. 
Firstly, the setting of mathematical models are different. The APCS equation and the 
Framingham-Asia applied the Cox's model but the original Framingham equation was 
derived from the Weilbull's model.
Secondly, the input parameters of the risk factors in the APCS and the 
Framingham-Asia equations are limited because the APCS and the Framingham-Asia 
were trying to derive equations that can be used with the limited sources of information 
and also be applicable to many countries around Asia. Therefore, the APCS and the 
Framingham-Asia equation used BMI, age, gender, blood pressure and total cholesterol 
to project the CVD events. On the other hand, the original Framingham equation 
included all of those variables and diabetes status, which is another potential risk factor 
of CVD.
Thirdly, the time frame differences, the APCS and the Framingham Asia 
equations are both based on an 8-years cohort study, while the original Framingham 
equation is based on 10-years of follow-up period. Therefore, when conducting the 
validation of the mathematical models, the average number of CVD patients per year
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has been used to compare the number of actual CVD hospital admissions in a single 
year.
In term of the outcome limitations, the APCS equation and the Framingham- 
Asia equation estimated only the number of all CVD events but cannot estimate the 
CVD conditions seperately. The original Framingham equation is more flexible in 
being able to calculate the CVD events sepreately for IHD or Stroke. However, all three 
equations calculate both fatal and non-fatal events together, which cannot identify the 
exact number of people who die from or are alive with CVD. Therefore, the CVD 
mortaliy probability is applied to the number of all CVD events, to get the number of 
people who are likely to die from CVD. Then, deduct this number from the number of 
all CVD events to obtain the number of people who are alive with a CVD condition 
(Table 5.3).
Additionally, this analysis assumed that all individual had no previous history of 
CVD because the APCS, Framingham-Asia and the orginal Framiningham equation 
were derived based on the general population. However, in reality, the general 
population may contain healthy or asymptomatic people and people who currently have 
CVD conditions. Ideally, the estimation should remove the people who currently have 
CVD, but according the descriptive analysis of the NHESIV, Thailand (Chapter 4), 
there were a small proportion of the population of people who have CHD or Stroke, 
which can effectively be ignored from the analysis.
When validating the equations against the actual number of the hospital 
admissions due to CVD in Thailand, the APCS equation and the Asia-Framingham 
equation both closely estimated the total number of CVD patients (Table 5.4). The 
original Framingham equation overestimated the total number of CVD patients in both 
men and women. The validation showed a close estimation at age 35 to 44 years and 45
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to 54 years in both men and women when applying the APCS and the Framingham-Asia 
equations. However, all three equations overestimated the risk in the older population, 
because the CVD risk equations are derived from middle age groups populations. The 
APCS and the Framingham Asia equations are derived from cohorts age 30 to 75 years. 
The original Framingham equation was derived from cohorts aged 30 to 62 years. When 
applying the equations to the younger age groups (15 to 34 years), they did not estimate 
CVD events accurately. Additionally, the younger generation in Thailand may have a 
different lifestyle than the older generation, such as undertaking less physical acitivites 
and an unhealthy diet. Moreover, there are a limited number of studies that derieved 
CVD risk equations for a population aged under 30 years old.
In terms of the mortality data, the number of deaths from CVD may be 
underestimated, because the average 10-year CVD mortality probability has been 
calculated from the national CVD mortality rate in Thailand during 1996 to 2006, but 
the estimation is based on the year 2009. Hence, the death registry in Thailand might be 
under-reporting or miss classifying the causes of death in its data. Moreover, the CVD 
mortality rate in 2009 was presented as a total mortality rate, but not presented by age 
groups and gender. Therefore, the 10-years mortality during 1996 to 2006 was used 
instead because it was the best available data during the period of this study.
In conclusion, the APCS equation and the Asia Framingham equation performed 
the better estimation than the original Framingham equation for the Thai population. 
Although the Asia Framingham equation has perform the estimation nearly the same as 
the APCS equation, the Asia Framingham equation was derived from the Framingham 
cohort which has the different population characteristic with the Asia population. The 
APCS equation was derived from the Asia cohort studies which including the Thai 
EGAT cohort study. Additionally, the actual number of CVD event that use in the
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validation covered 75% of the hospital admission data in Thailand which may 
underreport the number of CVD cases overall. Moreover, The APCS equation is 
applicable for the Asia population which will enhance the capability of the model to 
apply it in different setting. Therefore, this study will use the APCS equation as the risk 
engine in the next stages of modelling.
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Chapter 6 : Health care costs of CVD in Thailand
Abstract
Cardiovascular disease (CVD) has become a leading cause of death and 
disability in Thailand because the life style of population has changes to the 
unhealthy life style which increase the level of CVD risk factors. The number of 
hospital admissions from CVD has continuously increased year by year, which 
increases health care expenditure for the health care service providers. This chapter 
undertakes to analyse the costs of hospitalisation for CVD inpatients in Thailand, 
2009.
The costs of hospital admission have been analysed from the health service 
providers perspective. The direct medical costs and direct non-medical expenditure 
during hospital admission have been included in the analysis. The descriptive analysis 
has been performed, to present the overall health care costs of CVD, in mean and 
absolute total costs of hospital admissions, which will reflect the burden of health care 
expenditure at the national level.
The secondary anonymous inpatient data from the “Universal Coverage” (UC) 
health care scheme during 2009 has been obtained from the National Health Security 
Office (NHSO), Thailand. 327,435 CVD inpatients were classified according to ICD- 
10 code, of which 120-125 referred to IHD, 160-169 referred to stroke and 100-199 
referred to all CVD conditions.
Of the 327,435 CVD inpatients, 26.42% were aged 65 to 74 years old and 
23% were aged 75 years old and over, 51.69% were women and 48.31% were men. 
The average health care cost for all CVD conditions (100-199) was $21,921 per patient 
(£1 = $50*). The average health care cost for IHD patients was $32,884 per patient, 
while stroke patients had health care expenditure on average of $25,617. The average 
length of stay in hospital for stroke patients was higher than IHD patients and other 
CVD conditions. The average health care cost per day of IHD patients was higher 
than stroke patients. The absolute total cost increased as the age groups increased. 
Male patients had a higher cost of hospital admission than women. Overall in 2009, 
the health service providers spent $7,177 million on treatment of CVD. The total cost 
of IHD was $2,544 million and the total cost of stroke was $1,920 million.
CVD was a significant proportion of healthcare expenditure from a health care 
provider perspective.
*$ is the symbol of Thai currency (Baht).
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6.1 Introduction
Over the past decade, CVD have been one of the leading causes of premature 
death and disability and have become an increasing burden in Thailand (International 
Health Policy Program 2009). As a result of Thailand’s urbanisation the peoples’ 
lifestyles have changed, such as a decrease in the level of physical activities, changing 
their dietary patterns and habits which increase metabolic risk factors such as BMI, total 
cholesterol and blood pressure (Aekplakom et al. 2012, Satheannoppakoa et al. 2010, 
Chongsuvivatwong et al. 2010, Stolk et al. 2005, Roth et al. 2011).
The National Health Security Office, Thailand reported that the number of 
hospital admissions which are caused by CVD conditions has continuously increased 
and has tripled since 1992 (National Health Security office 2010). This has not only 
resulted in the increase of the number of the hospital admissions but has also affected 
the loss of productivity due to absence from work, a decline in the quality of life and 
increased health care expenditure, of both health care services providers and the 
patients’ families. In 2007, Thailand spent $36.5 million on inpatients medical care for 
non-communicable diseases, of which 10% of this expenditure was attributable to CVD 
(Garg and Evans 2011). There were several studies on the health care cost of CVD in 
Thailand. In 2007, the median cost of treatment for acute coronary syndrome (ACS) 
patients was $47,908 (£1 = $50). However, the cost of treatment varied depending on 
the diagnosis group, treatment procedures and complication of the diseases 
(Moleerergpoom et al. 2007). The annual hospital charges for treatment of multiple 
chronic conditions varied from $611 to $16,794, depending on the health status and 
severity of the disease in the patient (Thanapop, Pannarunothai and Chongsuvivatwong
2009). Some studies estimated the medical costs attributable to risk factors such as 
cigarette smoking and obesity. The average direct out-of-pocket cost of CHD which was
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attributable to smoking was estimated at $33,716.40 per patient or $1,773.68 million in 
total (Leartsakulpanitch, Nganthavee and Salole 2007). The total economic cost 
attributable to obesity has been estimated at $2,168.4 million spending on IHD and $ 
2,017.6 million spending on stroke, which includes health care costs, cost of premature 
death and the cost of productivity loss due to hospital-related absenteeism 
(Pitayatienanan et al. 2014).
In terms of the cost of the stroke rehabilitation, Archongka et.al (2008) found 
that stroke patients spent, on average $11,170.56 ± 5641.73 per patient at the medical 
rehabilitation (Archongka et al. 2008). Additionally, out of pocket expenses of stroke 
patients occurs when they need informal care, which is usually provided by their family, 
friends or neighbours.The cost of informal care for stroke patients has been estimated at 
$4,642.6 per month, based on 2006 prices. The average time spent on the domestic care 
of stroke patients was 94.6 hours, which implies that there is a loss of opportunity costs 
which are forgone because of unpaid work undertaken in caring for the patient 
(Riewpaiboon et al. 2009).
Although it is already known that CVD has become an economic burden in 
Thailand, the studies on the costs of hospital admissions is not up to date and is mostly 
limited to single health care units or single groups of patients. This chapter aims to 
calculate the national level of the total cost of CVD for Thailand during 2009.
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6.2 Methods
This is a prevalence-based study of the health care expenditure of CVD in­
patients in Thailand, 2009.
6.2.1 CVD
In this study, CVD is defined according to the international classification of 
diseases 10th version (ICD-10). The CVD conditions have been classified by the 
ICD-10th codes of which 120 to 125 refer to ischemic heart diseases, 160 to 169 refer to 
stroke and 100 to 199 refer to all CVD conditions. The list of ICD-10 codes is in 
appendix E.
6.2.2 Data sources
The health care costs of CVD have been analysed using data from the inpatients 
services in Thailand in 2009. The numbers and the costs of the anonymous inpatient 
data were obtained from the National Health Security Office (NHSO), Thailand. This 
data includes the inpatient hospital admissions in the Universal Coverage health care 
scheme (UC), which is the major health care insurance system in Thailand. 
Approximately 47.24 million of the population or 75.29% of the total population of 64 
million are in the UC scheme. The health care services cover 11,460 health care units 
nationwide, which include public hospitals managed under the ministry of public health, 
other public hospitals, private hospitals and sub-district health promoting hospitals. 
The data collection process has been described in chapter 3.
6.2.3 Data cleaning and verification
The anonymous CVD inpatients data has been classified by the ICD-10 code. A
descriptive analysis of all variables in the data set has been performed to look at data
coding, frequency and the distribution of data. If the total cost, the length of stay and the
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average cost per day is inconsistent, those records will be recorded as missing. The 
continuous variable has been checked for the outlier value. For example, the length of 
stay and the total cost of hospital admission. The length of stay has been examined for 
the outlier. The inpatients who were admitted into hospital for more than 365 days have 
been recoded to be missing. The outlier value of the total cost of hospitalisation data has 
been identified by calculating the cost of hospital admissions per day. The minimum 
cost of hospital admission was set at $500 per day (£10 per day) which was the 
minimum payment when patients were admitted to a public hospital. The maximum cost 
of hospital admission was up to $65,000 per day (£1300 per day), which was the 
possible maximum cost if the patients received a specialist medical procedure or were 
admitted to an intensive care unit (ICU).
6.2.4 Health care cost
This study has focused only on the health care service providers’ perspective. 
The total cost of treatment and hospitalisation included both direct medical cost and 
direct non-medical cost such as; room rates and meals, the prosthesis / medical devices 
used in treatment, medication that was used in hospitals, the medical diagnosis and the 
clinical resources, therapeutic radiology, medical equipment, medical procedure fees, 
nursing services, physical and rehabilitation services in hospital and other specialist 
diagnostic methods and the other treatments from health professionals. However, this 
study has not focused on the patient’s perspective. Therefore, the indirect costs, such as 
the cost of productivity loss due to absence from work and the patients and their family 
out of pocket expenses have not been included in this analysis.
6.2.5 Statistical Analysis
The descriptive analysis has produced the results in percent, mean and absolute
total cost of hospitalisation. The unit of hospitalisation cost will be presented in Thai
159
currency (Baht, (£1 = $50)).The total cost of hospital admissions will be calculated by 
multiplying the number of CVD patients by an average cost of hospital admission per 
patient. The statistical analysis has been performed by STATA software version 12 
(StataCorp LP 2011).
6.3 Results
Table 6.1 shows the number and percentage of the 327,435 patients who had a 
primary diagnosis with CVD conditions (ICD-10,100-199), classified by CVD condition, 
age group, gender, length of stay and the discharge status. Of the 327,345 patients, 
23.6% had IHD, 22.9% had stroke and 53.5% had other CVD conditions. The number 
of CVD inpatients increased respectively by age groups but slightly decreased at age 75 
years and over. The number of IHD and stroke patients was high in the middle and 
elderly age groups, with the number of patients increasing at age 45-54 years and reach 
the highest at age 65-74 years. Although the number of CVD inpatients in younger 
adults aged 15-24 years and 25-34 years was lower than in the older age groups, the 
proportion of patients who had other CVD conditions was higher than the older age 
groups. For examples, at age 15-24 years, of 4,706 patients, 3.1% had IHD, 12.8% had 
stroke and 84.2% had other CVD conditions. While at age 55-64 years, of 74,073 
patients, half of them had IHD and stroke and half of them had the other CVD 
conditions.
When comparing between genders, the number of inpatients with IHD and 
stroke in men was higher than in women. Conversely, the number of patients with other 
CVD conditions was higher in women than in men. However, overall more women 
were admitted to hospital with CVD conditions than men.
When classifying patients by the length of stay, patients with CVD condition 
were mostly admitted to hospital for less than one month. 24% of patients in this group
160
were admitted with IHD, 22% admitted with stroke and 54% admitted with other CVD 
conditions. However, there were 4,438 inpatients who were admitted between 1 to 3 
months, 52% of them admitted with stroke, 15% admitted with IHD and 34% admitted 
with other CVD conditions. Additionally, patients who were admitted to hospital for 
more than 3 months were mostly stroke patients.
For the discharge status, 273,787 patients had improved from their illness when 
discharged from the hospital. 23.7% of them improved from IHD, 20.1% improved 
from stroke and 56.2% improved from the other CVD conditions. 1,163 patients had 
complete recovery after being admitted to hospital of which 21.2% recovered from IHD, 
13.2% of them recovered from stroke and 65.5% recovered from the other CVD 
conditions. However, there were 30,969 patients who did not improve from their illness 
and 21,399 patients were discharged because they died in hospital.
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Table 6.1 Number and percentage of CVD patients classified by CVD conditions, 
Universal coverage health care scheme (UC), Thailand 2009
Categories IHD Stroke Other CVD All CVD
Age
15-24 146(3.1%) 600(12.8%) 3,960(84.2%) 4,706(100%)
25-34 614(7.3%) 1,266(15%) 6,549(77.7%) 8,429(100%)
35-44 3,483(14.2%) 4,774(19.4%) 16,337(66.4%) 24,594(100%)
45-54 10,997(20.9%) 12,211(23.3%) 29,317(55.8%) 52,525(100%)
55-64 19,945(26.9%) 16,902(22.8%) 37,226(50.3%) 74,073(100%)
65-74 23,894(27.6%) 20,129(23.3%) 42,475(49.1%) 86,498(100%)
>75 18,314(23.9%) 19,067(24.9%) 39,299(51.2%) 76,610(100%)
Gender
Men 42,692(27%) 40,736(26%) 74,768(47%) 158,196(100%)
Women 34,701(21%) 32,213(20%) 100,325(59%) 169,239(100%)
Lengths of stay
< 1 month 76,720 (24%) 72,289(22%) 173,487(54%) 322,496(100%)
>1-3 months 646(15%) 2,290(52%) 1,502(34%) 4,438(100%)
>3-6 months 22(6%) 281(71%) 92(23%) 395(100%)
>6-9 months 1(1.6%) 56(84.9%) 9(13.6%) 66(100%)
>9-12months 2(15.4%) 9(69.2%) 2(15.4%) 13(100%)
Unspecified 2(7.4%) 24(88.9%) 1(3.7%) 27(100%)
Discharge Status
Complete recovery 247(21.2%) 154(13.2%) 762(65.5%) 1,163(100%)
Improve 64,988(23.7%) 54,949(20.1%) 153,859(56.2%) 273,787(100%)
Not improve 7,162(23.1%) 10,492(33.9%) 13, 1315(42.9%) 30,969(100%)
Died 4,969(23.2%) 9,340(43.7%) 7,090(33.1%) 21,399(100%)
Unspecified 27(23.1%) 23(19.7%) 67(57.3%) 117(100%)
Total 77,393(23.6%) 74,949(22.9%) 175,093(53.5%) 327,435(100%)
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Table 6.2 shows the absolute total cost of hospital admissions by categories and 
CVD conditions. Overall, CVD patients cost $7,199 million (£143million) of which 
IHD patients cost $2,531 million (£50million), stroke patients cost $1,907 million (£38 
million) and the other CVD conditions cost $2,680 million (£53 million). The absolute 
total cost increased with each increasing along with age but slightly decreased at age 75 
years and over. When compared between genders, male patients had an absolute total 
cost of hospital admission more than women, which was $3,888 million (£77million) in 
men and $3,231 million (£64 million) in women. The health care costs to treat men 
with IHD and stroke cost more than women. On the other hand, more was spent on 
women than men with other CVD conditions. The graph which compares the absolute 
total costs by age groups, gender and CVD conditions is presented in appendix G.
In terms of the length of stay, the absolute total health care cost was highest in 
patients who were admitted to the hospital for less than one month because the number 
of patients in this group was higher than the other groups. The total cost spent on 
patients who had IHD and were admitted to hospital for less than 1 month was $2,353 
million (£47 million). Patients with stroke and admitted to hospital for less than 1 month 
cost $1,261 million (£25 million). Additionally, patients with other CVD conditions 
cost as much as IHD patients, which was $2,328 million (£46 million). Furthermore, 
patients who were admitted between 9 to 12 months had a higher absolute total cost 
than patients who were admitted between 1 and up to 9 months.
When classified by the discharge status, the highest absolute health care cost 
was in patients who improve from illness, which cost $5,710 million (£114 million) in 
total, of which $2,215 million (£44 million) was spent on IHD patients and $1,268 
million (£25 million) spent on stroke patients and $2,227 million (£44 million) spent on
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other CVD patients. However, the total cost of hospital admissions was higher in 
patients who died from CVD.
Table 6.2 The Absolute total cost of hospital admission by categories and CVD 
condition (THB ($)*)
Categories IHD stroke other CVD All CVD
Age groups
15-24 2,257,119 27,325,711 79,120,065 108,702,894
25-34 14,390,400 37,450,052 127,964,733 179,805,186
35-44 108,533,174 141,845,311 319,239,325 569,617,811
45-54 380,368,138 325,286,934 532,507,274 1,238,162,346
55-64 744,748,695 419,013,435 579,576,458 1,743,338,588
65-74 814,269,234 489,638,746 582,287,556 1,886,195,536
75+ 466,645,916 466,828,809 460,208,145 1,393,682,870
Gender
Men 1,532,931,439 1,038,994,870 1,316,312,781 3,888,239,089
Women 998,281,238 868,394,128 1,364,590,777 3,231,266,142
Length of stay
< 1 month 2,353,265,367 1,261,968,543 2,328,073,213 5,943,307,123
>1-3 months 159,254,375 462,529,711 297,183,150 918,967,236
>3-6 months 15,696,554 129,767,646 44,386,186 189,850,386
>6-9 months 573,153 28,518,983 9,063,731 38,155,866
>9-12months 1,883,622 6,503,539 1,716,157 10,103,318
Discharge Status
Complete recovery 8,020,575 3,389,411 17,132,857 28,542,843
Improve 2,215,026,299 1,268,554,308 2,227,019,320 5,710,599,928
Not improve 77,724,478 164,419,209 134,613,690 376,757,378
Died 229,479,019 470,848,354 301,279,921 1,001,607,294
Total___________
*Note: (£1 = $50)
2,531,212,676 1,907,388,998 2,680,903,557 7,119,505,231
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Table 6.3 shows the summary of total cost of hospitalisation by CVD conditions 
in 2009. There were 327,435 CVD patients admitted to hospital under the UC health 
care scheme. 77,393 patients were admitted for IHD, 74,949 patients were admitted for 
stroke and 175,093 patients were admitted for the other CVD conditions.
The average length of stay was highest in stroke patients which was 6.72 days, 
IHD patients stayed in hospital on average 4.12 days, while patients who had other 
CVD conditions stayed in hospital on average 3.99 days. The average cost per day was 
highest in IHD patients, which cost $10,681 per day and second highest in stroke 
patients which cost $4,067 per day, while the other CVD conditions cost $3,614 per day.
The average cost per patients was highest in IHD patients, stroke and other 
CVD respectively. IHD patients cost on average $32,884, stroke patients cost on 
average $25,617 and the other CVD patients cost on average $15,465 .
The total cost of IHD was $2,544 million and the total cost of stroke was $1,920 
million. The total cost of the other CVD conditions was $2,707 million, which was 
higher than IHD and stroke.
Overall, the CVD patients admitted to hospital stayed on average 4.65 days, the 
average cost per day was $5,393 and the average cost per patients was $21,921. The 
health service providers spent in total $7,177 million on treatment of CVD.
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Table 6.3 Summary of total cost of hospitalisation by CVD conditions in 2009
CVD
Conditions
Total 
number of
cases
Average 
length of stay 
(days)
Average 
cost per 
dav
(THE*)
Average cost 
per patient 
(THE*)
Total cost 
(THB*)
=(number of
cases*
average cost 
per patients)
IHD
(120-125) 77,393 4.12 10,681 32,884 2,544,991,412
Stroke
(160-169) 74,949 6.72 4,067 25,617 1,920,018,748
other CVD 175,093 3.99 3,614 15,465 2,707,858,769
All CVD 
(100-199) 327,435 4.65 5,393 21,921 7,177,705,909
*Note: (£1 = $50).
6.4 Discussion
Although the analyses focused only on patients covered under the UC health 
care scheme, it covered the majority (75.29%) of the total population. The other health 
care schemes that were not included in the analysis were the Social Security health care 
scheme (SS), which covered 15.42% of population and the Civil Servant health care 
scheme (CS) which covers 8.2% of population. Another limitation is that data covers 
mainly public hospitals, and only 60 private hospitals. Therefore, the cost of hospital 
admission is not properly representative in This data. Additionally, this analyses focuses 
only on the total expenditure that occurred when patients were admitted to hospital. So, 
it was only from a health service provider perspective. There may have been hidden 
costs occurring when the patients were discharged from hospital. They may have 
needed long-term care and rehabilitation. Other cost related to patients as well as the 
productivity loss and absenteeism were not the focus of this study. Furthermore, there 
was a limitation of the dataset which did not provide the information on the type of
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medical procedures that had been used for treatment, which may have an affect on the 
cost of hospitalisation when patients required specialist treatments.
Considering the health care costs by age groups (Table 6.2), the absolute total 
health care cost was higher in the middle to elderly age groups because the number of 
cases was higher than younger age groups. Although the younger age groups had lower 
numbers of hospital admissions which 1.44% of CVD inpatients were in age 15 to 24 
years, when exploring the primary diagnosis of this age group, it was found that most 
patients at age 15 to 24 had been diagnosed with other CVD conditions such as arteritis 
hypotension, endocarditis etc.
When comparing the health care cost by discharge status (Table 6.2), it was 
found that patients who died from CVD had the highest expenditure compared to those 
who completely recovered and those who did not improve. This was because the 
patients who died were more likely to have stayed in hospital longer than patients in the 
other groups. When investigating the average length of stay by discharge status, it was 
found that patients who died from CVD had an average length of stay 7.23 days. While, 
patients who improved from CVD after admission to hospital stayed on average 4.6 
days and patients who completely recovered from CVD stayed on average 4.05 days. 
On the other hand, patients who did not improve from CVD stayed on average 3 days.
Although the average cost per patients in the other CVD conditions is lower than 
IHD and stroke, the total cost of other CVD conditions was at the highest at $2,707 
million, because the number of total cases in this group is higher than IHD and stroke. 
However, IHD and stroke have a higher cost per patient (Table 6.3).
In conclusion, this study found that CVD had a significant impact on the
hospitalisation costs and economic burden on Thailand. In 2009, the health service
providers spent $7,177 million on hospital admissions due to CVD conditions. The total
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expenditure for IHD patients was $2,544 million and for stroke patients was $1,920 
million.
168
Chapter 7 : : The impact of reducing risk factors for 
CVD in Thailand
Abstract
Cardiovascular disease (CVD) is considered as one of the main health problems 
in Thailand, which is not only increasing in the number of hospital admissions year by 
year, but is also having an effect of increasing the health care expenditure for the 
treatment and long-term care of CVD patients. The aim of this chapter is to cany out a 
CVD cost-offset model at population level to estimate the impact of risk reduction 
strategies on the number of CVD hospital admissions, Disability Adjusted Life Years 
(DALYs) and the costs of hospitalisation.
The CVD cost-offset model has been implemented on a Microsoft Excel 
spreadsheet. The number of the mid-year population, classified by age, gender and the 
CVD risk factors profile from the NHESIV in 2009 have been used as the baseline 
population data. The CVD risk factors profile included age, gender, systolic blood 
pressure, total cholesterol and cigarette smoking status. The APCS equation (Asia 
Pacific Cohort Studies Collaboration et al. 2007) has been applied to calculate the 
probability of getting CVD over the next eight year period. The model has provided an 
estimate number of CVD events, both fatal and non-fatal and by deducting the projected 
number of deaths from that total, will provide the number of patients who will live with 
CVD. The model also calculates the DALYs from the estimated number of fatal and 
non-fatal events. The cost of hospital admissions has been estimated by using the costs 
of hospitalisation from 2009. A 3 percent discounted rate has been applied in both the 
costs and DALYs, for adjusting the costs and benefits that occur in the different time 
periods. Four CVD risk scenarios have been investigated, these are:l) do nothing 
scenario; 2) optimistic scenario; 3) achieve the UN millennium development goal; and 
4) worst case scenario.
The model has estimated the impact of reducing the risk factors among the 
population. If the level of risk factors remain the same as it was in 2009, (do nothing 
scenario), the number of CVD cases will reach 3,361,472 patients over the next eight 
years, which is estimated to be 5,620,626 DALYs and cost approximately $58,169 
million for hospital admissions. However, if the health policy can reduce the levels of 
risk factors, as in the optimistic scenario or achieve the UN millennium development 
goal, there will be a significant reduction in the number of hospital admissions of 
540,097 cases or 533,052 cases respectively. This will result in saving health care 
expenditure of approximately $9,000 million and 750,000 DALYs during the next eight 
years. On the other hand, if the trend of risk factors increases as predicted in the worst 
case scenario, there will be an increase of 442,963 CVD cases. This will increase the 
DALYs figure by 623,925 and increase the hospitalisation costs by approximately 
$7,000 million.
The findings of this study suggest that reducing the levels of CVD risk factors in 
the population will have a significant impact on reducing the number of CVD cases, 
saving DALYs and saving health care costs. The health policy should enhance the 
primary prevention programs which are targeted at reducing the CVD risk factors in the 
population.
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7.1 Introduction
CVD is considered one of the main potential health problems in Thailand. The 
burden of disease and injury study in Thailand in 2009 estimated 1,146,064 DALYs lost 
from CVD, which includes both IHD and stroke (International Health Policy Program 
2012). The DALYs lost from stroke was ranked as the third highest in men and the 
second highest in women. While, IHD was ranked as the sixth and fourth highest cause 
of death and disability in men and women respectively. Although the overall mortality 
rate in Thailand has decreased during the past decade due to the improvement in the 
health care services; the prevalence of CVD has continuously increased (Bureau of 
Non-Communicable Disease,Department of Disease Control,Ministry of Public health 
2010). The increase in the prevalence of CVD has affected the increasing need for 
medical and long term care for CVD patients. As a consequence, CVD has become a 
burden for both patients and the health service providers in terms of health care 
expenditure.
The increase in the prevalence of CVD is related to socio-economic and lifestyle 
changes in the population in Thailand, which has increased the risk of CVD 
(Aekplakom, et al. 2010). It has been proved that the classical CVD risk factors such as 
ageing, high blood pressure, high total cholesterol and cigarette smoking are related to 
instances of CVD (Yusuf et al. 1998, Lloyd-Jones et al. 1999, McGorrian et al. 2011, 
Yusuf et al. 2004). The Ministry of Public Health, Thailand has encouraged the 
reduction of these modifiable risk factors at the population level. Many public health 
interventions have been implemented, such as health education, advocating physical 
activity, promoting healthy diets and changing smoking regulations (Ministry of Public 
Health 2012). However, this raises the following questions: will the investment in 
public health programs reduce the further demand for health care in the population and,
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if so, how much benefit will be gained from reducing the risk factors at population level? 
among population?
In terms of CVD modelling, several studies have projected the number of future 
CVD events and future health care expenditure for the country, based on the current 
information of the risk factors levels in the population (Mui 1999, Heidenreich et al. 
2011, Kang et al. 2011). Some studies have found that reducing the levels of risk factors 
among the population will reduce the number of deaths and disability from CVD as well 
as saving costs on the number of hospital admissions (Grover et al. 1998, Capewell, 
Morrison and McMurray 1999, Goldman et al. 2001, Whitfield et al. 2006, Moran et al.
2010). Many studies in the health economic field have investigated the cost- 
effectiveness of secondary prevention programs and treatment strategies, such as 
comparing the multidrug regimen for prevention of CVD (Lim et al. 2007, Conly et al. 
2011, Cobiac et al. 2012), coronary artery revascularization procedures (Mannan, 
Knuiman and Hobbs 2008), treatment of high blood pressure (Dodhia et al. 2012).
This study steps back from the secondary prevention strategies, but focuses on 
the primary prevention strategies which should be implemented in the general 
population, to prevent them from being admitted into hospital due to CVD. The aim of 
this chapter is to estimate the impact of public health risk reduction strategies on the 
potential benefits of investment. The mathematical model has been conducted, which 
integrated the modified risk equation from the Asia Pacific Cohort study collaboration. 
The eight year probability of CVD events has been calculated based on the population 
level risk factors information from 2009. The model has estimated the number of people 
who are likely to be admitted to the hospital with CVD conditions which include both 
IHD and stroke, as well as the burden of the disease in tenns of DALYs. The outcomes
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of interest in this chapter are represented by the impact in terms of the number of CVD 
hospital admissions avoided, DALYs saving and the health care financial savings.
7.2 Method
7.2.1 The CVD cost-offset model
A CVD cost-offset model has been carried out in order to: 1) estimate the 
number of CVD hospital admissions during the next eight year period; 2) estimate the 
burden of disease in terms of DALYs; and 3) estimate the cost of hospital admissions 
due to CVD conditions. The CVD cost-offset model has been used to assess the impact 
of risk reduction strategies on the number of hospital admissions, DALYs and direct 
health care costs. The impact of changing the risk factors at the population level has 
been investigated through 4 different scenarios. The analysis process has been described 
below.
The CVD cost-offset model has been conducted using a Microsoft Excel 
spreadsheet. The number of the mid-year population by age group and gender in 2009 
has been used as the baseline population. The CVD risk factors such as age, systolic 
blood pressure, total cholesterol and regular smoking, from the 4th National Health 
Examination Survey (NHESIV) in 2009 (Aekplakom, et al. 2010), have been used as 
the input parameters to represent the mean level of risk factors of the Thai population, 
by age group and gender. Table 7.1 shows the input data of the cost-offset model based 
on the number of mid-year population and the risk factors profile during 2009.
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Table 7.1 The input data: number of mid-year population and the mean level of 
risk factors by age group and gender in 2009
The mean level of risk factors at 2009
Men
Mid-year population 
2009 Age (years) SBP (mniHg) TC (mmol)
Smoking 
prevalence (%)
15-24 4,683,981 18.76 117.24 4.60 28.5%
25-34 5,149,508 29.92 120.80 5.27 42.3%
35-44 5,154,963 39.75 122.56 5.43 39.9%
45-54 4,058,120 49.33 126.44 5.46 42.6%
55-64 2,399,309 60.11 131.44 5.40 34.4%
65-74 1,362,752 69.17 134.60 5.31 30.5%
>75 749,125 79.22 137.22 5.20 23.5%
Total 23,557,758 52.80 128.39 5.28 34.0%
The mean level of risk factors at 2009
Women
Mid-year population 
2009
Age
(years)
SBP 
(m m 11 g)
TC
(mmol)
Smoking
prevalence(%)
15-24 4,532,018 18.97 106.19 4.90 0.7%
25-34 5,130,746 29.87 110.19 5.21 1.4%
35-44 5,408,488 39.65 116.04 5.30 1.8%
45-54 4,388,770 49.10 123.92 5.70 2.6%
55-64 2,694,633 60.02 129.45 5.92 3.0%
65-74 1,655,159 69.24 134.53 5.80 3.5%
>75 1,086,374 79.48 139.19 5.66 5.2%
Total 24,896,188 52.60 124.70 5.58 3.0%
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The probability of experiencing CVD events within an eight year period has 
been calculated by using the APCS equations (Asia Pacific Cohort Studies 
Collaboration et al. 2007). The risk factors that are included in the equation are age, 
systolic blood pressure, total cholesterol and smoking.
The model has calculated the probability of CVD events within an eight year 
period by age group and gender. Then, the eight year probability of CVD events has 
been multiplied with the number of the mid-year population to get the estimated number 
of CVD events in the next eight years. However, the APCS equation calculated the 
probability of all CVD events, which included both fatal and non-fatal CVD events. The 
number of CVD events resulting in mortality has been estimated by using the average 
10 year probability of dying from CVD in the general population during 1996 to 2006 
by age and gender. The probability of dying from CVD is shown in Appendix F. The 
number of people who are likely to die from CVD has been estimated by multiplying 
the number of the population in 2009 with the probability of dying from CVD by age 
groups and gender. Then, the model has deducted the number of people who are likely 
to die from CVD to obtain the number of people who will be alive with CVD conditions. 
The outcomes of interest are the number of people with CVD who are alive and the 
number of deaths from CVD conditions over the eight year period.
7.2.2 Disability Adjusted Life Years (DALYs)
Once the model had estimated the number of CVD events over an eight year 
period, the total DALYs for each age group and gender was calculated as the 
summation of the years lost due to disability (YLD) and the years of life lost due to 
premature death (YLL). Therefore, DALYs will present the burden of CVD which 
includes both non-fatal burden and the burden of premature death. The calculation 
procedure follows the WHO national burden of disease studies (Mathers, et al. 2001).
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DALY = YLD + YLL (7.1)
Where, YLD is the number of years lost due to disability and YLL is the number 
of years of life lost due to premature death.
7.2.2.1 Discounting and age weighting
It is a standard practice for a health economic analysis to discount the future 
benefits (Drummond, et al. 2005). This study has applied a 3% discount rate to years of 
life lost in the future, to estimate the net present value of years of life lost and for 
adjusting both future costs and health outcomes. A 3% discount rate has been applied in 
this study because it has been used in the Global burden of Disease study project (GBD) 
(Murray and Lopez 1996) and the burden of disease study project in Thailand 
(Bundhamcharoen et al. 2011).
The standard age weight from the GBD Study has been applied in the analysis. 
The assumption of using the age weight was based on the social preference which value 
a year life in younger adult higher than a year lived by someone in the elderly age group 
because the younger adult are consider as in the labour force which have more 
economic productivity than the elderly age group. The GBD study performs an 
exponential function to express the age-weighting as follows:
Age weight = C x e (7.2)
Where, C is the age-weighting correction constant (GBD standard value 0.1658), 
p is determines the importance of age-weights (GBD standard value 0.04).
1.2.2.2 Calculating YLL
YLL is the number of years of life lost due to premature death which is 
calculated by multiplying the number of deaths with the standard life expectancies in 
each age-gender group.
175
YLL = N x L (7.3)
Where, N is the number of deaths and L is the standard life expectancy at age of 
death in years.
The estimated number of deaths in each age group has been entered to the 
spreadsheet to calculate YLL. The average age at death for each age group has been 
calculating by using the mid-point of age at death in each age interval.
Then, the standard life expectancies of these average age at death has been 
calculated by interpolation between the standard life expectancies at exact ages of death 
given from the West standard life tables(World Health Organization 2000). by single 
year of age
With 3% discounting and uniform age weights; YLL has been calculated with 
this formula:
YLL = —  ( l- e " 0 03L) (7.4)
0.03V '
Where, N is number of deaths and L is the Standard life expectancy at age of 
death in years.
When taking into account the 3% discount rate and age weight, YLL has been 
calculated with the full formula as follows:
YLL = NCe("V(p + r)2 (p + r)(L + a) — l ] -  e-(p+r)* [ - ( p  +  r )a - l ]J  (7.5)
Where,r is the discount rate (using GBD standard discount rate at 0.03 (3%)), 
C is the age-weighting correction constant (using GBD standard value 0.1658), |3 is the 
parameter foim age weighting function (using GBD standard value 0.04), a is the age of
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onset at death and L is the standard life expectancy at age of death in years which is the 
duration of time lost due to premature death (calculated from the standard life table).
7.2.2.3 Calculating YLD
YLD presents the years lost due to disability which is the one component of 
DALYs. The basic formula of YLD is:
YLD = I x D Wx L  (7.6)
Where, I is the number of incidence cases in the reference period, DW is the 
disability weight and L is the average duration of disability in years.
In this analysis, the estimated number of people who are alive with CVD 
conditions by age and gender has been entered into the spreadsheet as the number of 
incidence cases occurring during the eight year period (I). The disability weight that has 
been used as the average disability weight at 0.18 for all CVD conditions is taken from 
the GBD study undertaken in 2010 because the model has limitations on calculating the 
probability of CVD events by the specific CVD condition and it did not taken into 
account the severity of disease. The disability weight by CVD conditions of the GBD 
study is shown in Appendix G. The average age onset of disability and the duration of 
disability have been calculated by using DISMOD II software.
DISMOD II software has been developed by Jan J Barendregt, department of 
Public health, Erasmus University, Netherlands (EpiGear International Pty Ltd 2010). 
This software has been used as an analytical tool in the GBD study for checking the 
consistency of various data and for estimating the incidence, prevalence, duration and 
case fatality, when the partial data was not available. DISMODII has been commonly 
used in YLD calculations for estimating the incidence and duration of the disease from 
the available information about the country. An underlying generic disease model
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concept has been developed in DISMOD software to explore the causal relations and 
the disease process as shown in Figure 7.1.
Deaths from other 
causes
All other mortality rate
All other
Remission
rate
Incidence
Case fatality
Cases of disease Cause-specific deaths
General population
(without disease)
Figure 7.1 The conceptual generic disease model in DISMOD software (Barendregt 
et al. 2003)
The number of mid-year population, the background mortality, the prevalence 
of CVD and CVD mortality rate in the Thai population classified by age and gender in 
2009have been entered as the input information in the DISMOD software. This analysis 
assumed the remission rate from CVD is equal to zero. The DISMOD software will 
estimate the age onset of getting CVD and the duration of disability from CVD by age 
and gender. Then, the YLD has been calculated by using the following formula:
With a 3% discount rate and uniform age weight, YLD has been calculated 
using the formula as follows:
YLD = I x D W x l h £ ^ L )  (7.7)
0.03
Where, I is the number of incidence cases in the reference period, DW is the 
disability weight and L is the average duration of disability in years.
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When applying the discount rate and non-uniform age weight, the full formula 
of YLD is:
YLD =  /  x  DWx Ce*™’ /(/?  +  r ) 2[ - ( /?  +  r ) ( I  +  - l ] -  [ - ( /?  +  r )a  - 1 J
(7.8)
Where, DW is the disability weight, r is the discount rate (using GBD standard 
value 0.03), C is the age-weighting correction constant (using GBD standard value 
0.1658), p is the parameter for standard age function (using GBD standard value 0.04), 
a is the age onset of disability (calculated from DISMODII software), and L is the 
duration of disability (calculated from DISMODII software).
Once the model has calculated the YLL and YLD, DALYs will be calculated by 
the summation of YLL and YLD together to obtain the number of total DALYs, which 
takes into account both death and disability to reflect the burden of CVD in Thailand.
7.2.3 Health Care Cost for CVD patients
The average total cost of hospital admissions from CVD has been calculated 
from the inpatient services in Thailand during 2009. The costing data obtained from the 
national health security office includes the universal coverage health care scheme. 
The results of the health care costs have been analysed and presented in Chapter 6. The 
health care service providers spent on IHD $32,884 (£657) per patient, on stroke $
25,618 (£512) per patient and on all CVD conditions $21,921 (£438) per patient.
Because of the limitations of the APCS equation, which estimates the total CVD event
only, the average cost of all CVD conditions has been used to estimate the total health
care costs for the next eight years. The estimated total health care cost has been
calculated by multiplying the average cost per patient with the estimated number of
CVD cases. However, this analysis is based on the price at 2009; the discount rate has
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been applied to estimate the present value of the health care expenditure with the 
following formula:
Where, P is the present value, F is the payment that will be made t years in future, 
r is the discount rate (0.03), and t is time (years).
7.2.4 The impact of changing CVD risk factors
The model has taken into account the CVD risk reduction scenario analysis 
which targets the following three CVD risk factors; systolic blood pressure, total 
cholesterol and the prevalence of smoking at population level. The model estimates the 
impact of changes in only three CVD risk factors due to the input variables in the APCS 
equations. There are some underlying assumptions in the CVD cost offset analysis. The 
model assumes that the population structure and the health care system remains the 
same as they were in 2009. Therefore, there is no change in the number of the 
population by age group and gender over time and the mean age of each of the age 
group remain the same in the model.
The model has estimated the impact of changing the risk factors on the number 
of CVD patients, the number of DALYS and the cost of hospitalisation in four different 
scenarios. Table 7.2 shows the summary of the percentages of changing the risk factors 
in the scenario analysis for the CVD cost offset model which are described as follows:
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Table 7.2 Summary of the risk reduction scenario analysis for the CVD cost offset 
model
Scenario
% Change of the risk factors level
Systolic blood 
pressure Total Cholesterol Smoking
l)Do nothing 
scenario 0% 0% 0%
2)The optimistic 
scenario -5% -5% -5%
3)Reach the UN 
millennium 
development goal -5% 0% -30%
4) The worst case 
scenario +3.35% +11.7% -30%
1) Do nothing scenario: this scenario assumes that there is no change in CVD risk 
factors over time. The level of CVD risk factors remain the same.
2) The optimistic scenario: this scenario assumes that all CVD risk factors have been 
reduced in the population through public health initiative strategies. The target risk 
factors have been reduced 5%.
3) Reach the UN millennium development goal: this scenario estimates what will 
happen if the risk reduction strategies in Thailand can achieve the UN millennium 
development goals. The target of this goal is to reduce 25% of the global premature 
mortality from non-communicable disease (NCDs) based on the 2010 levels and to 
achieve it by 2025. This is a goal referred to by some as the "25 x 25" target 
(Kontis et al. 2014). The target risk reductions are: a reduction of 30% in the prevalence 
of tobacco smoking; reducing alcohol consumption by 10%, reduction of 30% in the 
average salt intake of the population, stop the rising prevalence of obesity, reduce 25%
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of the prevalence of high blood pressure and stop the rise in prevalence of diabetes. 
Based on the information available for the model, this scenario analyses the targets on 
reducing 30% of smoking and assumes that the level of systolic blood pressure has been 
reduced by 5% to achieve this goal and the other risk factors remain the same as in 2009.
4) The worst case scenario: This scenario assumes that the trend of risk factors in the 
population will be changed according to the information provided from the WHO global 
observatory, Thailand country profile data (WHO 2011). The trends of the risk factors 
of the Thai population who are aged 25 years and over have been presented in Appendix 
J. The percentage of change has been calculated by:
n, current value - starting value , . .%Change =  = x 100 (7.10)
starting value
During 1980 to 2009, there was a +3.35% increase in the level of systolic blood 
pressure in the population and +11.7% increase in the total cholesterol level. However, 
the percentage of smoking in the population reduced by 30% because of the 
effectiveness of the smoking regulation policy in Thailand (Sangthong et al. 2011).
7.3 Results
7.3.1 The estimated number of CVD patients over an 8 year period
Table 7.3 shows the estimated number of CVD patients over the next eight years 
by age group, gender and the risk reduction scenarios. The model estimates the highest 
number of patients in the “worst case scenario”, which is 3,804,435 patients and the 
second highest figure is in the “do nothing scenario” which is 3,361,472 patients. 
However, if the public health interventions can reduce the level of CVD risk factors, as 
in the “optimistic scenario”, the estimated number of CVD patients will decline to
182
2,821,375 patients. Additionally, if the health policies achieve the UN millennium 
development goal, the number of total CVD patients will decrease to 2,828,420 patients.
When comparing the estimated number between men and women by age group 
and the risk reduction scenarios; overall, the model estimated the number of CVD 
patients was higher amongst women than men. However, the UN millennium goal 
scenario estimated the number of male CVD patients to be higher than the figures for 
women in most age group except at age 75 years and over. This might be because 
reducing cigarette smoking by 30% could have a higher impact on men as they have a 
higher prevalence of regular smoking than women (Appendix K).
When comparing the total estimated number of CVD patients by age group and 
the risk reduction scenarios, the estimated number of CVD patients increases 
respectively with the increasing of age group in both men and women. The worst case 
scenario estimated the highest number of CVD patients, following by the do nothing 
scenario. While, the optimistic scenario and the reaching UN millennium development 
goal estimated nearly the same number of patients (Appendix K).
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7.3.2 The estimated DALYs over 8 year period
Table 7.4 shows the estimation of the absolute total DALYs and DALYs lost 
from CVD per 1,000 population over the next eight years by age group gender and the 
risk reduction scenarios. The total DALYs overall is highest in the worst case scenario, 
which has a total loss of 6,244,551 DALYs. The second high is in the do nothing 
scenario which has a total loss of 5,620,626 DALYs. In addition, when the model 
assumed that the CVD risk factors have been reduced, as in the optimistic scenario, the 
total DALYs lost will be reduced to 4,859,439 DALYs. Furthermore, if the model 
assumed that CVD risk factors can be reduced as in the UN millennium goal scenario, 
the total DALYs lost will be reduced to 4,868,151. Both the optimistic scenario and the 
UN millennium goal scenario estimated the DALYs as nearly the same.
When comparing DALYs across age group, it was found that the number of 
DALYs lost from CVD increase respectively with an increase in age group. The 
DALYs is higher in the older adults, (age 35 years and older) than in the younger adults 
(ages 15 to 34). The absolute total DALYs is highest at ages 65 to 74 years.
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7.3.3 Estimate the impact of the risk reduction scenario
Table 7.5 presents the summary results of the CVD cost-offset model compared 
the four scenario analysis and the impact of changing CVD risk factors, on the number 
of CVD hospital admissions, total costs of hospitalisation and the DALYs. Do nothing 
scenario in the model has estimated that over the next eight year period there will be 
3,361,472 CVD patients if the levels of risk factors remain the same as in 2009. 
However, if the levels of risk factors decline as in the optimistic scenario (all risk 
factors reduce by 5%), it will reduce the number of CVD hospital admissions by 
540,097 people. Additionally, if the health interventions can achieve the UN 
millennium development goal, there will be a reduction in the number of CVD hospital 
admissions by 533,052 people. On the other hand, if the trends of risk factors increase 
amongst the population as in the worst case scenario, the number of CVD hospital 
admissions is estimated to be 3,804,435 which will be an increase of 442,963 CVD 
patients.
In terms of the total cost of hospitalisation, when applying the discount rate of 
3%, it is estimated that the health service providers will spent $58.1 thousand million
(£1,163 million) on medical expenditure for CVD patients over the next eight year 
period. However, if the health interventions can reduce the levels of risk factors as in 
the optimistic scenario, there will be $9,346 million (£186 million) saving on the
hospitalisation costs. In addition, if the health policy can achieve the UN millennium 
development goal, it will save $9,224 million (£184 million) of the health care
expenditure. Conversely, if the trend of CVD risk factors continuously increase as in 
the worst case scenario, the health care expenditure will increase by $7,665 million
(£153 million) over the next 8 year period.
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Furthermore, the model estimate 5,620,626 DALYs lost due to CVD in Thailand 
over the next eight years if the levels of risk factors remain the same as in 2009. 
However, the government would be able to save 761,187 DALYs if all levels of risk 
factors could be reduced as in the optimistic scenario. Moreover, if the health policy can 
reach the UN millennium development target, there will be 752,475 DALYs saving in 
the next eight years. Or, if the trend of CVD risk factors continuously increase as in the 
worst case scenario, the total DALYs will reach to 6,244,551 DALYs during the next 
eight year period, which is an increase of 623,925 DALYs overall in the Thai 
population.
Table 7.5 Summary of the CVD cost-offset model showing the four differences 
scenarios
Conditions Scenario
1) Do nothing 
scenario
2) Optimistic 
scenario
3) Achieve the 
UN millennium 
development 
goal
4) Worst case 
scenario
Number of CVD 
patients 3,361,472 2,821,375 2,828,420 3,804,435
Number of CVD 
hospital admission 
saving, compare to 
"Do nothing 
scenario" -ref 540,097 (saving)
533,052
(saving) 442,963(increasing)
Total cost (THB) 73,686,851,301 61,847,395,792 62,001,814,904 83,397,048,087
Total cost (THB) of 
hospitalisation with 
3% Discount rate 58,169,080,864 48,822,905,356 48,944,805,230 65,834,399,874
Cost of 
hospitalisation 
saving (THB) -ref
9,346,175,508
(saving)
9,224,275,634
(saving)
7,665,319,010
(increasing)
Total DALYs 
(years) 5,620,626 4,859,439 4,868,151 6,244,551
DALYs saving 
(years) -ref 761,187 (saving)
752,475
(saving)
623,925
(increasing)
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7.3.4 Sensitivity analysis
The sensitivity analysis has been performed in 4 different parameters.
1) Using the WHO Standard Life Table (the Standard Life Table west level 26) 
vs. Thailand Life Table.
2) The application of age weight vs. without age weight.
3) Using upper and lower 95% confidence limits of the disability weight 
(mean = 0.181, 95%CI (0.08-0.29))
4) Using upper and lower 95% confidence limits of the cost of hospital 
admission (mean=$21,921, 95%CI(b21,717-b22,125).
The model has applied both WHO standard Life table vs. Thailand Life Table in 
the analysis. Each life table has re-estimated the DALYs when using age weight vs. no 
age weight. In each analysis of applying age weight vs. no age weight, it also used the 
upper vs. lower limit of the disability weight to get the range of estimated DALYs 
under the uncertainty of the different parameters. The 95% confidence limit of the cost 
of hospital admission was also applied in the model to estimate the possible range of the 
total expenditure that the health care providers have to pay for treatment of CVD 
patients.
Table 7.6 presents the estimation of the absolute total DALYs and the total cost
of hospital admission when applying to the different parameters in the sensitivity
analysis. In terms of DALYs estimation, when using the Standard Life Table vs.
Thailand Life Table, there is no difference when the age weight has been applied in both
life tables. However, the Thailand Life Table estimated DALYs slightly lower than the
Standard Life Table when not using age weight. Comparing using age weight and no
age weight in both life tables, the estimated DALYs using age weight is lower than no
189
age weight. The use of upper and lower 95% Confidence Limit of the disability weight 
shows the possible range of DALYs when the severity of disability was taken into 
account. The lower limit of disability weight refers to mild CVD condition and the 
upper limit of disability weight refers to severe CVD condition. For example, in the do 
nothing scenario, when using the standard life table and age weight, the model estimates 
total DALYs lost from CVD is 5,620,626 which the possible DALYs are ranged 
between 2,987,263 to 8,462,573. The DALYs estimated by age groups and gender 
shows in the appendix L and appendix M.
In terms of the sensitivity analysis of the cost of hospital admission, the model 
estimates the total cost when applying the upper and lower 95% confidence limit of cost 
to estimate the range of total cost with the 3% discount rate and compare between four 
scenarios as shown in Table 7.6.
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7.4 Discussion
In 2009, there were 327,435 CVD patient admissions to hospitals which had a 
total health care expenditure of $7,177 million (£143 million) and the BOD Thailand
study in 2009 estimated the total DALYs of IHD and Stroke together was 1,146,064 
DALYs (International Health Policy Program 2012). If the levels of CVD risk factors 
remain the same as in 2009, the number of CVD patients will increase approximately 10 
times and the total DALYs of CVD will increase to 5,620,626 DALYs over the next 
eight year period. However, if the trend of risk factors increase as in the worst case 
scenario, the number of CVD patients will increase to 3,804,435 and increase to 
6,244,551 DALYs over the next eight year period. As a consequence the health care 
expenditure will increase as well as the DALYs also increasing (Table 7.3-7.5).
The CVD cost off-set model has estimated that there are potential benefits of 
reducing the CVD risk factors at the population level. The optimistic risk reduction 
scenario and reaching the UN millennium goal scenario are both estimated to have the 
potential benefit of reducing CVD risk factors on the number of CVD hospitalisations 
avoided, total cost of hospital admissions savings and the DALYs saving being nearly 
the same. Although in the UN millennium goal did not take into account the reduction 
of total cholesterol, there are still high impacts on reducing level of systolic blood 
pressure and reducing the prevalence of smoking.
In terms of the DALYs estimation (Table 7.4), the DALYs calculation
incorporated the age weight which considers the value of the years of life lost at an
elderly age as less than in younger adults. The use of age weighting is controversial
because the societal perspective is concerned about the economic productivity, the value
of the years of life are weighted different among age group but in the equality
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perspective, the values the years of life are weighted equally for all age group. However, 
this model allows for the analysis to perform the estimation of DALYs with and without 
using an age weight. The DALYs calculation without the age weight has been presented 
in (Appendix L). When applying age weight in the analysis, it found that DALYs in the 
younger age group (15-34) has increased and DALYs in the older age group has 
decreased.
Additionally, this analysis has used the standard life table West Level 26 to 
calculate the life expectancy in the population because the GBD study and BOD study 
in Thailand had used the standard life table, instead of the country life table, for 
comparing the results with the other studies. However, the DALYs estimation which 
used the recent Thailand specific life table at 2012 has been analysed and presented in 
(Appendix M). When applying the country specific life table to calculate DALYs, it was 
found that the number of DALYs lost was not different with applied age weight but it 
has slightly dropped without applied age weight, compared to the standard life table, 
because the standard life table has a higher life expectancy at birth than Thailand life 
table (World Health Organization 2000). The life expectancy at birth in the standard life 
table is 80 years in men and 82.5 years in women. While, the life expectancy at birth in 
the Thailand life table in 2012 is 71 years in men and 79 years in women.
7.4.1 Limitation
There are some limitations of the CVD cost-offset model. Firstly, the model has 
been carried out under limited conditions and there are some underlying assumptions. 
The model is static and compares the estimation at two points of time from 2009 and 
over the next 8 year period, apart from 2009. The model assumed that the number of 
mid-year of population and the population structure by age group and gender remain the 
same as in 2009, but the reality is that people in the cohort of 2009 will gain more age.
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Several studies have suggested that Thailand will become an ageing society by 2050 
because of the falling fertility rate in the Thai population, (Knodel and Chayovan 2008, 
National Statistical Office 2007). It was estimated that in a few decades, Thailand will 
for the first time have a greater population aged 60 years and over, than the population 
aged less than 15 years old (Knodel and Chayovan 2008). Therefore, the population 
structure in the future may be different from now because there may be more people in 
the elderly age group.
Secondly, the CVD risk factors are modifiable. Some risk factors might vary 
with the age difference and can change over time. Younger adults and older adults 
experience different levels of risk factors. For example, older adults may experience 
high blood pressure more than younger adults. Some behavioural risk factors are 
dynamic which may change anytime based on individual behaviour, such as cigarette 
smoking. This model is not able to capture the dynamic changing of the CVD risk 
factors of the individual because the estimation is based on the mean level of the risk 
factors by each age group and gender.
Thirdly, the model uses the APCS equation to calculate the eight year 
probability of getting CVD. This equation has some limitations in terms of the number 
of independent variables, such as age, gender, systolic blood pressure, total cholesterol 
level and cigarettes smoking status. Some potential risk factors such as diabetic status 
and BMI level were not included in the equation which may have underestimated the 
risk of CVD in people who have a high BMI or diabetes. Furthermore, although the 
equation is able to calculate the overall probability of getting CVD, it is not able to 
calculate the probability of specific CVD conditions, such as stroke and IHD, separately. 
However, this equation is suitable for the Asian population. It has been validated in the 
performance of the equations in the Thai cohort (Asia Pacific Cohort Studies
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Collaboration et al. 2007) and also in this study (Chapter 5). The model could perform a 
more precise estimation if the country-specific CVD risk assessment equation was 
available.
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Chapter 8 : Conclusion and recommendation for
future research
8.1 Conclusion
This study was carried out to estimate the future prevalence of CVD in Thailand 
and the potential economic and health benefits of strategies to reduce the population risk 
factors during an eight year period. The main empirical findings and discussions have 
been presented and summarized within the respective chapters: Chapter 4: risk factors 
associated with CVD in Thailand from the 4th National health examination survey 
2008-2009, Chapter 5: application of CVD risk assessment equations to the Thai 
population, Chapter 6: health care cost of CVD in Thailand, and Chapter 7: the impact 
of reducing risk factors for CVD in Thailand. This section will synthesise the main 
empirical findings to answer the study’s two research questions.
1) How will the prevalence of CVD develop in Thailand over the next 5-10 years if the 
health system remains as it is?
• This study estimated the number of CVD patients over an eight year period 
by undertaking the mathematical CVD cost-offset model. If the health 
system continues as it is and the CVD risk factor remain the same as it was 
in 2009; the number of CVD patients will increase from 327,435 patients in 
2009 to 3,361,472 patients over the next 8 years.
2) How much could the cost of hospital admissions and the number of DALYs from 
CVD be reduced, if the major multiple population risk factors were reduced through 
investment in public health initiatives?
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• Findings from this study suggested that reducing any combination of the 
CVD risk factors can reduce incidence of aquiring CVD in a healthy 
population, as well as saving the burden of disease in terms of DALYs and 
savings on health care expenditure.
• If the public health initiatives achieve the UN millennium development goal 
or achieve a reduction of 5% in the level of CVD risk factors such as systolic 
blood pressure, total cholesterol and prevalence of cigarette smoking in the 
population, the health service provider will save approximately $9,000 
million and achieve savings of approximately 750,000 DALYs over the next 
eight years.
• On the other hand, if the trend of risk factors increases, there will be an 
increase in health care expenditure of $7,600 million and an increase of 
623,925 DALYs during the eight year period.
The main findings of this study are consistent with other studies on CVD
modelling that focus on primary prevention and which target a reduction in modifiable
risk factors. Moran et al. (2010) projected the trend of CVD in China will increase
during 2010 to 2030, which relates to the aging population, increases in blood pressure
and diabetes levels but decreases in the trend of active smoking. Whitfield (2006)
presented the benefits of investment in primary prevention, which could prevent the
number of deaths and also reduce the number of hospital admissions as well as saving
costs of acute hospital admissions from CVD in the UK. Kontis (2014) has estimated
that there will be delay or reduction in the number of deaths worldwide from the chronic
disease, including CVD, if the UN millennium development goal is achieved (Kontis et
al. 2014). Some CVD policy model studies found the effectiveness of treatment
intervention, such as using statins, aspirin and beta-blockers on the number of deaths
prevented, years of life gained without CVD and hospital admissions avoidable was
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significant (Grover et al. 1998, Capewell, Morrison and McMurray 1999, Babad et al. 
2002). However, the effectiveness of treatment interventions is beyond the scope of this 
study.
8.2 Strengths and limitations of the research
8.2.1 Strengths
To the best of the author’s knowledge, this is the first study that has developed a 
CVD policy model specifically for use in Thailand. The benefit of mathematic 
modelling is the capability to estimate the future occurance of CVD events based on the 
current available information and the scientific evidence, instead of following-up people 
over a long period of time. This study provides the information for the health policy 
developers to plan and invest in primary prevention programs for chronic diseases such 
as CVD, rather than waiting until the problems occur or the prevalence of CVD 
increases in the population.
In terms of the implications for policy and practice in Thailand, many primary 
prevention programs for CVD have been implemented. Some primary interventions 
have been successfully implemented, such as smoking regulation which has reduced the 
prevalence of smoking in the Thai population during the last decade (Sangthong et al. 
2011). However, some primary prevention programs such as promoting a healthy diet 
and undertaking physical activity have not been evaluated regarding their impact on 
reducing the risk factors of CVD. This is because CVD is caused by a combination of 
risk factors and it is difficult to measure the impact on the health benefits during a short­
term period. The CVD cost-offset model can be used as the financial tool for helping 
develop the health policy for long-term planning and targeting the investment in 
primary prevention programs for reducing the instances of CVD. The findings in this
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study show that there will be huge benefits of reducing the CVD risk factors by 
preventing the number of hospitalisations, reducing the burden of disease (DALYs) and 
savings in the future health care expenditure.
Additionally, the CVD cost offset model that has been developed in this study 
usd the APCS equation as the risk engine to calculate the probability of instances of 
CVD events during the eight year period. The APCS equation is generalisable for 
applying to other Asian populations because it was derived from the pools of data from 
the cohort studies around Asia. Therefore, this model can be replicate to other settings 
in Asian countries, if the esssential information of the population data and the risk 
factors profiles are available.
Moreover, the estimated number of CVD patients has been validated with the 
actual number of CVD patients who admitted in the hospital in 2009 which shows an 
accurate estimation in the middle and elderly age groups.
8.2.2 Limitations
This study encounterd a number of limitations, which need to be considered.
8.2.2.1 Model limitation
In terms of the model’s limitation, the CVD cost-offeset model is static, as it 
performs the estimation at two points in time between 2009 and the following eight 
years. The model did not taken into account the dynamic changing of the risk factors 
and changes in the population age structure over time. In addition, the risk engine that 
has been used in this study is the APCS equation. Although, this equation is suitable for 
Asian populations and has been validated with the actual CVD events in Thailand; the 
number of independent variables that have been applied in the equation are limited. The 
equation incorporated age, gender, systolic blood pressure, total cholesterol and the
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prevalence of smoking, but some risk factors such as diabetic status and BMI were not 
included in the analysis. Additionally, the equation has been able to calculate the 
probability of all CVD events which included both fatal and non-fatal CVD events, but 
it cannot calculate the probability of stroke or IHD separately.
8.2.2.2 Data limitation
In terms of the limitation of data availability, various data sources are required 
to conduct the model. The model was developed based on the population information of 
demographic and risk factors data in 2009. Therefore, the essential information for that 
year was gathered to apply and validate the model, such as the number of hospital 
admissions classified by age group and gender and the number of people who died from 
CVD in 2009. However, some information from 2009 is missing because it is not 
accessible and available during the period of study, such as the number of CVD patients 
in private hospitals, the number of patients in the social security health care scheme and 
in the civil servant health care scheme, which accounts for approximately 25% of the 
population and is missing from the validation data. The same limitation was 
encountered with the CVD mortality data in Thailand. It was gathered by a review of 
the informationcontained in the health statistic report and the annual report from the 
ministry of Public Health. Most documents present the overall mortality data,but do not 
classify it by age group and gender, as is required by the model. Therefore, the 10-year 
trend of CVD mortality during 1996 to 2006 has been used instead of the CVD 
mortality in 2009 because of the limitation of data availability.
8.3 Challenges of this study
This study used a combination of the various evidence, background
knowledgeand literature, such as the epidemiology, biostatistics, mathematics,
demographics and health economics to construct the mathematic CVD cost offset
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model. A number of challenges occured whilst undertaking the study on health 
economic modelling. Completing the study required both technical skills, such as the 
advanced use of Microsoft Excel spreadsheets, learning how to perform analysis on 
statistical packages and how to calculated DALYs, as well as integrating all of this 
background knowledge to carry out the development of the model.
Another challenge was aquiring the various data required in this study, such as 
the demographic data on the number of the population classified by age and gender, the 
background mortality rate, the probability of dying from CVD in the general population, 
the CVD risk factor profile from the health survey, the actual number of hospital 
admissions due to CVD classified by age and gender and the cost of hospitalisation. 
The model needed different data from different sources. Some data can be accessed and 
gathered through the literature review, such as the mortality data from the national 
health statistical report. However, some of data needed to be collected from 
organisations in Thailand such as the national health examination survey data, 
hospitalisation data and the health care cost of CVD. To aquire this data, authority was 
required and permission had to be sought and obtained in writing before access to the 
data was granted. Although these are the secondary data sources, the data collection 
process took time because of the need to contact many organisations and some data 
source owners did not allow access to their data, such as the hospitalisation data from 
the social security health insurance system and the civil servant health insurance system. 
However, this study used the best available data in Thailand, which could be accessed 
during the period of the study to carry out the model.
8.4 Recommendations for future research
This study contributes to the initial CVD cost-offset model for estimating the 
future burden of CVD events and the future potential benefits of reducing the risk
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factors of CVD in the population level in Thailand. However, the future development of 
the model is required to fullfill the gap of this study. The areas for future research are 
suggested as follows:
• A more sophisticated and dynamic model can be developed by applying the 
Markov model or Discrete event simulation model, if the specific CVD risk 
equations and the data are available.
• Further study can focus more on the CVD risk factors in younger adults. During 
the period of this study, there was no CVD risk equation available that was 
suitable for the younger adult (aged under 30 years) Thai population. Although, 
several studies have derived the CVD risk equation for projecting the CVD risk 
in younger adults (Pencina et al. 2009, Expert Panel on Detection, 
Evaluation,and Treatment of High Blood Cholesterol in Adults 2001), it was 
derived using western countries data which is not suitable for use with the Thai 
population.
• The APCS equation can be jusified to the Thai setting. However, a country 
specific CVD risk equation should be applied to get the precise estimation. 
During the study period, Thailand had the RAMA-EGATs risk score but it was 
only suitable for middle aged men in urban areas (Supina et al. 2009) and the 
equation was not published. Once, a country-specific CVD risk equation is 
available, the model can be configured with the equation to calculate the risks of 
getting CVD specifically for the Thai population.
• A future study may develop the model which takes into account the complexity 
of the risk factors. For example, the people with the highest risk conditions 
related to CVD, such as having diabetes mellitus, having chronic kidney dieases 
and being obese, are more likely to have a higher probability than the general
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population of getting CVD. The specific CVD risk equation for these groups 
may be applied in the model.
• The dynamics of the risk factors should be taken into account in a further study 
because in reality most CVD risk factors are modifiable and can change over 
time when people change their health behaviour. For example, cigaratte smoking 
behaviour is dynamic as people can start and stop smoking at anytime during 
their life.
• Thailand has been estimated to become a more aging population than the labour 
force population in the next few decades. This study has estimated a high 
probability of getting CVD in an aging population because they are in the high 
risk groups of CVD, which have higher levels of CVD risk factors, such as 
higher blood pressure and higher total cholesterol, compared to the younger 
population. A future study should take into account the changes in the 
population age structure, which will benefit in supporting the information on the 
health care financial costs and the burden of disease related to CVD for the 
health policy, to prepare for an aging society in the future.
• The cost-effectiveness study of the specific primary preventions programs in 
Thailand should be studied to provide information on which intervention is the 
best value for money for the health policy implementation and an evaluation 
study on the cost-effectiveness of the existing CVD prevention interventions 
will be useful for encouraging investment in the prevention programs.
• Future research should investigate health care expenditure from the patients 
perspective because CVD patients require long-time care.There are many hidden 
and out-of-pocket costs that occur with patients and their family but few studies 
have been undertaked in Thailand.
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Appendix A: The literature search strategies 
The literature search strategies
The literature search strategies are followed as descript below;
Inclusion criteria
The literature review included primary studies and research which have been 
relevant to the research topic such as the cardiovascular disease study, mathematical 
risk CVD risk assessment equation and the health economic modelling. The review 
included research articles, journal articles, reports, books, websites and theses. The 
published literatures are reviewed in electronically searching on the online database or 
hand searching for the hard copies. The review is focus on both English and Thai 
languages which was published in 1990 onwards. However there might be some 
unpublished literature which have related to the topic will be selected such as; the 
ministry of public health policy documents, conference papers and reports.
Exclusion criteria
The literature review excluded primary studies or research which were not 
directly relevant to the research topic. The review excluded non-English or non-Thai 
languages and the pre 1990 studies. The literature search excluded congenital heart 
disease which is caused by the dysfunction of the heart at birth. Rheumatic heart disease 
which is caused by infection is also excluded from the literature search because it is 
beyond the scope of the study.
Limitation of the literature reviews
The cardiovascular diseases are focused on the cardiovascular related diseases 
such as coronary heart disease, heart failure, heart attack, ischemic heart disease, stroke 
and myocardial infarction. However, some type of cardiovascular diseases which related 
the infection or genetic disorder will not covered in the reviews such as Rheumatic heart 
disease, Congenital or birth heart defects and Arrhythmia.
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List of electronic databases
• Cochrane Library
• Medline (EBSCO)
• Applied Social Sciences Index and Abstracts (ASSIA) database
• Scopus
• Web of Science
• Cumulative Index to Nursing and Allied Health Literature (CINAHL)
• Ethos, British library database
University databases
• Centre for Review and Dissemination (CRD) database, University of York
• SCHARR Library, University of Sheffield 
Other electronic sources
• Netting the evidence Google search engine
• Google scholar
• Organization websites
o World health organization
o National Institute for Health and Clinical Excellence (NICE) 
o Ministry of Public Health, Thailand 
o National Health Security Office, Thailand 
o Health System Research Institute, Thailand 
o International Health Policy Program, Thailand
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Search Terms and Keywords
Cardiovascular diseases are a group of diseases. The main heading search 
terms used in Medical Subject Heading (MeSH) were “cardiovascular diseases”, 
“cardio-vascular disease” , “heart disease”, “coronary heart disease”, “ishemic heart 
disease” “stroke”, “cerebrovascular disease”, “cerebrovascular accident”.
Figure 1A: Overall terms of cardiovascular diseases
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1. Prevalence and burden of cardiovascular diseases
Explanation of search terms used: / = MeSH Heading exp = exploded MeSH Heading; 
aterisk (*) denotes any character; ti = title word; ab = abstract word; pt = publication 
type; adj = adjacency; "" = phrase search; unless otherwise stated, tenns searched all 
fields.
1. cardiovascular*:ti,ab.
2. cardiovascular disease*ti,ab.
3. cardiovascular diseses/
4. heart disese*ti,ab.
5. heart adj 1 disease*ti,ab.
6. heart disease/
7. coronary heart disease*ti,ab.
8. coronary adj 1 heart adj 1 disease*.ti,ab.
9. coronary disease/
10. ischemic heart disease*ti,ab.
11. ischemic adjl heart adjl disease*.ti,ab.
12. myocardial ischemia/
13. myocardial infarc*ti,ab.
14. myocardial adjl infarc*.ti,ab
15. myocardial infarction/
16. stroke*.ti,ab.
17. stroke/
18. cerebrovascular disease*.ti,ab.
19. cerebrovascular adj 1 disease*.ti,ab.
20. cerebrovascular disease/
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21. cerebrovascular accident*.ti,ab.
22. cerebrovascular adj 1 accident*.ti,ab.
23. cerebrovascular accident/
24. cerebrovascular*.ti,ab.
25. heart attack*.ti,ab.
26. heart failure*.ti,ab.
27. heart failure/
28. or/1-27
29. epidemiology*,ti,ab.
30. burden*,ti ab.
31. burden adjl disease*.ti,ab.
32. global* adjl burden*.ti,ab.
33. disabilit* adjl adjust* adjl life adjl year*
34. disabilit* adjust* life* year*
35. DALY*.ti,ab.
36. or/29-35
37. prevalence*.ti,ab.
38. incidence*.ti,ab.
39. mortalit*.ti,ab.
40. morbidit*.ti,ab.
41. trend*.ti,ab.
42. distribution*.ti,ab.
43. situation*.ti,ab.
44. pattern*.ti,ab.
45. or/37-44
46. 28 and 29
227
47. 28 and 36 and 45 
48.46 or 47
2. Mathematical risk assessment methods
Explanation of search terms used: / = MeSH Heading exp = exploded MeSH Heading; 
aterisk (*) denotes any character; ti = title word; ab = abstract word; pt = publication 
type; adj = adjacency; "" = phrase search; unless otherwise stated, terms searched all 
fields.
1. cardiovascular* :ti,ab.
2. cardiovascular disease*ti,ab.
3. cardiovascular diseses/
4. coronary heart disease*ti,ab.
5. coronary adj 1 heart adj 1 disease*.ti,ab.
6. coronary disease/
7. stroke*.ti,ab.
8. stroke/
9. cerebrovascular disease*.ti,ab.
10. cerebrovascular adjl disease*.ti,ab.
11. cerebrovascular disease/
12. cerebrovascular accident*.ti,ab.
13. cerebrovascular adj 1 accident*.ti,ab.
14. cerebrovascular accident/
15. cerebrovascular*.ti,ab.
16. o r /1-15
17. Prediction model*.ti,ab.
228
18. Prediction*.ti,ab.
19. Estimation*.ti,ab.
20. Cohort study*.ti,ab.
21. Follow up study*.ti,ab.
22. Prediction equation*.ti,ab.
23. Risk score*.ti,ab.
24. logistic regression equation*.ti,ab.
25. Risk prediction equation*.ti,ab.
26. Multiple risks prediction*.ti,ab.
27. or/17-26
28. 16 and 27
3. Modelling technique
Explanation of search terms used: / = MeSH Heading exp = exploded MeSH Heading; 
aterisk (*) denotes any character; ti = title word; ab = abstract word; pt = publication 
type; adj = adjacency; "" = phrase search; unless otherwise stated, terms searched all 
fields.
1. cardiovascular*: ti, ab.
2. cardiovascular disease*ti,ab.
3. cardiovascular diseses/
4. coronary heart disease*ti,ab.
5. coronary adjl heart adj 1 disease*.ti,ab.
6. coronary disease/
7. stroke*.ti,ab.
8. stroke/
229
9. cerebrovascular disease*.ti,ab.
10. cerebrovascular adj 1 disease*.ti,ab.
11. cerebrovascular disease/
12. cerebrovascular accident*.ti,ab.
13. cerebrovascular adj 1 accident*.ti,ab.
14. cerebrovascular accident/
15. cerebrovascular*.ti,ab.
16. o r /1-15
17. Mathematic* Model* *.ti,ab.
18. Decision* model* *.ti,ab.
19. Economic* model* *.ti,ab.
20. Decision tree model*.ti,ab.
21. Markov's Model* *.ti,ab.
22. Simulation* Model**.ti,ab.
23. Micro-simulation* model* *.ti,ab.
24. or/17-23
25. 16 and 24
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Appendix B: The constants and p coefficient for the original 
Framinham equation.
Table IB: Weibull accelerated failure-time model regression coefficients of risk 
factors and CVD in the Framingham heart study (Khonputsa, et al. 2011)
Risk factor Men Women
Ischemic heart disease
Age (years) -0.037 -0.036
Total cholesterol (mg/dL) -0.005 -0.006
Diabetes mellitus (yes=l, 
no=0)
-0.461 -0.695
Systolic blood pressure 
(mmHg)
-0.009 -0.01
Smoking (yes=l, no=0) -0.384 -0.221
Constant 1 8.39 9.32
Constant2 0.82 0.83
Stroke
Age (years) -0.081 -0.06
Total cholesterol (mg/dL) Non-significant Non-significant
Diabetes mellitus 
(yes=l,no=0)
-0.391 -0.684
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Appendix C: The letter of approval for data accessing
N ational Health Exam ination Survey O ffice (N HESO )
126 Fifth Floors, Boromarajonani College o f  N ursing Building, 
Bam rasnaradura Infectious Disease Institute 
Talad-K w an, M uang D istrict, N onthaburi 11000, Thailand
Dear Dr. M alcolm D avid W hitfield,
The N ational Health Exam ination Survey O ffice (N HESO ), Thailand agrees to support Miss 
Rungkam Inthawong for her PhD research work at Sheffield Hallam University. The N HESO  will 
support her research activities in accessing to the N ational Health Exam ination Survey IV, 2008-2009 
(NHESIV) data o f  the requested variables, providing w ork facilities and assisting in  contact w ith other 
organizations in Thailand.
Sincerely yours.
(D r. Wichai A ekplakom )
Principal Investigation o f  NHES IV 
N ational Health Exam ination Survey Office 
Email address: raw ap'dm ahidol.ac.lh
Other address:
Dr. Wichai A ekplakom  
Departm ent o f  Com m unity M edicine.
Faculty o f  Medicine, Ram atitibadi Hospital. M ahidol University 
Rama VI Rd. Rajdevi.
Bangkok 10400, Thailand  
Tel: +662 20115 IS
E T c rn .
January 24, 20 1 1
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Appendix D: Letter of approval from Sheffield Hallam University, 
Faculty of Health and Wellbeing Research Ethics Committee
Centre for
Health and 
Social Care
Research
Faculty of Health and Wellbeing Research Ethics Committee 
Health & Social Care Research Ethics Review Group
Report Form
Title:
Principal Investigator: 
Recommendation:
Acceptable:
Not acceptable, see  comments: 
Acceptable, but see  comments: 
Comments:
Assessing the impact of reducing risk factors for 
cardio-vascular disease in Thailand.
Rungkarn Inthawong
See attached feedback on review forms.
Signature: Date: 19 April 11
Peter Almark,
Chair
HSC R esearch Ethics Review Group
Please remember that an up-to-date project file must be maintained for the duration 
of the project and afterwards. The project file might be inspected at any time.
Note: Approval applies until the anticipated date o f completion unless there are 
changes to the procedures, in which case another application should be made.
Centre for Health and Socal Care Research
Faculty of Health and Wellbeing Sheffield Haliam University Montgomery House 
32 Collegiate Crescont Collogiato Crescent Campus Slreffield S10 2BP UK 
Telephone +44 (0)114 225 6854 Fax +44 (0)114 225 4377 
E-mail chscr@shu.ac.uk www.shu.ac.ult/chscr
Sheffield
Hallam University
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R esearch  p roposal review form: S ept 2010
Faculty of Health and Wellbeing 
Faculty Research Ethics Committee 
Health and Social Care Division
Research Proposal Review Form
Review Summary
N am e of re sea rch er: R ungkam  Inthawong
P roject title: A ssessing  the impact of reducing risk factors for cardio-vascular 
d is e a se s  in Thailand
N am e of superv isor: Prof. Malcolm D. Whitfield 
Dr. Karen Collins
Code for D ecision: S a tisfac to ry  Review Achieved
S atisfacto ry  Review w ith  som e advice 
U nsatisfac to ry  Review - n eed s a m en d m en ts  
[PLEASE SELECT ONE OF THESE THREE]
S ig n a tu re  of Reviewer: P eter A llm ark
D ate: 1 8 /0 4 /2 0 1 1 ___________
F eedback  : T h is p roposal h a s  a lready  been  approved  in  te rm s of th e  RF1 p ro cess . In  
te rm s  of e th ic s  it  involves u s in g  an o n y m o u s d a ta  w hich  th e  s tu d e n t h a s  p e rm iss io n  to  
acce ss  from  its  ow ner. It is a  w ell-w ritten  protocol an d  I have no  co n ce rn s a b o u t th e  
e th ics . I have decided th a t  a  single e th ic s  review is suffic ien t in  th is  ca se  given th a t  th e  
p roposal h a s  been  review ed a lready  for th e  RF1 an d  th a t  it  is very low risk .
Site/Project files
A n u p - to -d a te  p ro je c t  o r  s i te  file m u s t  b e  m a in ta in e d  fo r  th e  d u r a t io n  o f  th e  
p ro je c t  a n d  a f te rw a rd s . T h e  file m ig h t  b e  in s p e c te d  a t  a n y  tim e .
M ental Capacity
S p e c ia l  p r o c e d u r e s  n o w  a p p ly  to  a n y  r e s e a r c h  t h a t  in v o lv e s  a d u l t s  w i th o u t  
m e n ta l  c a p a c ity  to  c o n s e n t  to  t h a t  r e s e a r c h .  T h is  a p p l ie s  b o th  to  t h e  N H S  a n d  to
1
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Research proposal review form: Sept 2010
Social Care Research. Please contact Peter Allmark to discuss if that applies to 
this study.
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Research proposal review form: Sept 2010
C hecklist for Independent Scien tific  R eview  -
PA - This has already been done as part of the RF1 process
General Yes No N /A
The aim s of the  project are  clearly sta ted
The project is original in concept w ith evidence to support 
the project’s originality in th e  literature review
The project is useful and  relevant to clinical practice, policy 
m aking or workforce planning
The project is feasible in the time available
Service u se rs  have been involved in  the developm ent of the 
proposal where possible
A com pleted project safety plan is included with the proposal
A completed registration form is included
M ethod /  design /  analysis Yes No N /A
The design is appropriate for the identified aim s
A clear rationale for the use of system atic litera tu re  review is 
included
The review procedure chosen is appropriate
The sam pling strategy chosen is appropriate for the identified 
aim s.
A power calculation h as been undertaken  if appropriate.
Methods to be used  to identify, approach and  recru it 
partic ipan ts have been included
T rustw orth iness and  rigour of d a ta  collection are considered
M easurem ent issues are  addressed  in relation to clinically 
appropriate m easuring tools.
The validity an d  reliability of the outcom es m easu res chosen 
have been considered (this included questionnaires to be 
used)
An appropriate p lan  of analysis is included with reflection on 
the im plications of the sam ple size.
The project a ttem pts to look a t individual d a ta  as well as 
aggregated d ata
There is a logical and  feasible research  time plan  with clearly 
delineated m ilestones.
Itemised costings are included
Issues concerning racial and cu ltu ra l diversity have been 
considered
Participant inform ation and consen t forms have been 
included
Have issues around  controlling bias been considered
Has a  statistical opinion been included if appropriate
Have indem nity issues been considered (FIN 12 included if 
appropriate.)
Have funding arrangem ents been m ade clear (ENT 1 
enclosed if appropriate)
Have m ethods for the dissem ination of resu lts been 
considered.
Have intellectual property arrangem ents been considered (if 
appropriate)
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Research proposal review form: Sept 2010
C hecklist for Ethical Approval
SAFETY ISSUES - Refer to the project safety p lan  a s well a s  the 
protocol.
Yes No
Is there is  any potentia l for physical or psychological harm or 
distress to  research participants?
X
If Yes:
a) Are adequate m echanism s in place to m inim ise the  risk and  to 
tackle any harm  or d istress th a t occurs?
b) Is the potential risk  of harm  balanced by potential benefit to 
partic ipants?
Is there is  any potentia l for physical or psychological harm or 
d istress to  the researcher(s)?
X
If Yes:
a) Are adequate  m echanism s in place to m inim ise the  risk  and  to 
tackle any harm  or d istress th a t occurs?
Are any o f the  participants likely  to  belong to  a so-called  
vulnerable group, for exam ple, children, people w ith  m ental 
health  problem s or w ith  learning disability, people in  a 
dependent relationship to  the researcher(s)?*
X
Is there a nam ed Project Safety Supervisor? X
* See note on Mental Capacity on the front sheet.
RIGHTS ISSUES Yes
No
Are issu es o f confidentia lity , privacy and data protection  
adequately covered in relation to:
X
a) The recru itm ent of participants?
b) The protection of the privacy of participants?
c) The protection and  storage of confidential inform ation 
generated by the study?
Will inform ed con sent be obtained from th e participants? X
Is there a satisfactory:
a) Participant inform ation sheet?
b) Partic ipant consent form? [Note: a  consen t form is not required 
for questionnaire s tud ies.1
D oes the research involve the  rem oval o f  any human tissu e  
from participants? Human tissu e  is, in  effect, any sam ple 
taken  from the human body apart from nails and hair.
X
Does th is proposal adequately address any issu es o f ethnic  
diversity or other diversity issues?
X
Do you believe th is proposal needs sp ec ia list e th ics review? X
238
Appendix E: The international statistical classicfication of diseases and 
related health problems 10th revision
Diseases of the circulatory system (100-199)
Code Diseases
100-102 Acute rheumatic fever
100 Rheumatic fever without mention of heart involvement
101 Rheumatic fever with heart involvement
102 Rheumatic chorea
105-109 Chronic rheumatic heart diseases
105 Rheumatic mitral valve diseases
106 Rheumatic aortic valve diseases
107 Rheumatic tricuspid valve diseases
108 Multiple valve diseases
109 Other rheumatic heart diseases
110-115 Hypertensive diseases
110 Essential (primary hypertension)
111 Hypertensive heart disease
112 Hypertensive renal disease
113 Hypertensive heart and renal disease
115 Secondary hypertension
120-125 Ischaemic heart diseases
120 Angina pectoris
121 Acute myocardial infarction
122 Subsequent myocardial infarction
123 Certain current complications following acute myocardial infarction
124 Other acute ischaemic heart disease
125 Chronic ischaemic heart disease
126-128 Pulmonary heart disease and diseases of pulmonary circulation
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Code Diseases
126 Pulmonary embolism
127 Other pulmonary heart diseases
128 Other diseases of pulmonary vessels
130-152 Other forms of heart disease
130 Acute pericarditis
131 Other diseases of pericardium
132 Pericarditis in diseases classified elsewhere
133 Acute and subacute endocarditis
134 Nonrheumatic mitral valve disorders
135 Nonrheumatic aortic valve disorders
136 Nonrheumatic tricuspid valve disorders
137 Pulmonary valve disorders
138 Endocarditis, valve unspecified
139 Endocarditis and heart valve disorders in diseases classified elsewhere
140 Acute myocarditis
141 Myocarditis in disease classifield elsewhere
142 Cardiomyopathy
143 Cardiomyopathy in diseases classified elsewhere
144 Atrioventricular and left bundle-branch block
145 Other conduction disorders
146 Cardiac arrest
147 Paroxysmal tachycardia
148 Atrial fibrillation and flutter
149 Other cardiac arrhythmias
150 Heart failure
151 Complications and ill-defined descriptions of heart disease
152 Other heart disorders in diseases classified elsewhere
160-169 Cerebrovascular diseases
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Code Diseases
160 Subarachnoid haemorrhage
161 Intracerebral haemorrhage
162 Other nontraumatic intracranial haemorrhage
163 Cerebral infarction
164 Stroke, not specified as haemorrhage or infarction
165 Occlusion and stenosis of precerebral arteries, not resulting in cerebral 
infarction
166 Occlusion and stenosis of cerebral arteries, not resulting in cerebral 
infarction
167 Other cerebrovascular diseases
168 Cerebrovascular disorders in diseases classified elsewhere
169 Sequelae of cerebrovascular disease
170-179 Diseases of arteries, arterioles and capillaries
170 Atherosclerosis
171 Aortic aneurysm and dissection
172 Other aneurysm and dissection
173 Other peripheral vascular diseases
174 Arterial embolism and thrombosis
177 Other disorders of arteries and arterioles
178 Diseases of capillaries
179 Disorders of arteries, arterioles and capillaries in diseases classified 
elsewhere
180-189 Diseases of veins, lymphatic vessels and lymph nodes , not elsewhere 
classified
181 Portal vein thrombosis
182 Other venous embolism and thrombosis
183 Varicose veins of lower extremities
184 Haemorrhoids
185 Oesophageal varices
186 Varicose veins of other sites
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Code Diseases
187 Other disorders of veins
188 Nonspecific lymphadenitis
189 Other noninfective disorders of lymphatic vessels and lymph nodes
195-199 Other and unspecified disorders of the circulatory system
195 Hypotension
197 Postprocedural disorders of circulatory system, not elsewhere classified
198 Other disorders of circulatory system in disease classified elsewhere
199 Other and unspecified disorders of circulatory system
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Appendix F: The mean of 8-10 years probability of CVD and the 
estimated number of 8-10 years CVD patients.
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Figure IF The mean of 8-10 years probability of CVD in men who aged > 15 years, 
NHESIV
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Figure 2F The mean of 8-10 years probability of CVD in women who are aged > 15 
years, NHESIV.
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Figure 3F The estimated number of men who are alive with CVD in Thailand in 
2017-2019
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Figure 4F The estimated number of women who are alive with CVD in Thailand 
during the next 8-10 years
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Figure 5F Comparing the actual number of CVD patients with the estimated 
number of CVD patients in the 3 different equations amongst Thai men by age 
groups, in 2009
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Figure 6F Comparing the actual number of CVD patients with the estimated 
number of CVD patients in 3 different equations among Thai women by age 
groups in 2009
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Appendix G: The absolute total cost of hospital admission by age
group gender and CVD condition
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Figure IE The absolute total cost of hospital admission by age group and CVD 
condition, Thailand 2009 (THE)
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Figure 2E The absolute total cost of hospital admission by gender and CVD 
conditions, Thailand 2009 (THB)
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Table 2F Average 10-year probability of dying from CVD classified by age group 
and gender
Age Average 10-years probabilities
Male Female Total
15-24 0.0001615 0.0000682 0.0001157
25-34 0.0004228 0.0001504 0.0002881
35-44 0.0006494 0.0002597 0.0004527
45-54 0.0012168 0.0006489 0.0009253
55-64 0.0023593 0.0014100 0.0018620
65-74 0.0041849 0.0029262 0.0035060
75+ 0.0072546 0.0060533 0.0065584
total 0.0010553 0.0007045 0.0008777
250
Appendix I: The disability weight of the cardiovascular disease from 
GBD study 2010
Cardiovascular and circulatory disease Estimate 95% Cl
Acute myocardial infarction: days 1 -2 0.422 0.284-0.566
Acute myocardial infarction: days 3-28 0.056 0.035-0.082
Angina pectoris: mild 0.037 0.022-0.058
Angina pectoris: moderate 0.066 0.043-0.095
Angina pectoris: severe 0.167 0.109-0.234
Cardiac conduction disorders and cardiac dysrhythmias 0.145 0.097-0.205
Claudication 0.016 0.008-0.028
Heart failure: mild 0.037 0.021-0.058
Heart failure: moderate 0.07 0.044-0.102
Heart failure: severe 0.186 0.128-0.261
Stroke: long-term consequences, mild 0.021 0.011-0.037
Stroke: long-term consequences, moderate 0.076 0.050-0.110
Stroke: long-term consequences, moderate plus cognition 
problems
0.312 0.211-0.433
Stroke: long-term consequences, severe 0.539 0.363-0.705
Stroke: long-term consequences, severe plus cognition 
problems
0.567 0.394-0.738
source: (Murray et al. 2012b)
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Appendix K: Estimated number of CVD patients over the next 8 years 
in Thailand
800 ,000
700 ,000
600.000
500 ,000
400.000
300.000
200.000
100,000
Men Women 
Do nothing scenario
Men Women Men Women Men Women
Optimistic scenario Reaching UN Worst case scenario
millenium goal
i 15-24 
l 25-34 
135-44 
145-54 
155-64 
I 65-74 
>75
Figure IK Estimated number of CVD patients over the next 8 years in Thailand by 
genders and risk reduction scenario
1 1 9 ,5 3 5
m m1 1 / ,0 9 4
0  2 0 0 ,0 0 0  4 0 0 ,0 0 0  6 0 0 ,0 0 0  8 0 0 ,0 0 0  1 ,0 0 0 ,0 0 0  1 ,2 0 0 ,0 0 0
■ W o rst case  sc e n a rio  ■  R each ing  UN m illen ium  goal
■ O p tim istic  sc e n a r io  ■ Do n o th in g  sc en a rio
Figure 2K Estimated number of CVD patients over the next 8 years in Thailand by 
age groups and risk reduction scenarios
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